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Abstract 
The aim of this thesis was to develop a series of gadolinium(III) contrast agents 
based on the DOTA and AAZTA molecules used widely in the literature that will 
locate preferentially in hypoxic tumour cells. Three contrast agents were 
synthesised with alkyne tags, by adapting compounds already produced in the 
literature. 
Whilst contrast agents in the clinic locate preferentially in cancer cells over 
normal tissues, they do not have the ability to inform a clinician about the type, 
or the environment of the cancer. One cancer environment that often leads to 
poor patient prognosis is hypoxia, as hypoxic tumours are both chemotherapy 
and radiotherapy resistant, whilst also promoting metastasis at a cellular level.  
Under hypoxic conditions nitro-aromatic compounds can be enzymatically 
reduced to either the hydroxylamine or amine compounds. Once this has 
occurred either a leaving group can be lost, or partial ring breakdown occurs, 
which can then be attacked by molecules within the cell such as glutathione to 
form a covalent bond. This tethers the hypoxic marker within the hypoxic cell. 
Currently this technology is only used with nuclear medicine techniques, whilst 
this thesis outlines how this principle is to be used in conjunction with MRI 
technology.  
The hypoxia markers were synthesised with azide functionalities to allow the 
two halves of these molecules to be conjugated using the copper (I)-catalyzed 
azide-alkyne cycloaddition. The conjugation occurred as the last step to 
produce a series of final compounds.  
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Once synthesised these contrast agents were characterised using NMR 
relaxivity calculations, to prove their effectiveness as contrast agents. They 
were also to undergo enzymatic tests using xanthine oxidase and glutathione to 
see if the nitro-aromatics can be reduced under hypoxic conditions, and thus 
their ability to locate within the hypoxic region of a tumour. Unfortunately this 
ODVWVWHSZDVQ¶WFRPSOHWHGGXHWRWLPHFRQVWUDLQWV 
.   
iii 
 
Acknowledgements 
)LUVW,¶GOLNHWRWKDQNProf Neil Thomas and Dr Walter Köckenberger for allowing 
me to undertake this project, followed by Cancer Research UK and The 
University of Nottingham. 
6HFRQGO\,¶G,LNHWRWKDQNDOOSDVWDQGSUHVHQWPHPEHUVRIWKH1HLO7KRPDV
group and everyone who worked on A/C-Floor with me with note to David for 
proof reading my thesis. Special mention goes to the following: 
Andrew and Austin for keeping me entertained and occasionally covering me in 
acetone! 
James and Terry for teaching me the rules of football against my will. 
6DUHQWKDIRUKDYLQJWKHNLQGHVWKHDUW,¶YHHYHUNQRZQ 
Will for all the help advice and chats. 
Stef also for all the help but also for the holidays and fun times. 
Shailesh, Sarah, Andrea, Gavin, Dan, and Dave thanks for all the help, advice 
and FULGD\¶VGRZQWKHSXE 
$OOWKHWHFKQLFLDQVZKR¶YHNHSWXVXSDQGUXQQLQJQRWDEO\*UDKDP/HH'DQH, 
Shaz, Kevin DQG+XZZKR¶YHDOZD\VEHHQIUHHWROHQGDKDQGZKHQ,¶YHPRVW
needed it.  
The CBS ski group ± Lee/Chrissy/Ross/Hutch etc for giving me something to 
look forward to each year. 
)LQDOO\,QGLDQG$GLWLWKHSHRSOHZKR¶YHNHSWPHZDQWLQJWRWXUQXSHYHQRQ
WKHZRUVWRIGD\VDQGWKHQWDNHQPHRXWIRUD1DQGR¶VWRFKHHUPHXS,
ZRXOGQ¶WEHKHUHZLWKRXW\RXUIULHQGVKLS 
Next I¶GOLNHWRWKDQNWKHPDQ\ RWKHUIULHQGV,¶YHKDGRYHUWKH\HDUVLQ
particular the group from Cloister, Sophie/Ellie/Sara/Paulina/Hsu and Zoe.  
Also for helping me retain my sanity I must thank both Notts Uni water polo and 
Hucknall Ladies water polo. I may never want to see the inside of Crisis again 
but I will miss you all, in particular Chari, Hannah, Ellie, Becky, Maxine, Katy 
and Naomi.  
)LQDOO\,¶GOLNHWRWKDQNP\IDPLO\0XP'DG$XQW\6KHLODDQG6DII\<RX¶YH
DOZD\VEHHQVXSSRUWLYHDQG,FRXOGQ¶WKDYHGRQHLWZLWKRXW\RX 
  
iv 
 
Contents 
Abstract .................................................................................................................................................. i 
Acknowledgements ............................................................................................................................... iii 
Contents................................................................................................................................................ iv 
List of Figures ....................................................................................................................................... x 
List of Schemes .................................................................................................................................... xi 
List of Tables ....................................................................................................................................... xiii 
List of Equations ................................................................................................................................. xiii 
Abbreviations ...................................................................................................................................... xiv 
Chapter 1 - Introduction ........................................................................................................................ 1 
1.1 Magnetic Resonance Imaging .............................................................................................. 1 
1.1.1 NMR Principles ..................................................................................................................... 2 
1.1.2 Applying NMR Principles to MRI. .......................................................................................... 6 
1.2 MRI Contrast Agents ............................................................................................................. 7 
1.2.1 Current Contrast Agents ..................................................................................................... 11 
1.2.2 Experimental Contrast Agents ............................................................................................ 13 
Increased inner-sphere water molecules ..................................................................................... 13 
Increased gadolinium concentration at site .................................................................................. 15 
Decreased molecular tumbling .................................................................................................... 18 
"Smart" MRI contrast agents ........................................................................................................ 20 
Alternative paramagnetic ions ...................................................................................................... 28 
1.2.3 The gadolinium (III) chelators that form the basis of the work in this thesis. ....................... 34 
1.3.1 Hypoxia ............................................................................................................................... 42 
1.3.2 Visualising hypoxia ± 2-Nitroimidazole ................................................................................ 43 
1.3.3 Alternative hypoxia markers ................................................................................................ 47 
Chapter 2 Aims and Objectives ........................................................................................................... 53 
v 
 
Chapter 3 - Results and Discussion .................................................................................................... 62 
3.1 Synthesis of Contrast Agent 1. ........................................................................................... 62 
3.2 Synthesis of Contrast Agent 2 ............................................................................................ 69 
3.3 Synthesis of Contrast Agent 3 ............................................................................................ 75 
3.4 Synthesis of Contrast Agent 4. ........................................................................................... 77 
3.5 Synthesis of Targeting Vector 1. ......................................................................................... 84 
3.6 Synthesis of targeting vectors 2-4 ....................................................................................... 88 
3.7 Synthesis of targeting vector 6 ............................................................................................ 94 
3.8 Conjugation of the contrast agent to the targeting vector.................................................... 99 
3.9 NMR Relaxivity testing ...................................................................................................... 106 
3.10 Enzymatic testing for activation of the targeting vectors under a hypoxic environment. . 112 
Chapter 4 Conclusions and Future Work. ......................................................................................... 115 
Chapter 5 Experimental .................................................................................................................... 119 
General Experimental ............................................................................................................. 119 
Chemical Experimental ........................................................................................................... 121 
1,4,7,10-Tetraaza-cyclododecane-1,4,7-tricarboxylic acid-tri-tert-butyl ester (36). .................... 121 
1,4,7,10 Tetraaza-cyclododecane-1,4,7,10-tetra carboxylic acid tri-tert-butyl ester 9H-fluoren-9-
ylmethyl ester (37). .................................................................................................................... 122 
1,4,7,10-Tetraaza-cyclododecane-1-carboxylic acid 9H-flouren-9-ylmethyl ester (38). ............. 123 
4,7,10-Tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododecane-1-carboxylic acid 9H-
fluoren-9-ylmethyl ester (39). ..................................................................................................... 124 
(4,10-Bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid tert-butyl ester 
(40). ........................................................................................................................................... 125 
(4,10-Bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid tert-butyl ester 
(40). ........................................................................................................................................... 126 
(4,7,10-Tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza -cyclododec-1-yl)acetic acid benzyl ester 
(75). ........................................................................................................................................... 127 
(4,7,10-Tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza -cyclododec-1-yl)acetic acid (tris-t-Bu-
DOTA) (76). ............................................................................................................................... 128 
(1,4,7-Tris-tert-butoxycarbonylmethyl-10-prop-2-ynyl carbamoylmethyl-1,4,7,10- tetraaza-
cyclododec-1-yl)-acetic acid tert-butyl ester (78). ...................................................................... 129 
vi 
 
(4,10-Bis-tert-butoxycarbonylmethyl-7-methoxycarbonylmethyl-1,4,7,10tetraaza-cyclododec-1-yl)-
acetic acid tert-butyl ester (77). .................................................................................................. 130 
(4,7,10-Tris-tert-butoxycarbonyl methyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid (76). .... 131 
2-Bromo-N-(prop-2-yn-1-yl) acetamide (80). .............................................................................. 132 
(1,4,7-Tris-tert-butoxycarbonylmethyl-10-prop-2-ynyl carbamoylmethyl-1,4,7,10- tetraaza-
cyclododec-1-yl)-acetic acid tert-butyl ester (78). ...................................................................... 133 
(1,4,7-Tris-carbonylmethyl-10-prop-2-ynyl carbamoylmethyl-1,4,7,10- tetraaza-cyclododec-1-yl)-
acetic acid (81). ......................................................................................................................... 134 
(1,4,7-Tris-carbonylmethyl-10-prop-2-ynyl carbamoylmethyl-1,4,7,10- tetraaza-cyclododec-1-yl)-
acetic acid europium (CA1-Eu). ................................................................................................. 135 
(1,4,7-Tris-carbonylmethyl-10-prop-2-ynyl carbamoylmethyl-1,4,7,10- tetraaza-cyclododec-1-yl)-
acetic acid gadolinium (CA1). .................................................................................................... 136 
1,4,7,10-Tetraaza-cyclododecane-1,7-dicarboxylic acid di-tert-butyl ester (83). ........................ 137 
4,10-Bis-benzyloxycarbonylmethyl-1,4,7,10-tetraaza-cyclododecane-1,7-dicarboxylic acid di-tert-
butyl ester (84). .......................................................................................................................... 138 
(7-Benzyloxy carbonyl methyl-1,4,7,10-tetraaza-cyclododec-1-yl)acetic acid benzyl ester (85). 139 
(4,10-Bis-benzyloxycarbonylmethyl-7-tert-butoxycarbonyl methyl-1,4,7,10-tetraaza-cyclododec-1-
yl)acetic acid tert-butyl ester (86). .............................................................................................. 140 
4,10-Bis-tert-butoxycarbonylmethyl-1,4,7,10tetraaza-cyclododecane-1,7-dicarboxylicacid di-tert-
butyl ester (91). .......................................................................................................................... 141 
(7-Carboxymethyl-1,4,7,10tetraaza-cyclododec-1-yl)acetic acid (92). ....................................... 142 
(7-Methoxycarbonylmethy-1,4,7,10tetraaza-cyclododec-1-yl) acetic acid methyl ester (88). ..... 143 
(4,10-Bis-tert-butoxycarbonylmethyl-7-methoxycarbonylmethyl- 1,4,7,10tetraaza-cyclododec-1-
yl)-acetic acid methyl ester (89). ................................................................................................ 144 
(4,10-Bis-tert-butoxycarbonyl methyl-7-carboxymethyl-1,4,7,10tetraaza-cyclododec-1-yl)-acetic 
acid (90). .................................................................................................................................... 145 
(7-tert-Butoxycarbonylmethyl-4,10-bis-prop-2-ynylcarbonylmethyl-1,4,7,10-tetraaza-cyclododec-
1-yl)-acetic acid tert-butyl ester (95)........................................................................................... 146 
7-Carbonylmethyl-4,10-bis-prop-2-ynylcarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic 
acid (96). .................................................................................................................................... 147 
4,10-Bis-methoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododecane-1,7-dicarboxylic acid di-tert-
butyl ester (87). .......................................................................................................................... 147 
7-Methoxycarbonylmethy-1,4,7,10-tetraaza-cyclododec-1-yl) acetic acid methyl ester (88). ..... 148 
4,10-Bis-prop-2-ynylcarbonylmethyl-1,4,7,10-tetraaza-cyclododecane-1,7-dicarboxylic acid di-
tert-butyl ester (93)..................................................................................................................... 149 
vii 
 
4,10-Bis-prop-2-ynylcarbonylmethyl-7-carboxymethyl-1,4,7,10tetraaza-cyclododec-1-yl)-acetic 
acid (94). .................................................................................................................................... 150 
1,7-Tris-tert-butoxycarbonylmethyl-4,10-bis-prop-2-ynyl carbamoylmethyl-1,4,7,10- tetraaza-
cyclododec-1-yl)-acetic acid tert-butyl ester (95). ...................................................................... 151 
1,7-Tris-carbonylmethyl-4,10-bis-prop-2-ynyl carbamoylmethyl-1,4,7,10- tetraaza-cyclododec-1-
yl)-acetic acid (96)...................................................................................................................... 152 
1,7-Tris-carbonylmethyl-4,10-bis-prop-2-ynyl carbamoylmethyl-1,4,7,10- tetraaza-cyclododec-1-
yl)-acetic acid europium (CA2-Eu). ............................................................................................ 153 
1,7-Tris-carbonylmethyl-4,10-bis-prop-2-ynyl carbamoylmethyl-1,4,7,10- tetraaza-cyclododec-1-
yl)-acetic acid gadolinium (CA2). ............................................................................................... 154 
2-tert-Butoxycarbonylamino-3-hydroxy-propionic acid (98). ....................................................... 155 
2-tert-Butoxycarbonylamino-3-hydroxy-propionic acid methyl ester (99). .................................. 156 
2-tert-Butoxycarbonylamino-acrylic acid methyl ester (100). ..................................................... 157 
Methyl-2-[(tert-butoxycarbonyl)amino]-3-(1,4,7,10-tetraaza cyclododec-1-yl) propanoate (102).
 ................................................................................................................................................... 158 
1,4-Dibenzyl-6-hydroxymethyl-6-nitroperhydro-1,4-diazepine (103). ......................................... 159 
6-Amino-6-hydroxymethylperhydro-1,4-diazepine  (104). .......................................................... 160 
1,4-Bis(t-butoxycarbonylmethyl)-6-[bis(t-butoxycarbonylmethyl)]amino-6-hydroxymethylperhydro-
1,4-diazepine (105). ................................................................................................................... 161 
1,4-Bis(t-butoxycarbonylmethyl)-6-[bis(t-butoxycarbonylmethyl)]amino-6-chloromethylperhydro-
1,4-diazepine (106). ................................................................................................................... 162 
1,4-Bis(t-butoxycarbonylmethyl)-6-[bis(t-butoxycarbonylmethyl)]amino-6-(prop-2-yn-1-
ylamino)methylperhydro-1,4-diazepine (110). ............................................................................ 163 
1,4-Bis(t-butoxycarbonylmethyl)-6-[bis(t-butoxycarbonylmethyl)]amino-6-(prop-2-yn-1-
ylcarbamate)methylperhydro-1,4-diazepine (114). .................................................................... 165 
1,4-Bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-(prop-2-yn-1-yl carbamate)methyl 
perhydro-1,4-diazepine (115). .................................................................................................... 166 
1,4-Bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-(prop-2-yn-1-yl carbamate)methyl 
perhydro-1,4-diazepine europium (CA4-Eu). ............................................................................. 167 
1,4-Bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-(prop-2-yn-1-yl carbamate)methyl 
perhydro-1,4-diazepine gadolinium (CA4). ................................................................................ 168 
2-Nitroimidazole (117)................................................................................................................ 169 
1-(2-Nitro-imidazol-1-yl)-propan-1-ol (119b). ............................................................................. 170 
2-Nitro-1-(2-p-toluenesulfonyloxyethyl)-1H-imidazole (122). ...................................................... 171 
1-(2-Azidoethyl)-2-nitro-1H-imidazole (TV1). ............................................................................. 172 
viii 
 
tert-Butyl-dimethy-(2-nitro-benzyloxy)-silane (124). ................................................................... 173 
1-(4-Nitrophenyl)prop-2-en-ol (129). .......................................................................................... 174 
1-Methoxymethoxy-1-(4-nitrophenyl)-2-propene (131). ............................................................. 175 
3-Methoxymethoxy-3-(4-nitrophenyl)propan-1-ol (133).............................................................. 176 
1-Azido-3-methoxymethyl-3-(4-nitrophenyl) propane (135). ...................................................... 177 
3-Azido-1-(4-nitrophenyl)propan-1-ol (137). ............................................................................... 178 
1-(3-Azido-1-chloropropyl)-4-nitrobenzene (TV3). ..................................................................... 179 
1-(2-Nitrophenyl)prop-2-en-1-ol (130). ....................................................................................... 179 
1-[1-(Methoxymethoxy)prop-2-en-1-yl]-2-nitrobenzene (132). ................................................... 180 
3-(2-Nitrophenyl)-3-(methoxymethoxy) propan-1-ol (134).......................................................... 182 
1-[Azido-1-(methoxymethoxy)propyl]-2-nitrobenzene (136). ...................................................... 183 
3-Azido-1-(2-nitrophenyl)propan-1-ol (138). ............................................................................... 184 
1-(3-azido-1-chloropropyl)-2-nitrobenzene (TV4). ...................................................................... 185 
1-(2-Nitrophenyl) propane-1,3-diol (139).................................................................................... 185 
3-Hydroxy-3-(2-nitrophenyl)propyl-4-methylbenzene sulfonate (140). ....................................... 187 
3-Azido-1-(2-nitrophenyl)propan-1-ol (138). ............................................................................... 188 
1-(2,4-Dinitrophenyl)prop-2-en-1-ol (142). ................................................................................. 189 
1-[1-(Methoxymethoxy)prop-2-en-1-yl]-2,4-dinitrobenzene (143). ............................................. 190 
3-(2,4-Dinitrophenyl)-3-(methoxymethoxy) propan-1-ol (144). ................................................... 191 
1-[3-azido-1-(Methoxymethoxy)propyl]-2,4-dinitrobenzene (145). ............................................. 192 
3-Azido-1-(2,4-dinitrophenyl)propan-1-ol (146). ......................................................................... 193 
1-(3-Azido-1-chloropropyl)-2,4-dinitrobenzene (TV5). ............................................................... 194 
1-N-Methyl-2-amino imidazole-5-carboxylic acid ethyl ester (149). ........................................... 194 
1-N-Methyl-2-nitroimidazole-5-carboxylic acid ethyl ester (150). ............................................... 196 
1-Methyl-2-nitro-1H-imidazole-5-carboxylic acid (153)............................................................... 197 
(1-Methyl-2-nitro-1H-imidazol-5-yl)methanol (152). ................................................................... 197 
2-Nitro-1H-imidazole-5-carbaldehyde (155). .............................................................................. 198 
1-Methyl-2-nitro-1H-imidazole-5-carbaldehyde (151). ............................................................... 199 
EG180 3-(Acetamino)-2-oxo-2H-chromen-7-yl acetate (159). ................................................... 199 
3-Azido-7-hydroxy-2H-chromen-2-one (DYE1). ......................................................................... 200 
ix 
 
6\QWKHVLVRIDOOµFOLFN¶SURGXFWV ................................................................................................. 201 
NMR Relaxivity Testing.............................................................................................................. 202 
Enzymatic Assay ....................................................................................................................... 202 
Bibliography ...................................................................................................................................... 204 
 
  
x 
 
List of Figures 
Figure 1. The relationship between ǻ( and Bo for spin up and spin down protons. (6) .......................... 3 
Figure 2 The angle of proton precession when in an external magnetic field. (6) ................................... 4 
Figure 3 Direction of the averaged total magnetism. (6) ......................................................................... 4 
Figure 4 The precession of Mo after RF pulse is applied. (6) .................................................................. 5 
Figure 5 A T1 weighted image using a contrast agent to show a brain lesion. ...................................... 9 
Figure 6 The three types of water molecule which undergo a change in relaxivity when in proximity to 
a paramagnetic ion. ..................................................................................................................... 10 
Figure 7 Contrast agents currently on the market.(13-15)....................................................................... 12 
Figure 8 HOPO based complexes. ..................................................................................................... 14 
Figure 9 A gadolinium fullerene complex (7). ...................................................................................... 16 
Figure 10 A gadolinium(III) contrast agent liposome. .......................................................................... 17 
Figure 11 A PAMAM dendrimer structure. .......................................................................................... 19 
Figure 12 The double gadolinium(III) ion complex with a xylene based core (10). The double 
gadolinium(III) ion complex with an iron terpyridine core (11). (29-30) ............................................ 20 
Figure 13 Antibody-enzyme conjugate. (34) .......................................................................................... 21 
Figure 14 Gd-DOTABAPTA 16 (40)  and the bispolyazamacrocyclic sensor (17). (41) ........................... 25 
Figure 15 Graphical representation of how the ratio between transverse and longitudinal relaxation 
rates are concentration independent but pH dependent. ............................................................. 26 
Figure 16 The breakdown of the large cyclodextran macromolecule on thiol reduction. Reproduced 
from Ref. (48) with permission from The Royal Society of Chemistry. ........................................... 27 
Figure 17 A liposome contrast agent with a SPIO core 22. ................................................................. 28 
Figure 18 Insertion of nanoparticles into a ferritin shell. ...................................................................... 29 
Figure 19 Manganese enhancement in a rat brain after brain ischemia. ............................................ 31 
Figure 20 Mn-DPDP 27. (62) ................................................................................................................. 32 
Figure 21 Distribution of spins in two distinct pools before and after a CEST irradiation pulse. .......... 33 
Figure 22 DOTA (28) and DO3A (29). (65) ............................................................................................ 34 
Figure 23 The SA and TSA [LnDOTA]- (Ln = Sc(III) on left, Tm(III) on right) conformers. Reprinted 
with permission from (65). Copyright (2003) American Chemical Society ...................................... 35 
Figure 24 The AAZTA ligand (44). (75) ................................................................................................. 40 
Figure 25 A modified AAZTA ligand (45) at the sp3 carbon. (79) ........................................................... 41 
Figure 26 Pathways taken by HIF-1 in normoxic and hypoxic conditions. .......................................... 43 
Figure 27 18F-FMISO 56. (81) ................................................................................................................ 45 
Figure 28 Optical 2-nitroimidazole based hypoxia markers. (88) (89) ...................................................... 46 
Figure 29 Cu-ATSM 59. (91) ................................................................................................................. 47 
Figure 30 Nitrobenzyl based cancer prodrugs (60,61). (93) (94).............................................................. 49 
Figure 31 Tirapazamine 62. (97) ........................................................................................................... 50 
Figure 32 AQ4N 63 and its hypoxia activated form (64). (96) ................................................................ 50 
Figure 33 Hypoxia activated quinone based drugs (65 and 66). (101) ................................................... 51 
Figure 34 a Tri-dentate Co(III) mustard complex (67) (106) ................................................................... 52 
Figure 35 Short triazole linker used to conjugate the MRI contrast agent to the hypoxia targeting 
vector. .......................................................................................................................................... 53 
Figure 36 DOTA based contrast agents to be synthesised. (CA1/CA2) .............................................. 54 
Figure 37 [GdAAZTA]- based contrast agent to be synthesised. (CA4) .............................................. 55 
Figure 38 Initial 2-nitroimidazole based targeting vector to be synthesised. (TV1) ............................. 56 
Figure 39 The nitrobenzyl based targeting vectors to be synthesised. (TV3/TV4/TV5) ...................... 57 
Figure 40 2-nitroimidazole based targeting vector to be synthesised (TV6)........................................ 58 
Figure 41 Coumarin dye to be synthesised. (DYE1) ........................................................................... 59 
Figure 42 Contrast Agent 1. ................................................................................................................ 63 
xi 
 
Figure 43 Contrast Agent 2 CA2 and a potential multimodal contrast agent 72. ................................. 70 
Figure 44 Contrast Agent 3. ................................................................................................................ 75 
Figure 45 Contrast Agent 4 ................................................................................................................. 77 
Figure 46 Targeting Vector 1 TV1. ...................................................................................................... 85 
Figure 47 The two possible regioisomers after propylene oxide opening. .......................................... 86 
Figure 48 Targeting vector 2 ............................................................................................................... 88 
Figure 49 Modified targeting vectors 3 and 4 ...................................................................................... 89 
Figure 50 Targeting vector 5. .............................................................................................................. 92 
Figure 51 Targeting vector 6 ............................................................................................................... 95 
Figure 52 Coumarin Dye DYE1 ......................................................................................................... 102 
Figure 53 Copper (I) ligands TBTA and THPTA. (163)......................................................................... 103 
Figure 54 Inversion recovery pulse sequence. (117) ........................................................................... 107 
Figure 55 A T1 weighted composite image of the DO3A complex with inversion times of 20 to 2500 
ms. ............................................................................................................................................. 108 
)LJXUH$W\SLFDOHYDOXDWLRQRI05VFDQY¶VWLPHQHHGHGWRFDOFXODWH71. ..................................... 108 
Figure 57 The correlation between calculated T1 and Concentration for Gd(III)DO3A (CA1). .......... 109 
Figure 58 Final complexes synthesised. ........................................................................................... 116 
List of Schemes 
6FKHPH7KHUHOHDVHRIȕ-galactopyranoside and carbonate to produce a water binding site in 
the presence of ȕ-galactosidase. (35) ......................................................................................... 22 
Scheme 2 Copper activation of a "smart" MRI contrast agent. (37) ............................................ 24 
Scheme 3 Activation of 4NO22MeSAGd under hypoxic conditions. (50) ..................................... 27 
Scheme 4 Cyclen 35 formation used by Richman et al. (71) ...................................................... 36 
Scheme 5 Synthesis of the protected DO3A complex (40) as developed by the Thomas group. 
(8)
 ............................................................................................................................................... 37 
Scheme 6 Formation of protected DO3A 40 developed by Machitani et al. (72) ......................... 38 
Scheme 7 Formation of the Europium(III) propargyl DOTA complex CA1-Eu. (73) .................... 39 
Scheme 8 Synthesis of the AAZTA ligand (44). (79) ................................................................... 41 
Scheme 9 The reaction undertaken by 2-nitroimidzole once under hypoxic conditions resulting 
in cell localisation. ..................................................................................................................... 44 
Scheme 10 The enzymatic conversion of a nitro group to an amine under hypoxic conditions.  
(83)
.............................................................................................................................................. 45 
Scheme 11 The release of a leaving group to produce a reactive methylene functionality in nitro 
benzene based compounds under hypoxic conditions.............................................................. 56 
Scheme 12 Mechanism by which the reduced nitro group will bind irreversibly in the hypoxic 
cell ............................................................................................................................................ 58 
Scheme 13 Initial synthesis of tert-butyl protected DO3A. ........................................................ 64 
Scheme 14 Used synthesis of DO3A. ....................................................................................... 65 
Scheme 15 Synthesis of the carboxylic acid derivative of the tri-protected DOTA complex (76).
 .................................................................................................................................................. 66 
Scheme 16 Methyl acetate route to the free carboxylic acid intermediate (76). ........................ 67 
xii 
 
Scheme 17 Attempts to introduce the propargyl group using standard peptide coupling 
methods. ................................................................................................................................... 68 
Scheme 18 Synthesis of 2-bromo-N-(prop-2-yn-1-yl)acetamide 80 .......................................... 68 
Scheme 19 Final synthesis route for complex 1 (CA1) ............................................................. 69 
Scheme 20 Route 1 towards the synthesis of a bifunctional chelator (86). ............................... 71 
Scheme 21Route 2 towards the synthesis of a bi-functional chelator (CA2). ........................... 72 
Scheme 22 Second synthesis of the bis-methylacetate substituted cyclen 88. ........................ 73 
Scheme 23 Final synthesis of the bi-functional chelator 86 and the respective lanthanide 
complexes CA2 and CA2-Eu. ................................................................................................... 74 
Scheme 24 Synthesis towards a DO3A-N-Į-aminopropinate based chelator CA3................... 76 
Scheme 25 Michael addition of the dehydroalanine 100 onto the unsubstituted cyclen 35. ..... 77 
Scheme 26 Synthesis of key intermediate 105 of the AAZTA based complex CA4. ................ 79 
Scheme 27 Attempted mesylation of the hydroxyl AAZTA complex 105. ................................. 79 
Scheme 28 Formation of [8,11-bis-tert-butoxy carbonylmethyl-3-oxo-4-oxa-1,8,11-triaza-
spiro[5.6]dodec-1-yl]]-aceticacid tert-butyl ester 107 in the presence of a base. ...................... 80 
Scheme 29 Attempt to form an ether linkage 109 using propargyl bromide.............................. 81 
Scheme 30 Attempted synthesis of the AAZTA based contrast agent CA4 using a nitrogen 
bridge. ....................................................................................................................................... 82 
Scheme 31 Attempt to form the carbamate derivative 114 using the Curtius rearrangement ... 83 
Scheme 32 Synthesis of the AAZTA based complex CA4. ....................................................... 84 
Scheme 33 Route 1 towards the synthesis of the 2-nitroimidazole based targeting vector TV1.
 .................................................................................................................................................. 85 
Scheme 34 Route 2 towards the synthesis of the 2-nitroimidazole based targeting vector TV1.
 .................................................................................................................................................. 86 
Scheme 35 Route 3 towards the synthesis of the 2-nitroimidazole based targeting vector TV1.
 .................................................................................................................................................. 87 
Scheme 36 Completed synthesis of a simple 2-nitroimidazole targeting vector TV1. ............... 88 
Scheme 37 Route 1 for the synthesis of an alternative targeting vector based on 2-
Nitrobenzene (TV2)................................................................................................................... 89 
Scheme 38 Synthesis of para and ortho-nitrobenzyl targeting vectors TV3 and TV4. .............. 91 
Scheme 39 Alternative synthesis of the ortho-nitrobenzyl targeting vector TV4. ...................... 92 
Scheme 40 Synthesis of the 2,4-dinitrobenzyl targeting vector TV5. ........................................ 94 
Scheme 41 Synthesis of the functionalised 2-aminoimidazole heterocycle 149. ...................... 96 
Scheme 42 Diazatisation of the substituted 2-aminoimidazole 149. ......................................... 97 
Scheme 43 Attempted synthesis of 1-methyk-2-nitro-imidazole-5-carbaldehyde 151. ............. 98 
Scheme 44 Alternative synthesis of 2-nitro-4(5)-imidazolecarboxaldehyde 155 and 1-methyl-2-
nitro-imidazole-5-carbaldehyde 151 .......................................................................................... 99 
Scheme 46 "Click reaction between contrast agent 1 CA1 and targeting vector 3 TV3. ........... 99 
Scheme 47 Attempts at the 'click' reaction using the protected DO3A complex (78) and 
targeting vector 1 TV1............................................................................................................. 101 
xiii 
 
Scheme 48 Synthesis of azido coumarin dye (DYE1)............................................................. 102 
Scheme 49 Conversion of Xanthine 162 and 2-nitroimidazole 117 using Xanthine oxidase and 
hypoxic conditions................................................................................................................... 112 
Scheme 50 Potential route to the protected amine DOTA derivative (167)............................. 117 
Scheme 51 Potential conjugation of the AAZTA complex 105 to a targeting vector with an 
ethylene diamine linker. .......................................................................................................... 118 
List of Tables 
Table 1 Comparison between the [GdDOTA]- and [GdAAZTA]- complexes with regards to 
relaxivity and transmetallation. (68) (80) (110) (111) (112)...................................................................... 55 
Table 2 Table of final compounds to be synthesised. (C1-7) .................................................... 59 
Table 3 Table summarising the solvent optimisation of the 'click' reaction. ............................ 100 
7DEOH<LHOGVIRUWKHµFOLFN¶UHDFWLRQXVHGWRSURGXFHWKHILQDOFRPSRXQGV .......................... 104 
Table 5 Relaxivity values of the compounds tested. ............................................................... 109 
Table 6 The methods used to try and achieve a hypoxic environment. .................................. 113 
 
List of Equations 
Equation 1 The relationship between precession of a proton and the external magnetic field. Ȗ 
is the gyromagnetic ratio (2.7 x 108rads-1T-1 for a proton). (5) ...................................................... 2 
Equation 2 The difference in energy between parallel and antiparallel aligned protons with 
regards to the magnetic field, gyromagnetic ratio and Plancks constant. (h (6.626 x 10-34Js)). (6)
 .................................................................................................................................................... 3 
Equation 3 The ratio between the number of protons found in the spin up and the spin down 
state. (6) ....................................................................................................................................... 4 
Equation 4 The relationship between the frequency and length of the pulse to produce the 
desire pulse angle. RF pulse (Ȧ1),  length of the pulse (tp). (6) ..................................................... 6 
Equation 5 The relationship between the concentration of the contrast agent and the 
magnetism present to produce the intensity seen on the MRI scan. (8) ....................................... 7 
Equation 6 An equation to show how the observed relaxation is the sum of relaxation rate 
contributions from both the underlying tissue and the contrast agent. (10) ................................... 8 
Equation 7 An equation to show how the relaxation rate of the contrast agent is dependent on 
both the inherent relaxivity of the contrast agent, and its localised concentration.  (10) ................. 8 
Equation 8 An equation to show the relationship between the observed T1, the T1 of the tissue 
and the relaxivity of the contrast agent. (10).................................................................................. 9 
Equation 9 An equation to show how the overall relaxation rate of the contrast agent is 
comprised of contributions from both inner sphere and outer sphere relaxation. (10) ................. 11 
Equation 10 Equation used to calculate the T1 value from the signal intensity. ........................ 61 
 
  
xiv 
 
Abbreviations 
2D 2 Dimensions 
3D 3 Dimensions 
AAZTA 1,4-Bis(hydroxycarbonylmethyl)-6-[bis(hydroxycarbonylmethyl)]amino-6-methyl-
perhydro-1,4-diazepine 
Ac Acetate 
ADEPT Antibody directed enzyme prodrug therapy  
ATP Adenosine triphosphate 
ATSM Diacetyl-bis(N4-methylthiosemicarbazone) 
BAPTA  1,2-Bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 
BOC tert-Butyloxycarbonyl 
BOLD Blood oxygen level dependent 
bs Broad singlet 
C Concentration 
C1  Complex 1 
CDI 1,1'-Carbonyldiimidazole 
CEST Chemical exchange saturation transfer 
CT Computed tomography 
d Doublet 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC Dicyclohexycarbodiimide 
DCM Dichloromethane 
dHb Deoxyhaemoglobin 
DIBAL-H Diisobutylaluminium hydride 
DIPEA Diisopropylethylamine 
DMAP 4-Dimethylaminopyridine 
DMF Dimethylformamide 
DNA Deoxyribonucleic acid 
DO3A 1,4,7-Triscarbonylmethyl-1,4,7,10-tetraazacyclododecane 
xv 
 
DOTA 1,4,7,10-Tetraazacyclododecanetetraacetic acid 
DPDP Dipyridoxal-diphosphate 
DPPA Diphenylphosphoryl azide 
DSPC 1,2-Diastearoyl-sn-glycerol-3-phosphocholine  
DTPA Diethylenetriaminopentacetic acid 
E.coli Escherichia coli 
EDC 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EF5 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentauoropropyl) acetamide 
EI Electron impact 
ESI Electrospray ionisation 
Et Ethyl  
FLOOD Flow and oxygen dependent contrast 
FMISO F-misonidazole 
Fmoc 9-Fluorenylmethyloxycarbonyl 
GSH Glutathione 
h Plancks constant (6.626 x 10-34Js) 
Hb Haemoglobin 
HBTU O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate 
HIF-1 Hypoxia inducing factor 1  
HOBt Hydroxybenzotriazole 
HOPO Hydroxypyridinone 
HPLC High performance liquid chromatography 
HRMS High resolution mass spectrometry 
I Intensity on MRI scan 
IR Infrared spectroscopy 
Kd Dissociation constant 
Kex Exchange constant 
LD50 50% of lethal dose 
Ln Lanthanide metal 
xvi 
 
M Magnetism present and Molar 
m Multiplet 
Ms Spin quantum number 
Me Methyl 
Mo Net magnetism 
MOM Methoxy methyl ether 
mp Melting point 
MRI Magnetic resonance Imaging 
Ms Mesyl 
N+1/2 Number of protons in the +1/2 spin state  
N
-1/2 Number of protons in the -1/2 spin state  
NMR Nuclear magnetic resonance 
PAMAM Polyamidoamine  
PBS Phosphate buffered saline 
PE Petroleum ether 
PEG Polyethylene glycol 
PET Positron emission tomography 
PO2 Oxygen partial pressure  
q Number of water molecules bound to the central ion 
q quartet 
QDOTAMA 1-(N-Quinolin-8-yl-acetamide)-4,7,10-tris(acetic acid)-1, 4,7,10-
tetraazacyclododecane 
r1 Relaxivity 
R1, CA Contrast agent relaxation rate 
R1, obs Observed relaxation rate 
R1, outer Outer-sphere contribution to relaxation rate 
R1, tissue Tissue relaxation rate 
R1,inner Inner-sphere contribution to relaxation rate 
R1p Longitudinal paramagnetic relaxation rate 
xvii 
 
R2p Transverse paramagnetic relaxation rate 
RF Radiofrequency pulse 
RNA Ribonucleic acid 
s Singlet 
SA Square antiprismatic 
siRNA Small interfering RNA  
SN2 Substitution Nucleophilic Biomolecular 
SPECT Single photo-emission tomography 
SPIO Superparamagnetic iron oxide 
Su Succinimide 
T Temperature 
t Triplet 
T1 Longitudinal relaxation time  
T1,obs Observed T1  
T1,tissue Tissue T1 
T2 Transverse relaxation time 
T2* Transverse relaxation time constant 
TBAF Tetra-n-butylammonium fluoride 
TBS tert-Butyl dimethylsilyl  
TBTA Tris(triazolyl)benzylamine 
tBu tert-Butyl 
TEA Triethylamine 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
THPTA Tris(hydroxypropyltriazolyl)methylamine 
Ts Tosyl 
TSA Twisted square antiprismatic 
TV Targeting vector 
UV Ultra-violet  
xviii 
 
ȕ Pulse angle 
Ǻo Applied magnetic field 
Ȗ Gyromagnetic ratio (2.7 x 108rads-1T-1 for a proton) 
įC Carbon NMR shift 
ǻE  Energy difference 
įH Proton NMR shift 
ț Boltzmann constant (1.38 x 10-23JK-1) 
ʅspin Magnetic moment 
Ȟmax Frequency maximum 
Ĳp Pulse length 
ĲR Rotational correlation time 
Ȧ1 Pulse frequency 
Ȧo Larmour frequency 
  
  
  
  
  
  
 
 
1 
 
Chapter 1 - Introduction 
1.1 Magnetic Resonance Imaging 
Non-invasive imaging of the human body is a valuable tool in modern medicine, 
with a range of techniques in clinical use. The major imaging system used 
today is X-ray technology that was originally invented in 1895 by Wilhelm 
Röentgen. (1) Though other imaging systems including computed tomography 
(CT), nuclear medicine such as positron emission tomography (PET) and single 
photon emission computed tomography (SPECT), ultrasound and magnetic 
resonance imaging (MRI) are also widely available. 
Without these techniques, clinicians would struggle to diagnose many serious 
diseases, such as multiple sclerosis, foetal spina bifida and certain cancers. 
These diseases would typically have been diagnosed only when they became 
much more advanced, resulting in a poorer prognosis and requiring patients to 
undergo significantly more invasive procedures.  
MRI is a favourable method of visualising the body for three major reasons: its 
non-invasive nature; JRRG VSDWLDO UHVROXWLRQ RI  µm in 3D; and lack of 
adverse effects from either the magnetic field or the radiofrequency (RF) pulses 
used clinically, even to foetuses. (2) 
The magnetic resonance phenomenon was discovered independently by Bloch 
and Purcell in 1946, but it was not until 1973 that the first image was produced. 
(3)
 In 1971 Damadian proved that natural and certain pathogenic tissues had 
different proton relaxation times, yet it took until 1977 for Damadian, Minkoff 
and Goldsmith to produce the first human scan using this technology. Although 
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this initial scan took five hours to complete, imaging has since been reduced to 
mere seconds and in 1999 the first portable MRI technology produced by 
Magne Vu (TM) became commercially available. (4) 
1.1.1 NMR Principles 
MRI is based on the same principles as nuclear magnetic resonance (NMR), 
though most medical MRI uses the protons within the body to produce an 
image. 
The nucleus of a hydrogen atom is a single positively charged proton that 
precesses constantly around an axis. Like all other nuclei a proton has its own 
magnetic field, called its magnetic moment, or µspin. 
If an external magnetic field is applied to a proton, the nucleus will experience a 
force that is called torque as it is forced to align with the applied field (Bo). The 
precession that the proton undergoes now it is aligned with the external 
magnetic field is proportional to the external field and described by the Larmor 
frequency (Ȧo) in Equation 1. (5) 
 
Equation 1 The relationship between precession of a proton and the external magnetic 
field. Ȗ is the gyromagnetic ratio (2.7 x 108rads-1T-1 for a proton). (5)  
During the application of the external field the proton will either align parallel or 
antiparallel with the field, thus creating two different proton spin-states. These 
spin states are both thermodynamically stable but differ slightly in energy. This 
difference is characterised by the spin quantum number ms, though the extent 
of the energy difference is dependent on the extent of the external magnetic 
field, as seen in Figure 1. (6)  
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Figure 1. The relationship between ǻE and Bo for spin up and spin down protons. (6)  
The energy difference in Hertz (Hz) can be calculated using Equation 2.  
 
Equation 2 The difference in energy between parallel and antiparallel aligned protons 
with regards to the magnetic field, gyromagnetic ratio and Plancks constant. (h (6.626 x 
10-34Js)). (6)  
The ratio between the populations of protons in each of these states is not 
equal, instead there are marginally more protons to be found in the +1/2 spin 
state compared to the -1/2 at room temperature, and the ratio of these spin 
states can be calculated using a Boltzmann equation (Equation 3). 
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Equation 3 The ratio between the number of protons found in the spin up and the spin 
down state. (6) 
At equilibrium the protons precess at an angle out of phase in the z axis in the 
magnetic field (Figure 2). 
 
Figure 2 The angle of proton precession when in an external magnetic field. (6)  
When the net magnetism (Mo) is calculated it is found to be aligned with the 
main field Bo in the z axis (Figure 3). 
 
Figure 3 Direction of the averaged total magnetism. (6)  
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It is impossible to measure the net magnetism when the protons are in 
equilibrium with the external field, as the net magnetism is in the order of 
microtesla (µT), and thus negligible when compared to the external field, which 
is in the region of 3-5 tesla (T). The net magnetism can be measured when it is 
rotated into the transverse x,y plane, and a transverse plane detector is used. 
The precession towards the x,y plane in the direction of the y axis can be 
caused by applying a RF pulse created by a coil placed along the x-axis (Figure 
4). 
 
Figure 4 The precession of Mo after RF pulse is applied. (6)  
The angle through which the RF pulse can rotate is related to Equation 4. Most 
MRI scanners calculate the length of the pulse so that the pulse angle (ȕ) is 
equal to ʌ/2 (90o) or ʌ (180o). 
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Equation 4 The relationship between the frequency and length of the pulse to produce 
the desire pulse angle. RF pulse (Ȧ1),  length of the pulse (tp). (6)  
After the pulse has been removed, the protons start to relax back to their 
equilibrium state. There are two types of relaxation, both independent of each 
other, longitudinal relaxation and transverse relaxation. 
The longitudinal relaxation time (T1) is inversely dependent on the field 
strength. During the RF pulse the population of protons in the spin up and spin 
down positions in the x,y plane is equal. Once the RF is removed the imbalance 
found at equilibrium is restored. This longitudinal relaxation can take up to a 
few seconds to equilibrate. (6)  
The transverse relaxation time (T2), also known as the spin-spin relaxation time 
is independent of field strength, and involves the loss of magnetism in the x,y 
plane back to zero at equilibrium. Compared to the T1 relaxation time, T2 is very 
quick and only requires milliseconds to reach equilibrium. For example the T1 
for fluids is 1500-2000 ms, whilst the T2 is 700-1200 ms, and the T1 for lipids is 
192 ms, compared to 10-100 ms for the T2. (2)  
1.1.2 Applying NMR Principles to MRI. 
Since clinical MRI uses protons to produce an image, it relies on the fact that 
the human body is composed of between 55% and 78% water depending on 
the tissue type. (7) These water molecules are found within three main 
environments: the fluids, such as blood and lymph; the water based tissues, 
including muscles and the brain; and finally the fat based tissues, such as the 
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adipose and bone marrow. The protons present in these environments have 
different relaxation times, with fat based tissue protons having a much shorter 
relaxation times than the fluid protons. Due to this effect an image in grey scale 
can be built up with regards to the magnetism at the point of acquisition. 
The other factor that affects the intensity of the image shown is the 
concentration of protons at the specific location. This relationship is shown in 
Equation 5. 
 
Equation 5 The relationship between the concentration of the contrast agent and the 
magnetism present to produce the intensity seen on the MRI scan. (8) 
During a typical MRI scan, the RF pulse is repeated at a constant rate and the 
overall data is averaged. This can help improve contrast as those protons in 
environments with long relaxation times will not fully relax in between pulses 
creating a lower intensity. Scans are either T1 or T2 weighted; the main 
difference between them is that in T1 weighted scans protons with a longer 
relaxation time appear darker whilst in T2 weighted images they appear 
brighter. T2 weighted images can also have less picture clarity as shorter T2 
relaxation times produce broader line widths, and if they get too broad this 
becomes indistinguishable from background noise. (8)  
1.2 MRI Contrast Agents 
MRI can detect different tissues due to variations in relaxivity of the protons in 
these environments. The same is the case with pathogenic tissues versus 
normal tissues as proven by Damadian in 1977. (9) However, in some cases the 
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pathogenic defects vary only slightly from the normal tissues, such as in the 
case of cerebral lesions of the blood brain barrier. In this instance a contrast 
agent is used as it allows for visualisation of tissue changes not easily seen on 
a standard magnetic resonance image. 
The total effect a contrast agent can have on improving the images can be 
calculated by measuring the relaxation rate using a MRI scanner. It must be 
remembered that the observed relaxation rate consists of contributions from 
both the intrinsic relaxation rate of the tissue, and the relaxation rate of the 
contrast agent, as seen in Equation 6.  
 
Equation 6 An equation to show how the observed relaxation is the sum of relaxation 
rate contributions from both the underlying tissue and the contrast agent. (10)  
Since the relaxation rate of the contrast agent is dependent on both the intrinsic 
relaxivity and the concentration of the contrast agent,  
Equation 7 can be produced.  
 
Equation 7 An equation to show how the relaxation rate of the contrast agent is 
dependent on both the inherent relaxivity of the contrast agent, and its localised 
concentration. (10)  
As R1 is equal to 1/T1 this leads to Equation 8 that shows the concentration of 
contrast agent is linearly proportional to the relaxivity.  
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Equation 8 An equation to show the relationship between the observed T1, the T1 of the 
tissue and the relaxivity of the contrast agent. (10)  
This equation illustrates that the two previously mentioned factors, 
concentration of protons and local relaxation, affect the intensity seen on the 
MR image. Since increasing proton density at specific locations is impractical, 
the best option is to add a compound that affects the relaxation time of the local 
protons. The current method of choice involves the use of a paramagnetic 
metal ion complex that enhances imaging by greatly decreasing T1, this is 
usually a gadolinium(III) based complex which contains seven unpaired 
electrons. These ions increase the relaxation rate of the surrounding and 
interchangeable water molecules, and thus increase the intensity in T1 
weighted images producing a bright white area (Figure 5). (10)  
 
Figure 5 A T1 weighted image using a contrast agent to show a brain lesion. 
 Reprinted with permission from (11). Copyright (2009) American Journal of 
Roentgenology  
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The complexed paramagnetic ion is surrounded by three types of water 
molecule. The inner-sphere water molecules are bound directly to the 
paramagnetic ion, these can interchange with the surrounding bulk water and 
produce the greatest effect on the overall relaxivity due to it proximity to the 
paramagnetic ion. The second-sphere water molecules, are hydrogen bonded 
to the organic chelate binding the paramagnetic ion. They undergo rapid 
exchange with the surrounding bulk water and their relaxivity is much less 
affected, due to the larger distance to the metal ion and the shorter period of 
time they reside on the complex before undergoing exchange. The final outer-
sphere or bulk water comprises of the water surrounding the complex as the 
contrast agent diffuses through the tissue (Figure 6). All of these spheres 
contribute to the total relaxation rate of the contrast agent as seen in Equation 
9. (12) 
 
Figure 6 The three types of water molecule which undergo a change in relaxivity when in 
proximity to a paramagnetic ion.  
Reprinted with permission from (12). Copyright (2010) The Pharmaceutical Society of 
Japan  
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Equation 9 An equation to show how the overall relaxation rate of the contrast agent is 
comprised of contributions from both inner sphere and outer sphere relaxation. (10) 
The mechanism of exchange found for the inner-sphere water molecules is a 
dissociative one, where the present molecule leaves the central gadolinium ion 
to form an eight coordinate complex in most cases, before another water 
molecule can coordinate to reform the parent structure. (8)  
Although paramagnetic ions such as gadolinium(III) effectively reduce T1 
relaxation time, the metal must be complexed sufficiently with organic ligands, 
as the metal ion itself has a high toxicity at the dose administered to patients. 
This is due to JDGROLQLXP,,,¶V VLPLODU VL]H DQG GRQRU DELOLW\ WR FDOFLXP(II). 
Therefore, free gadolinium(III) can bind to serum proteins at calcium sites and 
irreversibly enter bone. To prevent these side effects the chelator must strongly 
bind to the gadolinium(III) in a thermodynamically and kinetically stable manner. 
(10)
  
1.2.1 Current Contrast Agents 
There are several gadolinium(III) based contrast agents on the market, the 
most common of which are; Magnevist (1) (Bayer HealthCare 
Pharmaceuticals), (13) Omniscan (2) (GE Healthcare) (14) and Prohance (3) 
(Bracco Diagnostics) (15). These compounds are all administered intravenously 
(0.1 mmol/Kg dose) and are excreted via the kidneys within 24 hours. (16) They 
effectively visualise vasculature in the brain, spine and associated tissues, with 
regards to viewing lesions and abnormalities within these structures, however 
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there are many pathogenic tissues, such as certain tumours that are difficult to 
visualise effectively with the current contrast agents.  
Figure 7 Contrast agents currently on the market.(13-15) 
 These commercially available compounds are not perfect and are in need of 
optimisation. Due to the need for strong chelation, all of the commercially 
available compounds routinely used are octadentate, leaving only one free site 
for inner-sphere water molecules, and are therefore more dependent on 
second-sphere binding. They also are far from optimal with regards to inner-
sphere water molecule lifetimes, with a proton lifetime of 230 ns (Prohance) 
instead of the calculated optimal of 13 ns. (17) The other phenomenon affecting 
relaxivity is a property called reorientation correlation time (molecular tumbling), 
in which the slower the tumbling, the greater the increase in relaxivity. This 
effect is best observed in large rigid molecules, and thus the relatively small 
commercial contrast agents benefit little from molecular tumbling.  
Nephrogenic Systemic Fibrosis 
The most severe side effect of gadolinium(III) contrast agents is nephrogenic 
systemic fibrosis. This disease can cause fibrosis of the skin, joints, eyes and 
internal organs, which if severe enough can even lead to the death of the 
patient. Whilst first described in 2000, it was not until 2006 that the connection 
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between the disease and gadolinium (III) based contrast agents was made. The 
contrast agent most associated with this disease is Omniscan, a non-ionic 
linear agent, which has poor kinetic stability for gadolinium(III), and a Kd value 
of 1.4x10-17 M, (18) and is thus more likely to release into the blood, unlike 
Prohance which is more stable, due to its crown based structure,  (19) with a Kd 
value of 1.5x10-24 M. (18) As the pH in the kidneys is lower than that of the 
surrounding tissues the gadolinium(III) is more likely to be released by the 
chelators with poor kinetic stability. For this reason the disease is seen almost 
exclusively in patients with acute or chronic renal failure, who due to their 
slower glomerular filtration rate have the contrast agent lingering longer in their 
bodies, and thus the gadolinium(III) is more likely to separated from the chelate. 
Since this connection has been made, gadolinium(III) based contrast agents 
have been withheld from patients with a glomerular filtration rate of <30 mL min-
1
, resulting in there being no new reported cases of the disease since 2008. (20) 
1.2.2 Experimental Contrast Agents 
There are relatively few contrast agents that have passed into clinical usage: 
however, there are many novel therapeutics in the literature that are aimed to 
produce more effective and targeted contrast agents to be used in conjunction 
with MRI. These experimental ideas can be categorised with regards to how 
they try and improve upon the commercially available contrast agents, with the 
main areas of research outlined below. 
Increased inner-sphere water molecules 
By doubling the number of inner-sphere water molecules, you can double the 
number of water molecules affected by the paramagnetic ion. 
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Hydroxpyridinone ligands 
Hydroxypyridinone (HOPO) complexes are a series of molecules designed to 
replace the current eight coordinated nitrogen and oxygen donor chelators on 
the market today. The HOPOs are chelators that consist of just oxygen donors, 
and since they occupy fewer sites on the central gadolinium(III) ion an extra 
water molecule can bind forming a q = 2 (q = number of water molecules bound 
to the central ion,) chelate instead of the usual q = 1. Unlike other current 
contrast agents, the HOPO molecules do not require a change of conformation 
to achieve the eight coordinated intermediate, reducing the energy required for 
water exchange. This increased exchange rate results in a greatly increased 
relaxivity with values of 10.5 mM-1s-1, compared to 4-5 mM-1s-1 (20 MHz 298 K), 
for those compounds already on the market. Poor solubility was a problem with 
these compounds which has been partially solved by the addition of 
polyethylene glycol (PEG) to the terephthalamide ligand of the Gd-TREN-
bisHOPO-TAM complex (6) (Figure 8). (21)  
 
Figure 8 HOPO based complexes.  
Reprinted with permission from  (21). Copyright (2005) American Chemical Society  
 
4 5 6 
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Increased gadolinium concentration at site 
The sensitivity of MRI is very low, so to combat this, a high concentration of 
contrast agent is required. One way to produce this high concentration is to 
synthesise molecules capable of carrying a high payload. 
Fullerene ligands 
A recent development now available is the use of fullerenes to contain a 
payload of gadolinium(III) ions. Originally only 4 % of gadolinium(III) 
endohedrals were of the soluble Gd@C82 fullerene, since then it has been 
possible to produce a series of Gd@C60 fullerenes that are highly soluble and 
air stable. These are Gd@C60[C(COOH)2]10 7 and 
Gd@C60[C(COOCH2CH3)2]10, (Figure 9) and they have been proven to have 
similar relaxivities to the commercial contrast agents with values of 4.6 mM-1 s-1 
(20 MHz, 298 K) despite relying on outer sphere contributions. These 
compounds also prevent any release of gadolinium(III) ions, and thus reduce 
the risk of nephrogenic systemic fibrosis. (22) Other gadofullerenes such as 
Gd3N@C80(OH)26 (CH2CH2COOH)16 have shown relaxivity values of up to 282 
mM-1 s-1 (0.47 T, 298 K) at 2.4 T, which is over fifty times greater than that seen 
for the commercial contrast agents. (23)  
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Figure 9 A gadolinium fullerene complex (7).  
Reprinted with permission from  (22). Copyright (2003) American Chemical Society  
 
Liposomes 
A series of liposomes containing chelated gadolinium(III) ions have been 
synthesised. The liposome technology is well established and can carry 
significantly larger payloads than a single chelator. Since they have already 
been generally optimised with regards to stability, circulation times and 
membrane composition, liposomes of between 5-500 nm in size can be easily 
modified to include MRI active paramagnetic ions, or a fluorescent molecule for 
imaging and targeting vectors for localisation. A typical MRI contrast liposome 
can be seen in Figure 10. (24)  
7 
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Figure 10 A gadolinium(III) contrast agent liposome.  
Reprinted with permission from  (24). Copyright (2004) American Chemical Society  
One specific use of the contrast liposomes has been to target sites of apoptosis 
(programmed cell death). When tumour cells react to radiation and 
chemotherapy they usually undergo apoptosis, and by measuring this via a 
medium such as MRI, a patients response to a specific treatment can be 
visualised. When a cell undergoes apoptosis, the lipid phosphatidylserine 
translocates to the external layer of the cell membrane, which can then be 
detected via conjugation to the proteins annexin A5 or synaptotagmin I in the 
presence of calcium(II). Targets for these proteins can be incorporated into the 
liposome bilayer allowing for liposome localisation at the tumour site. (25) Other 
interesting targeting molecules such as the peptide Įvȕ3 integrin (a marker for 
angiogenesis) can be added via conjugation to the head of 1,2-diastearoyl-syn-
glycerol-3-phosphocholine (DSPC) via a PEG linker. (26)  
8 
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Decreased molecular tumbling 
Decreasing the molecular tumbling rate has been shown to increase relaxivity 
of the contrast agents at clinical imaging fields (0.5-1.5 T). The best way to 
achieve this is by significantly increasing the molecular weight of the contrast 
agent. 
Contrast agents attached to dendrimers 
Dendrimers are three dimensional oligomeric structures based on a single 
repeating unit. They produce structures that have a uniform surface chemistry, 
and due to their rigidity when  compared to linear polymers of a similar nature, 
they can decrease the tumbling properties of the gadolinium(III) ion, thus 
increasing its effect on T1 relaxivity. One of the basic dendrimeric structures is 
the starburst polyamidoamine (PAMAM) dendrimer 9 (Figure 11). These 
dendrimeric structures can chelate many gadolinium(III) ions in a single 
macromolecule allowing for a higher concentration of the paramagnetic ion, and 
therefore a greater effect on relaxivity can be seen. (27) The major issue with 
these contrast agents is their inability to cross membranes into surrounding 
tissues, thus limiting their usage to visualising vascular targets. There have also 
been questions raised about their toxicity, this time from the polyamide ligand. 
(28)
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Figure 11 A PAMAM dendrimer structure.  
Reproduced from Ref.  (27) with permission from the Centre National de la Recherche 
Scientifique (CNRS) and The Royal Society of Chemistry.  
Gadolinium dimers 
It has been discovered that a dimer with increased rigidity between the two 
metal centres has a greater increase in relaxivity than expected by doubling the 
number of free water molecule binding sites. This is due to decreasing the 
tumbling rate of the contrast agent. A dimer with a xylene based rigidity core, 
and a heptadentate chelator allowing for two water molecules to bind to each 
individual gadolinium(III) ion has been synthesised (10) (Figure 12). (29) Another 
similar molecule has been synthesised, this time with an iron terpyridine core 
and two terminal diethylenetriamine-N,N,N",N"-tetraacetate gadolinium(III) 
complexes (11) (Figure 12). Although this complex has greater rigidity and thus 
greater relaxivity, the thermodynamic stability of the complex is greatly reduced. 
(30)  
9 
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Figure 12 The double gadolinium(III) ion complex with a xylene based core (10). The 
double gadolinium(III) ion complex with an iron terpyridine core (11). (29-30)  
"Smart" MRI contrast agents 
Intelligent contrast agents that change their level of activity only in targeted 
regions can be synthesised. This can occur via one of two methods, by 
changing the q value, usually by losing masking group from the central 
gadolinium ion (31)  or by having an effect on molecular tumbling. (32) 
ADEPT MRI contrast agents 
The first MRI contrast agents sensors designed and synthesised were by Moats 
et al. (33) and were activated using ȕ-galactosidase an enzyme associated with 
the Antibody Directed Enzyme Prodrug Therapy (ADEPT) system. This 
technique uses a non-endogenous enzyme that has been conjugated to an 
antibody fragment that targets a receptor found primarily on tumour cells. This 
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complex is administered initially and allowed to localise, before a prodrug 
contrast agent is administered. The non-endogenous enzyme then cleaves a 
group attached to the central gadolinium(III) ion to produce the active contrast 
agent with a free water binding site, which can be used to decrease the 
relaxivity of the surrounding bulk water (Figure 13). (34)  
  
Tumour Cell
antigen
antibody-enzyme
complex
pro-drugdrug
 
Figure 13 Antibody-enzyme conjugate. (34)  
The enzyme ȕ-galactosidase cleaves the sugar ȕ-galactopyranosides from the 
contrast agent (12) to produce a free site on the gadolinium(III) ion for a water 
molecule to bind (Scheme 1) 
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Scheme 1 The release of ȕ-galactopyranoside and carbonate to produce a water binding 
site in the presence of ȕ-galactosidase. (35)  
Other work in this area uses the ȕ-glucoronidase enzyme, which has also been 
used to release free sites on the gadolinium(III) opening it up for inner-sphere 
water binding. (31) Yet more recent work has taken this principle to mask 
albumin binding groups, thus resulting in an increased relaxivity due to slowing 
the molecular tumbling. (36)  
Metal ion sensor contrast agents 
Metal ion sensors are of great importance as ions like calcium(II) are widely 
used for regulation in humans, whilst other metals including copper are 
DVVRFLDWHG ZLWK GLVHDVH VWDWHV VXFK DV :LOVRQ¶V GLVHDVH (37) The greatest 
challenge with these types of sensors is making the ligand specific enough for 
the metal to prevent false positive activation from other similar metals. To do 
this scientists must tune the ligands to force the selectivity, using properties 
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such as a preference for hard or soft donor atoms, and preferred co-ordination 
numbers. (32)  
A method to study biological copper has been developed that allows for a MRI 
contrast agent to become active in the presence of copper. Thus, cellular 
copper accumulation and trafficking can be monitored. A DO3A-based chelate 
is attached to a pyridine moiety with side chains containing copper binding 
groups (O, N, S) (14). When inactive the pyridine binds to the gadolinium(III) 
and blocks the two free water binding sites, whilst in the presence of copper, 
the pyridine and its side chain bind the copper, allowing for two water 
PROHFXOHVWRELQGWRJDGROLQLXP¶VLQQHU-sphere (15) (Scheme 2). This structure 
has a dual effect on decreasing the T1 relaxation, as there are two inner-sphere 
binding sites instead of the usual one, and the copper binding increases overall 
molecular weight thus decreasing molecular tumbling. The major problem so far 
regarding this technique is specificity, as the contrast agents are often activated 
by other biological metals including zinc, although work is continuing to solve 
this. (38) To an extent this problem has been improved upon using other ligands 
to bind the copper as developed by Li et al. (39) with the Gd-QDOTAMA complex 
and Que et al. (37) who developed a chelate with a sulfur based ligand. 
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Scheme 2 Copper activation of a "smart" MRI contrast agent. (37)  
The first calcium(II) sensors were also developed by Li et al. (40) and used a 
BAPTA ligand (16) that caused a q value change once calcium(II) had bound 
and could be used to measure intracellular calcium fluctuations. The acetate 
functionalities have since proven to be necessary for selectivity over 
magnesium(II) during the development of extracellular calcium(II) sensors. (41) 
These bispolyazamacrocyclic sensors (17) have since shown a 50% increase 
in relaxivity in extracellular brain models (Figure 14).  
14 15 
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Figure 14 Gd-DOTABAPTA 16 (40)  and the bispolyazamacrocyclic sensor (17). (41)  
Other metal sensors have been worked on, most predominantly with zinc in 
ZKLFK HOHYDWHG OHYHOV KDYH EHHQ DVVRFLDWHG ZLWK $O]KHLPHU¶V GLVHDVH (12) 
Sensors for metals including potassium, (42) magnesium, (43) and iron (44) have 
also had varied success in terms of metal selectivity and change in relaxivity.  
pH and redox sensor contrast agents 
It has been noted that in certain tumours physical changes occur within the 
cells, this includes a reduction in pH and a change of reducing potential, these 
WXPRXUVFDQWKHQEHWDUJHWHGXVLQJ³VPDUW´FRQWUDVWDJHQWV 
The major difficulty with pH sensors is in keeping the result independent of 
concentration of the contrast agent, something which is often difficult to 
determine in vivo. The first to achieve this was Aime et al. in 2006, (45) in which 
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he produced a slow tumbling complex that produced pH sensitivity by 
measuring the ratio between the transverse (R2p) and longitudinal (R1p) 
paramagnetic relaxation rate contributions. This can be seen in Figure 15.  
 
Figure 15 Graphical representation of how the ratio between transverse and longitudinal 
relaxation rates are concentration independent but pH dependent.  
Reprinted with permission from (45). Copyright (2006) American Chemical Society.  
Whilst this technique works well in principle the sensitivity required for in vivo 
imaging is not reached and thus other techniques have been explored. The 
inclusion of sulfonamide groups for pH sensitivity was first reported in 2001 by 
Lowe et al. (46) and has since been employed by Gianolio et al. (47) in a dual 
MRI/SPECT sensor. This is useful as the SPECT sensor can act as a measure 
of local concentration, whilst the changes in relaxivity from the gadolinium(III) 
report the local pH measurements.  
Contrast agents designed to be redox sensors usually exploit the reduction of 
disulfides to thiols caused by up regulation of the anti-oxidant response element 
seen in many cancers. Unusually these sensors work by showing a reduction in 
contrast in areas of high reducing potential. This is because the gadolinium(III) 
contrast agents are bound to structures either held together by disulfide bonds  
(48)
 (Figure 16) or directly bound to a large protein by a disulfide linker, (49) thus 
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once the disulfide bond is broken the molecular tumbling dramatically 
increases, reducing the overall relaxivity.  
 
Figure 16 The breakdown of the large cyclodextran macromolecule on thiol reduction. 
Reproduced from Ref. (48) with permission from The Royal Society of Chemistry.  
A more recent alternate contrast agent for measuring hypoxia is the 
4NO20H26$*G ³VPDUW´ 05, VHQVRU GHYHORSHG E\ 1DJDQR et al. (50) (20) 
(Scheme 3). This contrast agent blocks the two free sites of the DO3A complex 
with a nitro-aromatic sulfonamide under normoxic conditions. Yet under the 
reducing hypoxic conditions, the nitro group is reduced to an amine, which 
causes a shift in acidity of the nitrogen in the sulphonamide, allowing for the 
nitrogen to become protonated so it no longer co-ordinates to the central 
gadolinium(III) ion, thus leaving two free sites for water to bind. 
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Alternative paramagnetic ions 
Gadolinium(III) is not the only suitable paramagnetic ion with regards to MRI. 
Alternatives such as superparamagnetic iron nanoparticles and manganese 
have also been explored. 
Superparamagnetic iron oxide particles 
Although gadolinium(III) is a good ion for affecting the T1 of water molecules, it 
does not affect the T2 relaxation. For this purpose superparamagnetic iron 
oxide (SPIO) particles have been used. Introduced in 1985 shortly after the use 
of gadolinium complexes, the SPIO particles are becoming increasingly 
popular. (51) This is due to several reasons; firstly per unit of metal, SPIO 
causes the greatest change of relaxivity in comparison with other paramagnetic 
metals; secondly the iron itself is biodegradable and can be reused and 
UHF\FOHGE\WKHERG\¶s metabolic processes; and finally the dextran or dextran-
based coating can be easily manipulated to incorporate other ligands and 
groups. (52) These particles have therefore also been used instead of 
gadolinium(III) in many of the previously mentioned techniques, i.e. in the 
liposome technology (Figure 17). (24)  
 
Figure 17 A liposome contrast agent with a SPIO core 22.  
22 
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Reprinted with permission from  (24). Copyright (2004) American Chemical Society 
Another potential iron nanoparticle complex is the protein ferritin 23, a biological 
iron storage complex that consists of 24 subunits and can accommodate up to 
4500 iron atoms in the form of ferric oxyhydroxide. The iron can be removed 
from this carrier via dialysis to produce the protein shell apoferritin 24 leaving a 
central cavity with a diameter of approximately 7-8 nm. In a similar manner to 
the liposome technology this protein complex can be filled with SPIO, 
magnesium(II) or gadolinium(III) nanoparticles. The popular way of 
encapsulating the nanoparticles is to dissociate the apoferritin protein at pH 2 
(25), before reforming the shell in a nanopartical rich environment at pH 7 (26) 
as seen in (Figure 18). (53)  
 
Figure 18 Insertion of nanoparticles into a ferritin shell.  
Reprinted with permission from  (54). Copyright (2008) John Wiley and Sons  
The major advantages of the apoferritin complex 24 are its capability of carrying 
a large payload, whilst having little or no immunogenic effect. It also has the 
potential to become a multimodal contrast agent if other imaging functionalities 
DUHFRQMXJDWHGWRWKHDSRIHUULWLQ¶VRXWHUVXUIDFH 
23 24 25
 
 20 
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It has been mentioned that these coatings covering the SPIO nanoparticle can 
be easily manipulated so that targeting vectors or alternative imaging agents 
can also be incorporated. Thus one of the major new developments for this 
technology is in the synthesis of new theranostic molecules, usually SPIO 
nanoparticles that also contain a drug delivery mechanism, allowing for 
localisation, imaging and then treatment of a disease area. (55) This technology 
works as the nanoshell surrounding the iron oxide core can be conjugated to a 
series of different moieties, including targeting vectors, near infrared dyes 
(example Cy5.5) and drugs such as the cancer drugs doxorubicin, (56) docetaxel 
(57)
 or siRNA for RNA interference. (58)  
Manganese as an imaging agent 
Manganese is paramagnetic due to its five unpaired electrons; therefore under 
magnetic resonance conditions it shows similar properties to gadolinium(III) and 
decreases the relaxation times for T1 scans.  
Manganese(II) ions have similar properties to calcium(II), and during brain 
ischemia, there is an increased influx of calcium(II) and consequently 
manganese(II). This influx of calcium(II) is due to the fact that during brain 
ischemia the sodium/potassium ATPase pumps stop, causing depolarisation of 
the cell due to increased sodium levels. 
The result is the opening of calcium(II) channels, hence when calcium(II) and 
consequently manganese(II) enter the cell they begin to accumulate. This 
accumulation of manganese(II) can be detected by T1 weighted MRI images, as 
the manganese(II) decreases the relaxation of the surrounding protons (Figure 
19). This technique however has little clinical usage, as for manganese(II) to 
enter the brain, mannitol must be used to osmotically open the blood brain 
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barrier. The similarity of manganese(II) to calcium(II) means it is both neuro- 
and cardiotoxic. (59)  
 
Figure 19 Manganese enhancement in a rat brain after brain ischemia.  
Reprinted with permission from  (59). Copyright (2003) John Wiley and Sons  
Manganese(II) is also being used in a similar manner to gadolinium(III), for 
example when complexed with ligands such as diethylenetriaminopentacetic 
acid (DTPA). The manganese(II) can also be conjugated to a variety of 
targeting vectors and contrast enhancing moieties, including dendrimers. (60) In 
2000 manganese(II) dipyridoxal-diphosphate (Mn-DPDP) 27 was cleared for 
clinical use in liver imaging (Figure 20). (61) Toxicologically Mn-DPDP is superior 
to Gd-DTPA with a LD50 of 540 mmol Kg-1 compared to 60-100 mmol Kg-1 
shown by Gd-DTPA. It also shows a dramatic increase in relaxivity in tissues 
such as the liver and kidney compared to the blood, which reduces background 
noise. (62)  
32 
 
N N
O OOO
Mn
NHHN
O OP P
O
O O
O
O
O
OO
27
4-
 
Figure 20 Mn-DPDP 27. (62) 
Chemical exchange saturation transfer agents (CEST) 
A CEST agent creates contrast in an image by intensifying the darkness of the 
surrounding bulk water via proton or atom exchange. For these agents to work 
the compound must be in a constant state of chemical exchange in which there 
is a difference in chemical shift between the different states. A good example of 
this is a hydroxyl proton, constantly exchanging with bulk water protons.  
Initially, a state of saturation must be reached in pool B (the CEST agent¶s 
protons), this is when the number of protons in the spin up state equal the 
number of protons in the spin down state, creating a net magnetism of 0. This is 
achieved by applying a soft irradiation pulse specific to the pool B protons. 
Once saturation has been reached a transfer of spins begin with a transfer of 
spin down protons from pool B to pool A (the bulk water protons), and spin up 
protons from pool A to pool B. The overall result of this is to transfer saturation 
from pool B to pool A, thus reducing the signal from the bulk water and 
intensifying the darkness of the background (Figure 21). 
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Figure 21 Distribution of spins in two distinct pools before and after a CEST irradiation 
pulse.  
Reprinted with permission from (63). Copyright (2008) Annual Reviews   
 
This technology has major implications in cellular MRI, for use of endogenous 
CEST agents such as the hydroxyls in glucose can allow for tracking of the 
distribution, breakdown and synthesis of glycogen. Knowledge of these 
processes can greatly improve the diagnosis of diseases including diabetes.  
Of the exogenous CEST agents, those with the most promise appear to be the 
paramagnetic CEST agents. These use an anisotropic lanthanide such as 
europium(III) to create a difference in proton shift of the bound water molecule. 
Gadolinium(III) is not suitable as it is isotropic with seven unpaired electrons in 
seven f-orbitals, and it has an inner-sphere water lifetime that is too short. For 
optimum CEST the lifetime must be 0.5 ms, and not in the nanosecond range 
required for T1 relaxation. Other exchangeable protons available for CEST 
enhancement include co-ordinating hydroxyl or amide protons, and even the 
non-co-ordinating amides in close proximity to the metal. (63)  
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1.2.3 The gadolinium (III) chelators that form the basis of the work in 
this thesis. 
DOTA ligand 
The gadolinium(III) DOTA complex (28) is currently one of the clinical contrast 
DJHQWV LQXVH WRGD\XQGHU WKHQDPH'RWDUHP (64). With a central crown like 
structure and four acetate functionalities the ligand forms an octadentate 
complex with gadolinium(III) which has exceptional thermodynamic and kinetic 
stability. A common analogue of DOTA is DO3A (29), which only has three 
acetate functionalities, allowing the fourth nitrogen to be covalently bonded to a 
linker moiety that allows for further modifications.  
 
Figure 22 DOTA (28) and DO3A (29). (65)  
These compounds have been used in the contrast agent field since 1986,  (66) 
and since then have been used as the basis of many experimental contrast 
agents, including metal sensors, (67) dendrimers, (27) ADEPT agents (35) and even 
CEST agents. (63)  
 The unmodified DOTA chelator (28) has a relaxivity value of 3.5 mM-1 s-1 at 20 
MHz and 312K, (68) yet this value is produced as an average between the 
relaxivity values of two different DOTA conformers. Crystallographic studies 
35 
 
have shown that Ln(DOTA) can be found in either the square antiprismatic (SA) 
30 or the twisted square antiprismatic (TSA) 31 geometries as seen in Figure 
23. These structures differ in the twist angle between two square planes of the 
antiprism. These different structures are important as the TSA geometry has a 
significantly faster water exchange rate than that of a SA geometry. (65) 
Mechanistic studies have shown that the difference in the exchange rate 
between the two is up to 50 fold with the SA having a kex (exchange constant) 
value of 8.3x103 s-1, compared to 327x103 s-1 for the TSA geometry. Therefore 
even though the SA conformation is 4.5 times more prevalent in solution than 
the TSA, 90% of the relaxation is produced by the TSA conformer. (69)  
 
Figure 23 The SA and TSA [LnDOTA]- (Ln = Sc(III) on left, Tm(III) on right) conformers. 
Reprinted with permission from (65). Copyright (2003) American Chemical Society   
Whilst in theory [GdDO3A] should have almost double the relaxivity value of 
[GdDOTA]- due to the extra water coRUGLQDWLRQVLWHWKLVKDVQ¶WVKRZQWREHWKH
case, with a relaxivity value of 4.8 mM-1s-1 at 20 MHz and 312 K. This is 
because the coordination environment occupied by the two water molecules is 
suitable for binding of anionic ligands found within biological conditions, 
30 31 
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including phosphates and citrates. (70) Thus the overall relaxivity value is 
significantly lower than expected.  
Gadolinium(III) containing DOTA complexes were initially synthesised by 
Margastadt et al. in 1986. (71) This synthetic route included the formation of 
cyclen using the method developed by Richman et al. (72) (Scheme 4) This 
involves reacting the bisulfonamide sodium salt of ((tosylazanediyl)bis(ethane-
2,1-diyl))bis(tosylamide) 32  with (tosylazanediyl)bis(ethane-2,1-diyl) 
dimethanesulfonate 33 to produce the tosyl protected cyclen ring 34, which 
undergoes acid hydrolysis to form the unprotected cyclen 35. This can then 
undergo the addition of the acetate functionalities using tert-butyl bromoacetate 
followed by gadolinium(III) insertion to produce the Gd(III)DOTA complex.  
Scheme 4 Cyclen 35 formation used by Richman et al. (72) 
The synthesis of the DO3A based complexes are significantly more intricate as 
the reaction must be stopped after the addition of the third acetate functionality. 
Within the Thomas group DO3A gadolinium(III) complexes were synthesised 
using a six step process involving a series of orthogonal protections to produce 
the final DO3A complex (40) as outlined in Scheme 5. (8) This synthetic route is 
discussed in further detail in Chapter 3.  
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Scheme 5 Synthesis of the protected DO3A complex (40) as developed by the Thomas 
group. (8) 
This synthesis has since been streamlined within the literature with Machitani, 
et al. (73) forming the HBr salt of the DO3A complex (40) in a single step using 
strict equivalences of tert-butyl bromoacetate and at a high dilution (Scheme 6).  
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Scheme 6 Formation of protected DO3A 40 developed by Machitani et al. (73) 
The propargyl containing DOTA based complex with a potential for use in 
copper (I) mediated cycloaddition has been developed by Viguier et al. (74) This 
synthesis takes the DO3A starting material 40 and reacts it with 2-bromo-N-
(prop-2-yn-1-yl)acetamide 41 and base to produce the protected version of the 
desired compound 42 in a 78% yield before tert-butyl deprotection and Eu(III) 
insertion as seen in Scheme 7.  
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Scheme 7 Formation of the Europium(III) propargyl DOTA complex CA1-Eu. (74) 
AAZTA ligand 
The 1,4-bis(hydroxycarbonylmethyl)-6-[bis(hydroxycarbonylmethyl)]amino-6-
methyl-perhydro-1,4-diazepine (AAZTA) ligand (44) is a heptadentate ligand 
reported to produce stable complexes with gadolinium(III) (Figure 24). Due to 
this extra coordination site for water, the relaxivity of the complex is almost 
double compared to Dotarem. If the gadolinium(III) AAZTA complex is 
conjugated to a slow tumbling molecule the relaxivity can be dramatically 
increased. 
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Figure 24 The AAZTA ligand (44). (75)  
The gadolinium(III) complex of AAZTA is significantly more thermodynamically 
stable than the gadolinium(III) complex of DTPA. (76) This stability of the AAZTA 
complex is based on the location of the three nitrogen atoms, with the two in 
the ring and the third on the sp3 carbon. Due to their close spatial relationship 
there is no possibility of coordination extension and therefore the gadolinium(III) 
is held tightly. Despite this high stability, AAZTA only takes up seven of 
gadolinium(III)¶V nine coordination sites. Yet unlike [GdDO3A] the area 
occupied by the exchanging water molecules is not suitable for the binding of 
more kinetically stable anionic biomolecules, all of this contributing to the 
relaxivity value of 7.1 mM-1 s-1 at 20 MHz and 298 K. (77)  
With regards to modifying AAZTA the obvious site is the methyl group on the 
sp3 carbon. This position has been converted into a C17 alkyl chain, having the 
overall effect of producing AAZTA micelles and dramatically increasing the 
relaxivity of the compound to 30 mMí1sí1 (20 MHz, 298 K) due to effects on 
molecular tumbling. (78) Insertion of an alcohol group in the methyl position 
produces similar relaxivity properties to the parent compound (44), whilst 
producing a handle for further modification. (79) (Figure 25) 
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Figure 25 A modified AAZTA ligand (45) at the sp3 carbon. (79)  
The overall synthesis of the AAZTA ligand is relatively short, being only four 
steps for the parent compound, yet this is still three steps longer than the 
synthesis of DOTA or DO3A. The synthesis starts with a Mannich reaction, 
followed by a hydrogenation to convert the nitro functionality into an amine (50). 
The synthesis then proceeds with the addition of the acetate functionalities via 
an SN2 reaction (51) before a final deprotection to yield the final ligand (44), (80) 
as shown in Scheme 8. 
 
Scheme 8 Synthesis of the AAZTA ligand (44). (79)  
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1.3 Hypoxia and 2-Nitroimidazole 
1.3.1 Hypoxia  
Hypoxia is a microenvironment within the body in which an area is deprived of 
oxygen and can no longer undergo normal metabolic processes. This 
microenvironment is formed in some solid tumours, as during the rapid growth 
of the pathogenic cells the vasculature is not formed properly, preventing much 
needed oxygen and nutrients from reaching certain areas. Hypoxia can also be 
found during a stroke, a myocardial infarction and as a consequence of poor 
blood perfusion in diabetic limbs and arthritic joints. (81)  
Hypoxic regions in tumours cause major problems with regards to oncological 
treatment, as these areas are resistant to radiotherapy and chemotherapy. This 
is due to poor vascular delivery in conjunction with a reduced cell cycle, which 
in turn lessens chemotherapeutic effects, as most of the drugs in the clinic are 
anti-proliferation agents and not anticancer agents.The efficacy of radiotherapy 
however is not reduced because of poor vascular perfusion, but because the 
cytotoxic effect of this type of treatment relies on the presence of intracellular 
oxygen.  
The treatment resistance of the hypoxic region is not the only reason for poor 
patient prognosis with hypoxic tumours. Unlike normal human tissue, tumour 
cells are capable of adapting to the hypoxic conditions via a pathway induced 
by hypoxia inducing factor 1 (HIF-1). HIF-1 is a protein that consists of two 
proteins HIF-ĮDQG+,)-ȕ8QGHUQRUPR[LFFRQGLWLRQV+,)-ĮLVK\GUR[\ODWHG
by oxygen, which leads to ubiquitination and degradation. Yet under hypoxic 
conditions, HIF-ĮWUDQVORFDWHVWRWKHQXFOHXVDQGIRUPVDGLPHUZLWK+,)-ȕWR
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form HIF-1. This dimer acts as a transcription factor to induce the production of 
over 100 proteins. These proteins include those essential for glycolysis (a 
method of producing energy anaerobically), growth, neovascularisation, 
prevention of apoptosis, proteolytic enzymes that degrade the extracellular 
matrix promoting metastases and even proteins that down-regulate the immune 
response. (81)  
 
Figure 26 Pathways taken by HIF-1 in normoxic and hypoxic conditions.  
Reprinted with permission from (81). Copyright (2008) Society of Nuclear Medicine, Inc.  
Due to the increased treatment resistance and the up regulation of proteins that 
contribute to factors including metastases, patient prognosis is dramatically 
reduced when a hypoxic region is produced in a solid tumour. (82) Thus effective 
methods of treatment and visualisation are required to improve patient survival.  
1.3.2 Visualising hypoxia ± 2-Nitroimidazole 
Currently, major methods for visualising hypoxic cells use compounds based on 
the 2-nitroimidazole structure, a known marker of hypoxic tissues (81), (83). The 
main reason for this is that under hypoxic conditions the nitro group undergoes 
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an irreversible reduction and activation, due to a lack of oxygen to perform the 
reoxidation step. Once this occurs the molecule is trapped inside the cell as this 
reduction leads to a chain reaction that produces a suitable leaving group from 
the (imidazol-5-yl)methyl position (53) which is eliminated leaving a methide 
group (54) that is electrophilic enough to covalently bind to molecules inside the 
cell. (84)  
 
Scheme 9 The reaction undertaken by 2-nitroimidzole once under hypoxic conditions 
resulting in cell localisation. 
The initial cytochrome P450 reductase catalysed single electron transfer to the 
nitro compound is the rate determining step, as it is reversible under aerobic 
conditions, however under hypoxic conditions this radical is not converted by an 
oxygen molecule back to the parent compound. Instead it undergoes a series of 
conversions which lead to the formation of an amine (Scheme 10).  
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Scheme 10 The enzymatic conversion of a nitro group to an amine under hypoxic 
conditions. (85) 
2-Nitroimidazole is the most widely used of the nitroimidazole compounds, as it 
has a steady uptake into the cells and good retention, unlike the 4- or 5-
nitroimidazole which have a better uptake into cells, but are rapidly removed 
again before localisation can take place. This is because there are slight 
differences in redox potential between the 2- and 4-/5-nitroimidazoles, which 
affects the rate of reduction of the nitro group. The value of the redox potential 
of 2-nitroimidazole is -243 to -398 mV, whilst for 4- or 5-nitroimidazole the redox 
potential is below -400 mV. (86)  
A positron emission tomography (PET) agent commonly used to measure 
hypoxia is 18F±misonidazole (FMISO) 56. This is injected into patients and 
allowed to localise for one and a half hours before using a PET scanner to 
image the tumour. The timing is chosen as it allows for the 18F±FMISO to 
equilibrate and localise within the tissue, whilst also taking into account the 18F 
half life of one hundred and nine minutes. (87) Since 18F requires a cyclotron to 
be produced the supply is limited and expensive.  
 
Figure 27 18F-FMISO 56. (81) 
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Whilst optical imaging is not practical in vivo, these probes have been widely 
successful for accurately measuring hypoxia in an in vitro setting. One of the 
major 2-nitroimidazole based compounds in this group is pimonidazole 57. (88) 
Commercially available as Hydroxyprobe-1, pimonidazole staining has been 
shown to not only view hypoxic regions immunohistologically, but when 
normoxia is returned the staining of pimonidazole is seen to dramatically 
decrease.  
Assays used to measure radiobiological hypoxia include the comet assay and 
antibody binding to EF5 58 another 2-nitroimidazole based compound. The 
comet assay involves exposing tumours to irradiation followed by 
electrophoresis. The DNA that has been broken by irradiation migrates faster to 
produce a comet-like tail that lengthens proportionally to the number of DNA 
breaks. This technique was used to validate pimonidazole as an accurate 
measure of hypoxia. Antibodies have been produced to bind to adducts of EF5, 
these antibodies can contain a fluorescent tag, which allows for quantitative 
histological staining of the hypoxic tissue. (89)  
 
Figure 28 Optical 2-nitroimidazole based hypoxia markers. (88) (89)  
The final type of hypoxia marker based on 2-nitroimidazole are the fluorine MRI 
markers. So far three 19F labelled 2-nitroimidazole structures have been 
synthesised for use in 19F MRI, including trifluoroethoxy-misonidazole. Whilst 
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19F MRI is similar to proton MRI in sensitivity, it has a much greater signal to 
noise ratio as there is very little natural fluorine in human tissue. Although these 
compounds are advantageous in comparison with PET agents, as they avoid 
the radioactivity and limited shelf-life problems associated with 18F, the dose 
required for good quality images using 19F is 400-1,600 mg/m2 in comparison 
with the 15 µg/m2 required for 18F-FMISO. (90) The sensitivity of the 19F MRI is 
also reduced as the 2-nitroimidazole forms several adducts once activated, 
producing a broadened signal, and reducing the signal to noise ratio produced. 
1.3.3 Alternative hypoxia markers  
An alternative PET agent that can be used for hypoxia imaging is 64Cu-ATSM 
59. Diacetyl-bis(N4-methylthiosemicarbazone) (ATSM), has anti-tumour 
properties that are enhanced by chelation with Cu(II), the complex is taken up 
more rapidly than 18F ±FMISO 56, and the normoxic-hypoxic ratio seen is 
greater. The method by which Cu-ATSM is up-taken and located in hypoxic 
cells is thought to be related to the lipophilicity of Cu(II)-ATSM, whilst Cu(I)-
ATSM is charged and can be trapped within cells via irreversible intracellular 
UHGXFWLRQ<HWWKLVPHFKDQLVPGRHVQ¶WH[SODLQWKHGLIIHUHQFHVVHHQLQYDULDEOH
tumour types, so more work needs to be done to understand this compound 
further. (91)  
Cu(II)
N N
S S
NN
NHHN
59  
Figure 29 Cu-ATSM 59. (91) 
As hypoxia is just a state of low oxygen partial pressure (PO2), electrodes such 
as the Eppendorf PO2 Histograph, can be used to directly measure the level 
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of oxygen in the tumour. The relationship between this value and poor tumour 
prognosis due to the effects of hypoxia has been proven using this type of 
technology for cervical carcinomas. (92) The major disadvantages of this 
technology is that only a specific part of the tumour can be monitored at any 
one time, and unlike general imaging techniques the probes are invasive.  
Another direct method of measuring hypoxia is to use a MRI method called 
BOLD (blood oxygen level dependent). This technique exploits the fact that 
deoxyhaemoglobin (dHb) is paramagnetic, unlike oxyhaemoglobin (O2Hb), and 
thus can be seen on T2*-weighted images. For dHb decreases the relaxation 
rate of blood water, and is directly related to vascular oxygenation. The 
disadvantages with this technique are that, for smaller blood vessels, the 
partial-volume effects can produce inaccurate results, as can the flow effects of 
the blood. One method to solve the latter problem is a technique called FLOOD 
(flow and oxygen dependent contrast) which uses pulse sequences to decouple 
the flow effects from the static effects of the relaxation. This technique is 
valuable due to its non-invasive application, allowing for easy repetition of the 
test, complimented by the high spatial and temporal resolution of the technique. 
(81)
  
Whilst 2-nitroimidazole is the most commonly used, it is not the only compound 
able to undergo activation in hypoxic conditions. Nitro aromatics, aromatic and 
aliphatic N-oxides, quinones and metal complexes can all accept electrons, 
irreversibly causing a significant change in their intrinsic properties. These 
compounds have yet to be exploited for use in tumour imaging, but they have 
been used experimentally as prodrugs for cancer treatment.  
49 
 
Nitrobenzyl compounds are activated via an identical mechanism to the 
nitroimidazole compounds, however whilst the nitroimidazole drugs are often 
activated by uncontrolled fragmentation of the ring structure, the nitrobenzyl 
compounds are more commonly associated with the controlled release of 
known cancer drugs such as mustards (60) (Figure 30) (93) and paclitaxel (61) 
(Figure 30). (94)  
 
Figure 30 Nitrobenzyl based cancer prodrugs (60,61). (93) (94)  
For the nitrobenzyl compounds to be reduced under hypoxic conditions it is 
best if they have reduction potentials between -330 and -450 mV. (95) The best 
way to achieve this is by reducing the electron density of the ring itself, most 
commonly by putting in extra electron withdrawing groups including nitro groups 
in both the ortho and para positions. Electron withdrawing groups however can 
reduce the potency of the cytotoxic agent, so a balance must be struck. (96)    
Aromatic N-oxides contain one of the first potential hypoxia selective tumour 
activating drugs, tirapazamine 62 (Figure 31). These compounds accept two 
electrons in the N-4 position via a single electron transfer mechanism to 
produce the deoxygenated form and a hydroxyl radical. This radical attacks the 
C-¶ position of the ribose site in DNA causing cleavage. The DNA can then 
undergo oxidation and form a covalent adduct with tirapazamine. (97) 
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Unfortunately whilst tirapazamine showed a 200-fold selectivity for hypoxic 
tissues its use is limited as it can be metabolised to the radical species 
preventing diffusion through tissues. (98) Derivatives of tirapazamine have been 
synthesised with the N-2 replaced with a C-CN functionality, (99) which showed 
a retention in hypoxic selectivity, yet these were unsuccessful therapeutically 
due to their short half lives and low solubility. (100)  
 
Figure 31 Tirapazamine 62. (97) 
Unlike the aromatic N-oxides, the aliphatic N-oxides do not undergo a single 
electron process, yet reduction to the corresponding tertiary amine is inhibited 
due to competition between oxygen and the drug for binding in the CYP3A 
cytochrome C enzyme. This is best seen in the drug AQ4N 63 (Figure 32), 
which once activated binds tightly to DNA and inhibits topoisomerase II. Whilst 
not totally successful on its own, the drug showed more promise when 
potentiated by radiotherapy. (96)  
 
Figure 32 AQ4N 63 and its hypoxia activated form (64). (96) 
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Quinones are reduced via a single electron transfer to form the semiquinone 
radical anion. Groups have been added in the C-2 position that under hypoxic 
conditions will leave to form a reactive methide intermediate that can crosslink 
to DNA via the guanine-guanine crosslinks in the major groove. (101) In vivo 
these compounds showed little selectivity for hypoxic tissue, due to the 
quinines being good substrates for DT diphorase, a two-electron reductase that 
is not reversible in the presence of oxygen. (102)   
 
Figure 33 Hypoxia activated quinone based drugs (65 and 66). (101)  
The final group are the metal complexes, and in particular cobalt, although 
complexes with rhenium (103) and palladium (104) have also been synthesised. 
These complexes work on the principle that whilst cobalt(III) is relatively inert, 
cobalt(II) is very labile and readily releases its ligands. This occurs as cobalt(III) 
is in a d6 low-spin electron state, whilst cobalt(II) is in a d7 high spin, and the 
energy required for this interconversion is -200 to -400 mV, and thus in the 
range of cellular reductants. (85) To exploit this, chemotherapeutic agents such 
as 8-hydroxyquinolines (105) and nitrogen mustards, (106) have been chelated to 
the cobalt (III) complex. Whilst they showed promise in in vitro studies the 
selectivity for hypoxic cells was decreased in in vivo studies, and thus none of 
these drugs have reached the clinic. One way to try and combat this lack of 
stability is to increase the stability of the initial cobalt(III) complex by using tri-
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dentate nitrogen mustards (67) (Figure 34) instead of a mono or bi-dentate, as 
of yet no candidates have reached the clinic.  
 
Figure 34 a Tri-dentate Co(III) mustard complex (67) (106) 
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Chapter 2 Aims and Objectives 
The overall aim of this thesis was the synthesis of a MRI contrast agent that will 
accumulate in hypoxic tumour cells. Although 1H MRI contrast agents in the 
clinic accumulate preferentially in cancer cells over normal tissues, there are no 
known compounds that accumulate specifically in hypoxic cancer cells. 
Clinically PET is the most commonly used technique to image hypoxic cells, (81) 
however this requires the patient to be dosed with small amounts of radiation, 
which is more harmful for patients than MRI.  
The envisioned contrast agent was supposed to contain a gadolinium(III) 
central ion, with as high a q value as possible whilst still maintaining 
thermodynamic and kinetic stability in vivo. To enhance the relaxivity of the 
contrast agent, a high q value is desirable as the final molecules are too small 
to enable enhanced relaxation due to slower molecular tumbling. (78) The newly 
designed contrast agent was then to be conjugated to a known hypoxia 
targeting vector via a rigid linker.  
The linker chosen was a triazole, formed by the copper(I) catalysed azide-
alkyne cycloaddition, (107) with the azide and alkyne moieties able to react 
orthogonally to any other groups present within the complexes allowing for easy 
assembly (Figure 35). (108)  
 
Figure 35 Short triazole linker used to conjugate the MRI contrast agent to the hypoxia 
targeting vector. 
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The DOTA-based contrast agents are the most widely reported in the literature. 
(39) (66) (109)
 This is because the eight coordinate structure possesses highly 
favoured thermodynamic and kinetic properties making it unlikely to release the 
gadolinium(III) payload in an in vivo system. (70) These compounds are also 
easily manipulated to contain groups for conjugation. As an example the alkyne 
containing compound (CA1) has been synthesised by Viguier et al. (74) As CA1 
already carries the desired alkyne moiety this served as a starting molecule to 
be taken and adapted for use in this project. Furthermore, the synthesis the di-
propargyl containing DOTA based structure (CA2) was performed (figure 37). 
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Figure 36 DOTA based contrast agents to be synthesised. (CA1/CA2) 
As an alternative to the widely used DOTA based complexes a contrast agent 
based on the AAZTA structure was chosen to be synthesised for this project 
(Figure 38). This has a longer synthetic route, and fewer sites for adaptation, 
however the parent compound has been shown to have better relaxivity 
properties than the DOTA based complexes (CA1 and CA2) as it has a higher 
q value of 2, whilst still maintaining good metal retention properties in vivo. (80)  
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Figure 37 [GdAAZTA]- based contrast agent to be synthesised. (CA4) 
Table 1 Comparison between the [GdDOTA]- and [GdAAZTA]- complexes with regards to 
relaxivity and transmetallation. (68) (80) (110) (111) (112)  
 [GdDOTA]- [GdAAZTA]- 
Structure 
N N
NN
O O
O
O
O O
O O
GdIII
57
-
 
N
N
N
O
O
O
O
O OOO
GdIII
58
-
 
q Value 1 2 
Water Exchange rate 240 ns,  
 kex 0.41 x 107 s-1  
 
90 ns,  
 kex 0.87 x 107s-1  
Rotational 
Correlation times 
77 ps  74 ps  
Relaxivity  4.2 mM-1s-1 @ 20 MHz 
298 K  
7.1 mM-1s-1 @ 20 MHz 
298 K  
Resistant to 
transmetallation 
9  9   
 
Regarding the hypoxia targeting vector, 2-nitroimidazole based compounds are 
the most widely used in the clinic, (113) so the logical first step was to synthesise 
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a simple 2-nitroimidazole based targeting vector containing a short carbon 
chain connected to an azide moiety. It has to be considered that if the carbon 
chain is too short the targeting vector has the potential to be highly explosive. 
The compound with a 2-carbon chain between the 2-nitroimidazole and the 
azide functionality TV1 has been reported in the literature, (114) providing the 
initial starting place (Figure 39).  
 
Figure 38 Initial 2-nitroimidazole based targeting vector to be synthesised. (TV1) 
As an alternative to the 2-nitroimidazole based targeting vector, a series of 
nitro-benzyl compounds were also synthesised (TV3-5). Unlike with 2-
nitroimidazole, a leaving group must be present if the reduction of the nitro 
group is to lead to the contrast agent being tethered within the hypoxic cell, for 
the ring is not capable of the partial breakdown seen in the imidazole structure. 
The leaving group has to be attached to a methylene group in the ortho or para 
position with regards to the nitro functionality, otherwise it can not be released 
due to the resonance within the aromatic system (Scheme 11). (93)  
 
Scheme 11 The release of a leaving group to produce a reactive methylene functionality 
in nitro benzene based compounds under hypoxic conditions. 
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Whilst these compounds have less favourable electron potential values for 
enzymatic nitroreduction, (-600 to -400 mV (95) compared to -250 to -400 mV (86) 
for the 2-nitroimidazole based compounds) it has been shown that they can be 
reduced using human DT-Diaphorase. (115) The synthetic route toward these 
compounds is relatively simple having adapted a paper by Jiang et al. (116), to 
insert the side chain containing both an azide group and a suitable leaving 
group, in this case a chloride ion (Figure 40).  
 
Figure 39 The nitrobenzyl based targeting vectors to be synthesised. (TV3/TV4/TV5) 
The final envisioned targeting vector TV6 combines both the desirable 2-
nitroimidazole central structure with the substituent produced for the nitrobenzyl 
compounds. This should allow the nitro group to be reduced and the molecule 
to be attached indefinitely to structures within the hypoxic cell without requiring 
a temporary partial breakdown of the central ring structure. For this to occur the 
substituent must be in the 5- position on the imidazole, to allow for the flow of 
electrons to remove the chloride leaving group as seen in Scheme 12.  
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Figure 40 2-nitroimidazole based targeting vector to be synthesised (TV6). 
 
Scheme 12 Mechanism by which the reduced nitro group will bind irreversibly in the 
hypoxic cell 
Once all of the separate components have been synthesised the aim was to 
fuse both sides together to create a series of hypoxia targeting contrast agents. 
It is also to be noted that the di-propargyl DOTA based contrast agent (CA2) 
will be conjugated to both a hypoxia targeting vector and a fluorescent dye 
(DYE1) making the final product multi modal. The fluorescent dye chosen is a 
pro fluorescent coumarin dye widely used in the Thomas group. 
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Figure 41 Coumarin dye to be synthesised. (DYE1) 
 
Table 2 Table of final compounds to be synthesised. (C1-7) 
Contrast 
Agent 
Targeting 
Vector 
Final Compound 
CA1 TV1 
 
CA1 TV3 
 
CA1 TV4 
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Once all the complexes were synthesised they were to be tested with regards 
to their relaxivity properties and their ability to be reduced specifically under 
hypoxic conditions.  
The relaxivity testing was performed using a series of known concentrations of 
the complexes. These were then subjected to an inversion recovery pulse 
sequence to produce a MRI scan of the tube from which the signal strength 
could be extrapolated. Using the equation below (Equation 10) a reciprocal T1 
value could be deduced which was then plotted against the concentration of the 
complex. The gradient of this graph produces a relaxivity value in mM-1s-1 for 
the complex. (117)   
 
Equation 10 Equation used to calculate the T1 value from the signal intensity. 
The activity under hypoxic conditions was monitored using the enzyme 
Xanthine oxidase. The aim was to use the protocol set out by Bejot et al. (118) 
which uses xanthine and the azole complex as the reducing and oxidising 
substrates respectively. This reaction could be monitored at time points using 
UV spectroscopy as there should be a noted reduction in the absorption at 325 
nm, which corresponds to the absorption maximum of the nitro group 
containing chromophore.  
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Chapter 3 - Results and Discussion 
3.1 Synthesis of Contrast Agent 1. 
The initial aim of the project was to synthesise a gadolinium(III) chelate 
containing a propargyl linker. This novel class of compound has the unique 
advantage of a synthetic handle for orthogonal diversification ± the alkyne 
group. µClick¶ chemistry was then used to attach the chelate to a variety of 
azides which allows the chelate to be targeted to biological areas of interest, for 
example, hypoxic environments (typically associated with diseases such as 
cancer). The first complex CA1 was based on the DO3A gadolinium(III) 
complex which has the shortest synthetic route of the chelating agents, and is 
widely used in literature. (119) (109) (74) It will therefore acts as a good comparative 
standard with other technologies. It is also to be noted that the europium(III) 
derivatives were also synthesised, for use in NMR characterisation of the 
compounds, as NMR spectra can not be produced for the gadolinium 
compounds.This is due to the extensive paramagnetic nature of the 
gadolinium(III) having a deleterious effect on the NMR spectra as the signal is 
broadened  beyond useful recognition. 
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Figure 42 Contrast Agent 1. 
This complex (CA1) has already been reported in the literature by Viguier et al. (74)  
whic is based on the pivotal tert-butyl protected DO3A  compound.  Initially this 
intermediate was to be synthesised via a method developed within the Thomas 
group, which was reported to give an overall yield of 31% (Scheme 13). (8) This 
method involved the formation of the tri-Boc substituted cyclen ring 60 in 49% yield, 
before protecting the remaining free nitrogen with an orthogonal Fmoc group 61. The 
Boc group was then removed and replaced with three tert-butyl acetate groups 63, 
and then finally the Fmoc group was deprotected to produce the protected DO3A 
compound 64. However, both the introduction of the tert-butyl arms and the Fmoc 
deprotection proceeded in much lower yields, resulting in an overall yield of 7% 
(Scheme 13). As considerable quantities of the key intermediate (40) were required, 
an alternative route that was more robust was sought. 
64 
 
 
Scheme 13 Initial synthesis of tert-butyl protected DO3A (40). 
Following an established synthesis by Machitani et al. (73) it was observed that 
the three fold addition of the tert-butyl acetate substituents onto the cyclen 
could be controlled using exactly three equivalents and large dilutions (1 mg of 
cyclen 35 per 1 mL of acetonitrile) to give 85% yield, similar to the 91% 
reported in the initial paper (Scheme 14).  
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Scheme 14 Used synthesis of tri-protected DO3A (40). 
Once the tri-protected DO3A (40) had been synthesised, a variety of methods 
were investigated for the addition of the fourth substituent containing a free 
carboxylic acid group (76) (Scheme 15). Once in place, the carboxylic acid 
could be conjugated to propargyl amine to form the final contrast agent. 
Adapting literature reports by Miranda-Vera et al. a benzyl protected acetate 
group was introduced (75). (120) Cyclen based compounds are notorious for 
being unstable on silica, (121) so purification of the benzyl compound was 
difficult. A possible reason for this instability is that the compounds sit on the 
silica for an extended period of time as long columns are required to separate 
out the product from impurities. 
The synthesis was continued on the crude material with the aim to remove the 
impurities at a later stage. However classic benzyl deprotection strategies like 
the hydrogenation at atmospheric pressure or two methods of basic 
saponification could not deprotect the compound. (122) Acid hydrolysis was not 
attempted as it would also remove the tert-butyl protection groups. A second 
route in which the carboxylic acid group was added directly, (121) was successful 
but required HPLC purification. This proved to be impractical with regards to 
both time and scale.  
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Scheme 15 Synthesis of the carboxylic acid derivative of the tri-protected DOTA complex 
(76). 
As an alternative route to the desired product, a methyl ester protected acetate 
functionality was added in a 79% yield (77) and then deprotected using lithium 
hydroxide. Whilst this yielded the free carboxylic acid (76) removal of the excess 
lithium salt produced poor yields  of <20% (Scheme 16). (122)  
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Scheme 16 Methyl acetate route to the free carboxylic acid intermediate (76). 
To complete the synthesis of CA1 a dicyclohexylcarbodiimide (DCC) coupling 
with propargyl amine was attempted following work done by Heppeler et al. (123) 
However, this only resulted in a mixture of unreacted starting materials, thus O-
benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU) was 
used as the coupling agent. (124) Whilst this produced the desired product (78) by 
mass spectrometry, separation from aromatic impurities proved impossible. 
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Scheme 17 Attempts to introduce the propargyl group using standard peptide coupling 
methods. 
Instead of carrying out an exhaustive exploration of the many alternative coupling 
agents, a procedure by Mani et al. (125) was adapted. In this protocol propargyl amine 
is mono-coupled via an elimination-addition mechanism to bromo-acetylbromide 79 
(Scheme 18), before addition of the acetamide (80) to the tri-protected cyclen ring 
(40) (Scheme 19). 
Br
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rt, 2 h, 89%
79 80  
Scheme 18 Synthesis of 2-bromo-N-(prop-2-yn-1-yl)acetamide 80 
 Initially this reaction was carried out in DMF, which produced a 55% yield, yet when 
the reaction was run in acetonitrile the yield was improved to 77%. The tert-butyl 
69 
 
groups were then removed using hydrochloric acid as this produced a crystalline salt 
which was easier to handle than the standard trifluoroacetic acid (TFA) salt. The 
gadolinium(III) and europium(III) ions were then introduced using a procedure by 
Ferreira et al. (126) to give an overall yield of 45% for the gadolinium(III) chelate CA1 
from the cyclen starting material (35) and 44% for the europium(III) complex CA1-Eu 
(Scheme 19).  
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Scheme 19 Final synthesis route for complex 1 (CA1) 
3.2 Synthesis of Contrast Agent 2 
The next complex synthesised was a DOTA-based complex with two 
functionalised alkyne substituents CA2. This compound has the advantage of 
being able to attach two moieties with different functionality. This technology 
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could be used to create a multimodal contrast agent with a hypoxia targeting 
vector, and either a fluorescence or PET probe covalently attached to the 
gadolinium(III) contrast agent (Figure 43).  
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Figure 43 Contrast Agent 2 CA2 and a potential multimodal contrast agent 72.  
The synthesis started with a double Boc protection (Scheme 20). This was 
achieved by adapting a synthesis developed by Miranda-Vera et al. (120) which 
used Boc-oxysuccinimide instead of Boc-anhydride to produce the trans-bis 
product preferentially over the tri substituted product. This occurs as the cyclen 
ring 35 has two available electron pairs on N1 and N7, as the H-atoms on these 
amines are directed towards the centre of the ring, whilst the H-atoms on N4 
and N10 are directing outwards, a phenomenon that has been determined by 
X-ray crystallographic studies. (127) This also affects the basicity of the protons 
as the pKa values of the four amino groups are 10.5, 9.5, 1.6 and 0.8 
respectively. This is important as if the basicity of the leaving group is 
comparable to or higher than that of the unprotected amine groups on the 
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cyclen ring it will act as a base and promote the formation of the tri and tetra 
substituted cyclen ring. However if a weakly basic leaving group such as an 
oxysuccinimide (pKa 7.8) derivative is used only the di-protected cyclen ring will 
be formed.  
As this compound was synthesised in parallel with the previous compound, 
similar optimisation problems were encountered. A benzyl group was the initial 
orthogonal protection group used but the di-benzyl, di-tert-butyl substituted 
complex (86) could not be purified in acceptable yields due to instability on the 
silica column. (Scheme 20) 
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Scheme 20 Route 1 towards the synthesis of a bifunctional chelator (86). 
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Two synthetic routes to the methyl ester protected intermediate (88) were 
developed . Interestingly, the shorter synthesis (Scheme 21) that introduced the 
ester directly via methyl bromoacetate had a lower overall yield of 37% 
compared with 55% for the longer synthetic route (Scheme 22). However in 
either case, deprotection of the methyl ester with LiOH again gave 
disappointing yields of only 15%. 
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Scheme 21 Route 2 towards the synthesis of a bi-functional chelator (CA2). 
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Scheme 22 Second synthesis of the bis-methylacetate substituted cyclen (88). 
The procedure already used before by Mani et al. (125) was then applied to form 
the bi-functional complex (96). This successfully yielded both the europium(III) 
(CA2-Eu) and the gadolinium(III) complexes (CA2) in overall yields of 8 and 
12% respectively (Scheme 23).  
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Scheme 23 Final synthesis of the bi-functional chelator (86) and the respective 
lanthanide complexes CA2 and CA2-Eu. 
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3.3 Synthesis of Contrast Agent 3 
The synthesis of the Gd(III)DO3A-N-Į-aminopropionate complex CA3 was 
undertaken as an alternative to the Gd(III) DO3A based complex (CA1). This 
complex has optimised water exchange rates, with a kex of 4.0 x10-7 s-1, 
compared to 0.46 x10-7 s-1 for [Gd(DOTA)(H2O)]-, even though less than 2% of 
DO3A-N-Į-aminopropionate was found to be in the favourable TSA form. This 
acceleration of the water exchange is postulated to be due to steric crowding 
caused by the propionate group facilitating the departure of the water molecule 
from the central ion. (126)  
 
Figure 44 Contrast Agent 3. 
This synthesis uses dehydroalanine 100 in a Michael addition onto the cyclen 
35 instead of the standard SN2 addition used for the acetate functionality. This 
is due to the instability of the orthodox bromo and tosyl serine derivatives seen 
by Ferreira et al. (126) The dehydroalanine 100 was synthesised from protected 
serine (99), (122) (128) via a dehydration reaction using copper(I) and a 
dicarbodiimide as reported by Zhu et al. (Scheme 24) (129)  
76 
 
Originally the aim was to synthesise the target compound by reacting the 
dehydroalanine 100 with tert-butyl protected DO3A 40 synthesised previously, 
yet this reaction yielded only starting materials (Scheme 24). 
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Scheme 24 Synthesis towards a DO3A-N-Į-aminopropinate based chelator CA3. 
Mono addition onto an unfunctionalised cyclen ring 35 however yielded the expected 
compound, just in much lower yields than in the literature, 50% compared to 77% 
(Scheme 25). (126) The yield was highly capricious and often a maximum of 10% yield 
was attainable, despite the majority of cyclen 35 being converted according to mass 
spectrometry detection. This poor yield can be attributed to retention and breakdown 
of the complex on silica as seen with other cyclen based compounds. As the cyclen 
35 starting material is relatively expensive, and the dehydroalanine 100 difficult to 
handle, the synthesis of this compound was abandoned.  
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Scheme 25 Michael addition of the dehydroalanine 100 onto the unsubstituted cyclen 35. 
3.4 Synthesis of Contrast Agent 4.  
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Figure 45 Contrast Agent 4 
An alternative gadolinium(III) chelator to DOTA is the AAZTA complex. As 
explained previously AAZTA has significant advantages over DOTA for despite 
having similar thermodynamic properties it occupies fewer co-ordination sites 
on the central gadolinium(III) ion. Thus two water molecules are free to 
coordinate to gadolinium(III), which in turn improves overall relaxivity. (77)  
The synthesis starts with a nitro-Mannich reaction to produce the 1,4-diazepine 
ring with both amines protected by benzyl groups (103). This reaction was 
completed using a method developed by Gugliotta et al. (79) and obtained a 
quantitative yield, identical to that reported. Compound 103 was to then 
undergo a hydrogenation reaction to simultaneously remove both benzyl 
groups and reduce the nitro group to an amine. Initially the procedure by 
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Gugliotta et al. (79) which used ammonium formate and formic acid as the 
hydrogen source, yielded a small amount of compound 104 which was 
inseparable from degradation products of the starting material (103). Two 
atmospheric pressure hydrogenations were then attempted, one with and one 
without the addition of acetic acid. (122) (130) The acetic acid method was to try 
and prevent catalytic poisoning from the primary and secondary amines 
produced. After 24 hours the hydrogenation containing acid had degraded to 
unidentifiable materials, whilst the hydrogenation without acid only underwent 
one de-benzylation after 24 hours and after 72 had degraded completely. To 
solve this problem a modified version of the parr hydrogenation used by Sengar 
et al. (75) was attempted. The reaction was undertaken at room temperature 
instead of 60 °C and for 48 hours due to equipment limitations. It was then 
observed that if the filtered solution was concentrated in vacuo at 40 °C, the 
resultant product (104) was a crude pale yellow oil, obtained in 85%. However, 
if the solution was concentrated in vacuo at room temperature to remove the 
ethanol, and then freeze dried to remove the water the resultant product (104) 
was a colourless oil obtained in 98%. The acetate group addition was achieved 
using a modified version of the method published by Sengar et al. to yield a 
pale yellow oil (105) as expected in an identical yield of 56% (Scheme 26).  
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Scheme 26 Synthesis of key intermediate 105 of the AAZTA based complex CA4. 
Once compound 105 was synthesised on gram scale a range of reactions were 
attempted to insert propargyl functionality at the hydroxyl position. Initially a 
mesylation was attempted, (131) yet this yielded an unidentifiable material that 
was later proved to be the chlorinated product (106) as well as a small amount 
of the known cyclised material (107) by mass spectrometry (Scheme 27).  
N
HO N
N
O
O
OO
O
O
O
O
N
Cl N
N
O
O
OO
O
O
O
O
MsCl, TEA,DMF
N
N
N
O
O
OO
O
O
O
O
105 106 107
0 oC, 30 min
Scheme 27 Attempted mesylation of the hydroxyl AAZTA complex 105. 
The cyclised material (107) has been widely reported in the literature to occur in 
the presence of acid or base, as the configuration of the hydroxyl in relation to 
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one of the acetate functionalities allows for the hydroxyl to attack the carbonyl 
to produce a tert-butoxide ion and a stable 6-membered ring as shown in 
Scheme 28. (75) (79)  
 
Scheme 28 Formation of [8,11-bis-tert-butoxy carbonylmethyl-3-oxo-4-oxa-1,8,11-triaza-
spiro[5.6]dodec-1-yl]]-aceticacid tert-butyl ester 107 in the presence of a base. 
Synthesis of the ether linked compound (109) was then attempted via an SN2 
reaction using propargyl bromide. When triethylamine was used as a base only 
starting material (105) was observed by mass spectrometry (Scheme 29). 
When sodium hydride was used the compound was seen to almost entirely 
cyclise (107). Whilst a judicious choice of base with an intermediate pKa 
between these two extremes may have permitted the desired reaction, such 
optimisation was deemed to be too time-consuming to be practical. Thus the 
ether linker route was abandoned for other potential linkers. 
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Scheme 29 Attempt to form an ether linkage 109 using propargyl bromide. 
Conversion of the hydroxyl group to a chlorine (106) was achieved using thionyl 
chloride. The crude material was taken onto the SN2 reaction using propargyl 
amine, triethylamine and acetonitrile to allow for insertion of the propargyl group 
into the AAZTA structure (110). (79) When carried out on a small scale (100 mg), 
the reaction yielded the expected product in a low 35% yield, yet when 
performed on a larger scale (1 g) one of the tert-butyl groups was removed and 
this product was produced in a 40% yield. This was inconsequential as the next 
step was the removal of the tert-butyl groups.  Unfortunatly during the removal 
of the tert-butyl groups half the compound cyclised to form the amide derivative 
of the cyclised structure, and despite following literature procedure (79) the 
attempt to hydrolyse this using sodium hydroxide yielded only degraded 
material (Scheme 30). 
82 
 
N
HO N
N
O
O
OO
O
O
O
O
N
Cl N
N
O
O
OO
O
O
O
O
N
H
N N
N
O
O
OOO
O
O
O
N
H
N N
N
OH
O
OHOHO
O
OH
O
Thionyl Chloride
Propargyl Amine, 
K2CO3, DMF, rt,
16 h
35% over 
2 steps
1. TFA
2. NaOH
105 106
110111
rt, 2 h
rt, 16 h
 
Scheme 30 Attempted synthesis of the AAZTA based contrast agent CA4 using a 
nitrogen bridge. 
A recent paper by Gugliotta et al. (79) reacted the primary alcohol of the AAZTA 
(105) with isocyanates to produce carbamate compounds that were stable 
enough to withstand tert-butyl cleavage conditions (TFA), without producing 
any cyclised side product (107). Via a Curtius rearrangement (132) the 
isocyanate of propiolic acid (113) was generated in situ before addition of the 
free alcohol (105), to try and produce the carbamate (114). Whilst all of the 
AAZTA starting material (105) was consumed by mass spectrometry, the end 
product was unidentifiable (Scheme 31).  
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Scheme 31 Attempt to form the carbamate derivative 114 using the Curtius 
rearrangement 
Thus the synthesis was modified and the chloroformate AAZTA derivative (114) 
was produced using triphosgene. This was then reacted with propargyl amine 
to yield the corresponding carbamate in a yield of 32%. (133) The carboxylate 
groups were then deprotected using TFA, to yield the tetra TFA salt (115), 
before undergoing metal insertion using the same method as for the DOTA 
based complexes (CA1 and CA2). This produced the europium(III) complex 
(CA4-Eu) in an overall yield of 12% and the gadolinium(III) complex (CA4) in 
9% (Scheme 32). 
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Scheme 32 Synthesis of the AAZTA based complex CA4. 
3.5 Synthesis of Targeting Vector 1. 
To target the MRI contrast agents to hypoxic tumours a targeting vector must 
be conjugated via the alkyne functionality in the complexes. The initial vector 
synthesised consists of the known 2-nitroimidazole targeting vector conjugated 
to an azide moiety TV1. The azide is required to react with the alkyne on the 
FRQWUDVWDJHQWVWRIRUPWKHWULD]ROHOLQNHUXVLQJµFOLFN¶FKHPLVWU\. (108)  
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Figure 46 Targeting Vector 1 TV1. 
2-Nitroimidazole 117 was synthesised from 2-aminoimidazole hemisulfate 116, 
via a diazatisation and subsequent displacement method developed by Takuma 
et al. (134) This occurred in a 70% yield comparable to a literature yield of 76%. 
The 2-nitroimidazole 117 was then to be conjugated to the azide functionality 
via an SN2 reaction with dibromoethane as previously undertaken by Chu et al. 
(135)
 Whilst the corresponding product was confirmed by mass spectrometry the 
product 118 could never be isolated and confirmed by NMR. (Scheme 33) 
 
 
Scheme 33 Route 1 towards the synthesis of the 2-nitroimidazole based targeting vector 
TV1. 
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As an alternative to the SN2 reaction, an epoxide was used to form the ethyl 
linker as suggested by Bejot et al. (118). The epoxide used was propylene oxide 
which had the potential to yield two regioisomers (119a and b)(Figure 47).  
 
Figure 47 The two possible regioisomers after propylene oxide opening. 
Whilst not the originally intended compound propylene oxide is significantly less 
expensive and easier to handle than ethylene oxide. It also has the advantage 
of inserting an extra carbon into what could potentially be an explosive 
compound. During purification only the 119b regioisomer was isolated and 
characterised. A Mitsunobu reaction as outlined by Sen et al. (136) was then 
attempted to convert the hydroxyl group to an azide, yet this yielded only 
starting material (119b) by mass spectrometry and IR spectroscopy (Scheme 
34). 
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Scheme 34 Route 2 towards the synthesis of the 2-nitroimidazole based targeting vector 
TV1. 
Thus a route via a mesylate intermediate followed by displacement with an 
azide was explored (Scheme 35). (131) Whilst the mesylate was formed (121) 
and confirmed by NMR, yields were <10%, and azidation using sodium azide to 
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displace the mesylate (120) was unsuccessful as proven by mass spectrometry 
and IR spectroscopy.  
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Scheme 35 Route 3 towards the synthesis of the 2-nitroimidazole based targeting vector 
TV1. 
Finally inspired by a patent which produced similar compounds but with a PEG 
linker between the imidazole and the azide a method was deduced to produce 
the final compound TV1. (114) Initially 2-nitroimidazole 117 was conjugated to a 
tosyl protected ethanol group using ethylene glycol bis-p-toluenesulfonate and 
triethylamine (122). When run overnight the maximum isolatable yield was 
11%, yet when left for 4 days this increased to 86%. The tosyl group was then 
displaced using sodium azide at room temperature to produce the final 
compound (TV1) in a 58% overall yield from 2-aminoimidazole hemisulfate 116 
(Scheme 36).   
88 
 
NHN
NO2
NN
NO2
O
S O
O
NN
NO2
N3
NaN3, DMF
Ethylene glycol 
bis-p-toluenesulfonate,
TEA, DMF
rt, 16 h, 96%rt, 4 days, 86%
TV1117 122
 
Scheme 36 Completed synthesis of a simple 2-nitroimidazole targeting vector TV1. 
3.6 Synthesis of targeting vectors 2-4 
An alternative targeting vector to the 2-nitroimidazole is the nitrobenzyl series of 
compounds. For the leaving group to be activated successfully the nitro 
functionality must be in either the ortho or para position regarding the leaving 
group of choice. (137) Otherwise the resonnance will not allow the leaving group 
to leave and produce the reactive methylene. These compounds have been 
demonstrated to be successful with regards to hypoxia activated pro-drugs in 
the literature, even if they are not as widely used in comparison to the 
nitroimidazoles. (94) (138) (139) (140) (141) (142) 
 
Figure 48 Targeting vector 2 
The initial alternative target vector was TV2 (Figure 48). Despite numerous efforts at 
optimisation, the key Friedel-Crafts acylation/alkylation (Scheme 37) failed to 
produce the desired product (126), due to the deactivating effect of the nitro group. 
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Scheme 37 Route 1 for the synthesis of an alternative targeting vector based on 2-
Nitrobenzene (TV2). 
Thus two alternative target compounds were developed, still containing all the 
necessary functionalities, just in a different configuration (Figure 49).  
 
Figure 49 Modified targeting vectors 3 and 4 
These compounds were based on those designed by Jiang et al. (116) for 
ADEPT activation of cancer prodrugs using Escherichia coli nitroreductase. 
These compounds are still able to release a leaving group to form an activated 
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methylene, and still contain the azide linker, which will alloZ IRU WKH µFOLFN¶
reaction to the contrast agent. 
The synthesis of both compounds (TV3 and TV4) was initiated with a standard 
Grignard addition using vinyl magnesium bromide, followed by a methoxy 
methyl ether (MOM) protection of the alcohol produced (131/2). The Grignard 
(129/30) produced significantly lower yields (76% and 26% respectively 
compared to 95% for the para complex (129) in the literature) with the 
exceptionally low yield for the ortho compound (130) attributed to steric 
hinderance from the nitro functionality. A MOM protection in compatible yields 
was then undertaken followed by a hydroboration to allow for the anti-
Markovnikov hydroxylation product (133/4). This reaction also produced 
significantly lower yields than those suggested in the original paper 55/56% 
respectively for the para (133) and ortho compound (134) compared to 78% in 
the literature. Once this intermediate was obtained the synthesis deviated from 
the paper by Jiang et al. (116) and the free alcohol was converted to an azide 
using diphenylphosphoryl azide (DPPA), DBU and sodium azide. (143) Whilst the 
desired product  was obtained in excellent yields (97%) for the para compound 
(135), the ortho compound (136) produced a mixture containing product and an 
unknown aromatic impurity, which was separated after the next step despite 
dramatically reducing the yield (20% over 2 steps).  The MOM group was 
removed using standard acid hydrolysis to leave the free secondary alcohol 
(137/8) for conversion to a suitable leaving group. (122) The leaving group 
chosen was a chloride ion, and was initially to be introduced using an Appel 
chlorination. (144) This procedure however produced only starting material 
(137/8), so thionyl chloride was used to successfully produce the chloride in a 
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reasonable 60% yield for the para compound (TV3) and a 43% yield for the 
ortho (TV4), (145) respectively to give an overall yields of 17% and 2% over 6 
steps, as seen in Scheme 38.  
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Scheme 38 Synthesis of para and ortho-nitrobenzyl targeting vectors TV3 snd TV4. 
During the synthesis of all the nitrobenzyl compounds, MOM chloride became 
temporarily unavailable, thus a slightly altered route was attempted, during 
which the hydroboration occurred on the free alcohol compound (130) to 
produce the diol (139), before selectively tosylating the primary alcohol over the 
secondary using stoichiometric control (140). The tosyl group could then be 
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displaced by an azide (138) using sodium azide. The final chlorination could 
then occur as before as seen in Scheme 39 to yield the product (TV4) in an 
overall yield of 1% (Scheme 39).  
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Scheme 39 Alternative synthesis of the ortho-nitrobenzyl targeting vector TV4. 
 
 
Figure 50 Targeting vector 5. 
Another nitro-benzyl targeting vector is the 2,4-dinitrobenzyl complex TV5. It 
has been widely used experimentally for ADEPT purposes (146) (147) (148) using 
E.coli nitroreductase, it can also be reduced by both rat and human DT 
diaphorase under hypoxic conditions. (149) (150) There is however a 5-fold 
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reduction in the rate of reaction when human DT diaphorase is used compared 
to rat DT diaphorase. (115) These compounds also have a more favourable 
redox potential compared to the mono-nitro compounds, as the di-nitro mustard 
compounds have a redox potential of -450mV  compared to -620mV for the 
para-nitro compound. (93)  
Synthesis of this complex (TV5) was carried out in an identical manner to the 
original nitrobenzyl compounds, with most yields around 50% per step most 
likely due to the steric hindrance caused by the nitro group in the ortho-position 
(Scheme 40).  
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Scheme 40 Synthesis of the 2,4-dinitrobenzyl targeting vector TV5. 
3.7 Synthesis of targeting vector 6 
The final targeting vector TV6 (Figure 51), was a 2-nitroimidazole based 
compound with the leaving group and azide containing side chain in the 5 
position. This allows for the reactive methylene to be formed under hypoxic 
conditions due to the resonance throughout the ring. This compound is 
considered to be an optimum combination of the technology used for targeting 
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vectors 2-4 with the more electronically favourable 2-nitroimidazole 
heteroaromatic system. 
 
Figure 51 Targeting vector 6 
The initial synthesis of these complexes involved the construction of the central 
heterocyclic structure as seen in Scheme 41. These steps were performed 
according to patents by Matteucci et al. in which the imidazole (149) is built up 
from sarcosine methyl ester 147, ethyl formate and cyanoamine in a reported 
45% yield over 2 steps (151) (152). The patents proposes two different methods, 
one used potassium carbonate for the initial formylation of the sarcosine methyl 
ester (147) and sodium hydride for the second formylation, whilst the other 
used sodium hydride to achieve both formylations in one step. Both methods 
were tried, with the potassium carbonate method achieving a yield of 45%, 
whilst the yield for the sodium hydride method was 29%. The overall yield was 
drastically improved however if the initial formylation using potassium 
carbonate was left for 3 days rather than the suggested 16 hours, as this 
pushed the yield for the ring formation up to 75% (Scheme 41).  
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Scheme 41 Synthesis of the functionalised 2-aminoimidazole heterocycle (149). 
The next step was the diazotisation of the 2-position in the ring before inserting 
a nitro group. This was attempted using a variety of methods, initially following 
the patent by Matteucci et al. (151) which used acetic acid as the proton source. 
Unfortunately, this method did not deliver the desired product (150). A method 
by Takuma et al. used previously on the 2-aminoimidazole hemisulfate (116), 
was also unsuccessfull. (134) A review of the original literature revealed a method 
by Cavaller et al. using fluoroboric acid, with a copper powder catalyst. (153) This 
method produced a pure yellow solid (150), but the yield was less than 5%, so 
a similar procedure by Lancini et al. was followed. (154)  This method was 
identical to the Cavaller method, but the extraction solvent was changed from 
ethyl acetate to diethyl ether. However the material obtained was unidentifiable. 
Finally a method by Asato et al. (155) using sulphuric acid as the proton source 
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and no copper catalyst was used, and this resulted in a 43% crude yield of 150 
as seen in Scheme 42.  
N
NH2N
EtO
O
N
NO2N
EtO
O
NaNO2, H2O,
H2SO4
<5 oC 30 min,
rt, 2 h, 43%
149 150  
Scheme 42 Diazatisation of the substituted 2-aminoimidazole (149). 
Once the nitro group was in place (150) the aim was to reduce the ester in the 
5-position to an aldehyde (151). This was initially attempted with DIBAL-H at -
78 °C, yet after a reaction time of 8 hours with 2 batches of DIBAL-H the 
reaction had only reached 6% conversion by NMR and there were signs of 
degradation. (156) Stronger reducing agents were then used to convert the ester 
(150) to the alcohol (152) using either LiAlH4 (157) or LiBH4, (152) yet both of these 
yielded degradation products. The ester (150) was therefore hydrolysed to the 
carboxylic acid (153) in a 70% yield using sodium hydroxide. (151) The carboxylic 
acid (153) was then initially reduced using borane (1M in THF), in 45% yield to 
produce the corresponding alcohol (152). (158) This reaction was highly 
capricious and the initial yield could not be repeated, so a method that formed 
an anhydride using CDI before reducing with NaBH4 was explored, but also 
proved to be unsuccessful (Scheme 43). (159)  
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Scheme 43 Attempted synthesis of 1-methyk-2-nitro-imidazole-5-carbaldehyde 151. 
An alternative route to the aldehyde (151) was then attempted. This method 
was inititated by a nitration of 4(5)-imidazolecarboxaldehyde 154 with nitric acid 
at room temperature as referenced by Ballani et al. (160) This produced the 2-
nitro-4(5)-imidazolecarboxaldehyde as 155 expected. However the aldehyde 
(155) could not be subjected to the Grignard conditions used in the nitro-benzyl 
syntheses, (116) due to its insolubility in any solvent other than water or 
methanol. Thus 1-methyl-imidazole-5-carbaldehyde 156, was nitrated after 
refluxing in nitric acid, but the same solubility issues arose, so the route was 
abandoned (Scheme 44).  
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Scheme 44 Alternative synthesis of 2-nitro-4(5)-imidazolecarboxaldehyde 155 and 1-
methyl-2-nitro-imidazole-5-carbaldehyde 151 
 
3.8 Conjugation of the contrast agent to the targeting 
vector. 
To form the completed complexes, the Copper(I)-catalyzed Azide-Alkyne 
Cycloaddition was used. (107) ,QLWLDO RSWLPLVDWLRQ UHDFWLRQV ZHUH UXQ WR µFOLFN¶
contrast agent 1 CA1 to targeting vector 3 TV3 (Scheme 46). 
 
Scheme 45 "Click reaction between contrast agent 1 CA1 and targeting vector 3 TV3. 
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The reactions were monitored by HPLC and the key peak areas analysed using 
mass spectrometry. It was deduced that the most successful reactions would 
be those with the largest peak area for the targeted compound.  
An inital screen was run to identify the best solvent system for the reaction as it 
was noted that the targeting vector had poor solubility in water. Whilst the 
reaction did occur in 100% water it was found that using either a methanol or 
tert-butanol co-solvent increased product formation as seen in table 3.  
Table 3 Table summarising the solvent optimisation of the 'click' reaction. 
Reaction 
Solvent 
Amount and source of catalyst and reducing 
agent. 
Product peak 
area % 
Water Cu(II)SO4 100% + sodium ascorbate 100% 65 
1:1 MeOH:H2O Cu(II)SO4 100% + sodium ascorbate 100% 80 
1:1 tBuOH:H2O Cu(II)SO4 100% + sodium ascorbate 100% 78 
All of these reactions were run at room temperature for 24 h in 1mL of solvent. 
The next step was to screen the source of copper and the amounts used as 
seen in table 4.  
Table 4 Table summarising the catalyst optimisation of the 'click' reaction. 
Reaction 
Solvent 
Amount and source of catalyst and reducing 
agent. 
Product peak 
area % 
1:1 MeOH:H2O Cu(II)SO4 100% + sodium ascorbate 100% 80 
1:1 MeOH:H2O Cu(II)SO4 10% + sodium ascorbate 10% 23 
1:1 MeOH:H2O [Cu(I)(MeCN)4]PF610% 0 
All of these reactions were run at room temperature for 24 h in 1mL of solvent. 
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Overall the best conditions were determined to be stoichemetric amounts of 
copper and sodium ascorbate, yet when the reactions were purified a large 
amount of green by-product (containing a small amount of product by mass 
spectrometry) was produced, and then lost when filtering the solution for HPLC 
purification, resulting in only an 8% yield. 
To try and improve purification a method inspired by work reported by Mindt et 
al. was used. (161) In this strategy WKHµFOLFN¶UHDFWLRQtakes place before the tert-
butyl groups had been removed and gadolinium (III) has been inserted 
(Scheme 47). It was hoped that using standard silica chromatography would 
produce a higher yield as any product caught in the precipitate could also be 
loaded onto the column. Initial tests using the protected DO3A based contrast 
agent (78) and the 2-nitroimidazole based targeting vector (TV1) proved 
unsuccessful and no product was isolated.  
Scheme 46 Attempts at the 'click' reaction using the protected DO3A complex 78 and 
targeting vector 1 TV1 
For further optimisation coumarin dye DYE1 (Figure 52) was used instead of a 
hypoxia targeting vector. This had an advantage as the reaction could then be 
monitored using UV, for the coumarin dye used only fluoresces o
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triazole ring has been formed. It also prevented waste of the precious targeting 
vectors that had been synthesised in house and discussed earlier.   
 
Figure 52 Coumarin Dye DYE1 
The coumarin dye DYE1 was synthesised following a route developed by 
Sivakumar et al. which used 2,4-dihydroxybenzaldehyde 158 and N-acetyl 
glycine refluxed in acetic anhydride to produce the intermediate 3-(Acetamino)-
2-oxo-2H-chromen-7-yl acetate 159 as a yellow solid. (162) This then underwent 
acetate removal by acid hydrolysis followed by a diazatisation to produce the 
final coumarin dye DYE1 as a brown solid in an overall yield of 9%. This yield is 
much lower than the quoted 54% with most of the material lost during the initial 
step, which had a maximum achieved yield of 11% (Scheme 48). (162)  
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O 1. HCl, EtOH reflux, 1 h
2. NaNO2, <5 oC, 5 min
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150 oC, 4 h, 11% 85%
158 159
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Scheme 47 Synthesis of azido coumarin dye DYE1. 
To help prevent any copper displacing the gadolinium(III), copper(I) ligands 
THPTA 160 and TBTA 161 were used in the hope it would produce higher 
overall yields. (163)  
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Figure 53 Copper (I) ligands TBTA and THPTA. (163) 
When THPTA 160 was used it appeared to produce a brighter fluorescence 
than when TBTA 161 or no copper (I) ligand was used to the naked eye 
suggesting more formation of product. Yet when the reaction was analysed by 
HPLC it appeared that the number of side products dramatically increased, 
some of which were also UV active, and purification became more difficult.  
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As the completed contrast agents run almost at the solvent front on a C18 silica 
HPLC column, it was decided to investigate reverse phase silica 
chromatography as a method of purifiying these compounds. By monitoring the 
purification using reverse phase TLC, it was discovered that the column could 
be washed initially with methanol, which would remove any unreacted targeting 
vector, before flushing with water to elute the final compound. Assuming all of 
the contrast agent starting material had been consumed in the reaction the 
water fraction was pure. These compounds were then tested with xylenl orange 
to prove there was no free gadolinium(III) in the fractions. The yields for the 
compounds successfully synthesised have been summarised in table 4. 
Table 4 <LHOGVIRUWKHµclLFN¶ reaction used to produce the final compounds. 
Compound 
Name 
Compound Produced Yield 
C1 
 
42% 
 
C2 
 
8%, purified 
by HPLC.  
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C3 
 
21% 
CA1-DYE 
 
19% 
C4 
 
Not 
synthesised 
due to 
limited time 
constraints. 
C6 
O
O
N
H
N
N N
NN
NO2 N
N
N
O
O
O
O
O OOO
GdIII
-
 
Not 
synthesised 
due to 
limited time 
constraints. 
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-
 
Not 
synthesised 
due to 
limited time 
constraints. 
 
3.9 NMR Relaxivity testing 
A series of eight known contrast agent concentrations between 0.1 and 2.5 mM 
were used to calculate the relaxivity value of the contrast agents synthesised. 
The samples were made up in milli q water rather than the standard phosphate 
buffer due to the small quantities synthesised, and the need to recover the 
complexes for further testing. Whilst this prevents the results from being directly 
comparable with the literature any difference in relaxivity should be negligible 
for DOTA and AAZTA based compounds at physiological pH.  (70) (164) These 
samples were then subjected to an inverse recovery pulse sequence used to 
UHFRUG WKH105UHOD[LYLW\ GDWD7KLV VHTXHQFHEHJLQVZLWK DQ LQLWLDO ʌ
pulse which rotates the magnetism so it aligns with the ±Z axis. This then 
undergoes longitudinal relaxation and the magnetism realigns with the +Z axis., 
however before WKLVHTXLOLEULXPLVUHDFKHGDʌSXOVHLVDSSOLHGURWDWLQJ
the magnetism so it aligns in the X-Y plane. The time difference between these 
pulses is very short (t = 20-2500 ms) and the strength of the resulting 
magnetism seen in the X-Y plane is directly related to the T1 relaxation time. 
(117)
  The spectrometer was run at 20 MHz at 298K (Figure 54). 
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Figure 54 Inversion recovery pulse sequence. (117)  
The data recorded from these experiments is a MRI graphic (Figure 55). The 
intensity of each sample tube in this graphic is averaged and extrapolated using 
Matlab computer software. This data is then plotted as an exponential showing 
intensity as a function of time (Figure 56).  
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Figure 55 A T1 weighted composite image of the DO3A complex with inversion times of 
20 to 2500 ms. 
 
Figure 56 A W\SLFDOHYDOXDWLRQRI05VFDQY¶VWLPHQHHGHGWRFDOFXODWH71. 
The exponential inversion recovery function S(t) = S(0)(1-2exp(-t/T1)) was  
fitted by a non-linear Levenberg±Marquardt algorithm to provide S(0) and the  
T1 value, the reciprocal of which is then plotted against concentration (Figure 
57). The gradient of this plot gives the relaxivity (r1) of the contrast agent in mM-
1s-1. The results of which are shown in table 5.  
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Figure 57 The correlation between calculated T1 and Concentration for Gd(III)DO3A (CA1). 
Table 5 Relaxivity values of the compounds tested. 
Name and structure of Compound Relaxivity Value at 
20MHz, 298K. 
Gd(III)-DO3A 
 
8.3 ± 0.8 mM-1s-1 
CA1 
 
4.1 ± 0.4 mM-1s-1 
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CA2 
N N
NN
NH
HN
O
O
O
O
O
O
GdIII
+
 
 
3.4 ± 0.3 mM-1s-1 
CA4 
N
O N
N
O
O
OO
O
O
O
OO
H
N Gd
III
-
 
7.0 ± 0.5 mM-1s-F1 
C1 
N N
NN
H
N
O
O O
O
O
OO
N
NN
N N
O2N
GdIII
 
5.3 ± 0.7 mM-1s-1 
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C2 
N N
NN
H
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O O
O
O
OO
GdIII
N
NN
Cl
NO2
 
1.4 ± 0.06 mM-1s-1 
 
Initially the relaxivity of Gd(III)-DO3A was calculated so the data could be 
compared to that in the literature, however as the samples were analysed in 
pure water rather than a buffer this value was high at 8.3 mM-1s-1, almost 
double the literature value of 4.8mM-1 s-1 at 20 MHz and 312 K. This is because 
the angle at which the two water molecules bind is suitable for binding of much 
stronger molecules including phosphates found in biological systems and the 
buffers commonly used. (70) However CA1,2 and 4 which are the propargyl 
derivatives of the parent DOTA and AAZTA compounds were found to have 
comparable relaxivities to their parent compounds. For CA1 and CA2 reported 
values of 4.1 and 3.4 mM-1s-1 which corresponded to the DOTA value of 3.5 
mM-1s-1 (68), and CA4 has a reported value of 7.0 mM-1s-1 compared to 7.3 mM-
1s-1 (79) for the hydroxyl AAZTA derivative. As for the final compounds, whilst C1 
showed promise with a relaxivity value of 5.3 mM-1s-1, C2 had a very poor 
relaxivity value of 1.4 mM-1s-1 suggesting there are potential impurities, possibly 
the oxidised sodium ascorbate as this had a similar Rf-value on the HPLC 
column.  
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3.10 Enzymatic testing for activation of the targeting 
vectors under a hypoxic environment. 
To determine if the compounds synthesised were activated under hypoxic 
conditions a modified version of the assay developed by Bejot et al. was 
adopted. (165) This assay uses the enzyme Xanthine oxidase which converts 
xanthine 162 into uric acid 163. This oxidation requires a single electron 
transfer from the xanthine to an electron acceptor. (166) In normoxic conditions 
this acceptor is usually molecular oxygen, though under hypoxic conditions 
nitroimidazoles can be used as suitable alternatives. This then allows for the 
reduction of the nitro functionality to the hydroxylamine or the final amine 
compound (Scheme 49).  
 
Scheme 48 Conversion of Xanthine 162 and 2-nitroimidazole 117 using Xanthine oxidase 
and hypoxic conditions. 
The amount of enzyme in the assay had to be reduced compared to the 
literature precedence as the initial amount produced a rate too fast to be 
monitored by the UV spectrometer available. To confirm the validity of this 
assay a series of controls were run using 2-nitroimidazole 117 as the oxidising 
agent. This was chosen as the molecule is easily synthesised (as seen in 
Scheme 33) and known for its ability to be reduced under a hypoxic 
environment. (167) Whilst the aerobic assays worked as expected there were 
difficulties purging oxygen from the system using the methods suggested in the 
literature, as outlined in table 6.  
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Table 6 The methods used to try and achieve a hypoxic environment. 
Method for obtaining the hypoxic 
conditions. 
Rate of conversion of xanthine to 
uric acid, and reduction of 
nitroimidazole. 
Aerobic conditions. Xanthine consumed 0.78 mMmin-1U-1 
±0.025, Uric Acid formed 0.88 mMmin-
1U-1 ±0.06. No reduction of 2-
nitroimidazole 
Pre gassing the solution with nitrogen, 
before purging using a vacuum pump. 
Repeated >5 times. (Adapted from 
paper by Tatsumi et al. (168)) 
Xanthine consumed 0.76 mMmin-1U-1, 
uric acid formed 1.29 mMmin-1U-1. No 
reduction of 2-nitroimidazole 
Bubbling humidified argon through the 
substrate and enzyme buffer solutions 
for >20 minutes. (Adapted from Bejot 
et al. (165)) 
Xanthine consumed 0.50 mMmin-1U-1, 
uric acid formed 0.79 mMmin-1U-1. No 
reduction of 2-nitroimidazole 
Bubbling nitrogen through the 
substrate and enzyme buffer solutions 
for >20 minutes. (Adapted from Clarke 
et al. (169)) 
Xanthine consumed 0.76 mMmin-1U-1, 
uric acid formed 0.76 mMmin-1U-1. No 
reduction of 2-nitroimidazole 
Freeze substrate and enzyme buffer 
solutions. Put under vacuum and 
allow to defrost. Purge with argon. 
Repeat >4 times.  
Xanthine consumed 0.20 mMmin-1U-1, 
uric acid formed 0.23 mMmin-1U-1. No 
reduction of 2-nitroimidazole 
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Due to technological difficulties and time constraints this assay could not be 
taken further. 
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Chapter 4 Conclusions and Future Work.  
The initial aim of this thesis was to synthesise a series of building blocks 
containing either an alkyne or azide functionality to allow for copper(I) 
mediated cycloaddition to produce a series of final complexes.  
Overall three contrast agent units containing an alkyne functionality were 
synthesised. These then had their relaxivity values calculated, and all 
produced similar results to those seen by the parent compounds.  
In the end only the DO3A based contrast agent CA1 was conjugated to any 
of the hypoxia targeting vectors. This was due to it being the contrast agent 
available in the largest quantities as it had the shorter synthetic route. Hence 
it was used in most of the test conjugations and purifications, and when time 
ran out these were compounds used for final testing.  
With regards to the hypoxia targeting vector, four potential compounds were 
synthesised. One was based on a central 2-nitroimidazole structure, whilst 
the other three used a central nitro-benzene based structure. Unfortunately 
the assay to prove their effectivity under hypoxic conditions was not 
completed. To do so would require time to improve the seal on the UV 
cuvette, hopefully leading to a properly degassed soloution, before the 
addition of the Xanthine Oxidase. An alternative assay would use HT1080 
cells cultured under both normoxic and hypoxic conditions, in which the 
uptake of the hypoxia targeting vectors could be calculated by measuring 
their concentration in the lysed cells.  
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Of the targeting vectors synthesised the 2-nitroimidazole based compound 
(TV1) is by far the simplest synthetically, and would probably have the most 
favourable hypoxic retention, based on similar compounds in the literature.  
Only 2 final complexes were synthesised, C1, which combined the DO3A 
based contrast agent (CA1) with the 2-nitroimidazole based targeting vector 
(TV1). This produced a similar relaxivity value to the parent CA1 complex. 
Thus it can be concluded that there is no interference from the 2-
nitroimidazole or the triazole linker with regards to the relaxation rate 
produced by the bound gadolinium(III) ion. C2, synthesised from CA1 and 
the para-nitrobenzyl derivative targeting vectore (TV2), however produced a 
disappointingly low result, assumed to be due to contamination of the 
sample.  
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Figure 58 Final complexes synthesised. 
Whilst the methods outlined in Chapter 3 allowed for the production of the 
desired contrast agents, some of which were successfully completed, this 
has not been the most expedient way of conjugating a hypoxia targeting 
vector to a gadolinium based contrast agent. The reason for this is down to 
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the inclusion of the copper(I) mediated cycloaddition based linker, which 
caused significant synthetic problems, not only in the incorporation of either 
an alkyne or an azide into the original components, but also in the final 
conjugation to produce the targeted contrast agents.  
In the future I would design the compounds with a simple ethylene diamine 
linker, which in the case of the DOTA based structures would be easy 
enough to encorporate by producing the amine based analogue of the 
targeting vector (165) and reacting it with bromo acetylbromide, to produce 
the bromoacetamide (166) which can then be reacted with the protected 
DO3A (40) to form the protected complex (167) (Scheme 60). This could then 
undergo TFA deprotection of the tert-butyl protection groups and insertion of 
the gadolinium (III) ion to produce the final complex.  
 
Scheme 49 Potential route to the protected amine DOTA derivative (167). 
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As for the AAZTA derivatives the amine based analogue of the targeting 
vector (165) would also be used, and conjugated to AAZTA via the 
carbamate linker used in this thesis to incorporate the alkyne functionality.  
 
Scheme 50 Potential conjugation of the AAZTA complex 105 to a targeting vector with an 
ethylene diamine linker. 
Those compounds produced in this thesis had NMR relaxivities comparible 
with the parent DOTA or AAZTA based complexes and it is assumed that the 
alternative complexes suggested above would have similar properties as the 
groups co-ordinating to the central gadolinium ion would be the same, the 
only differences would come from potential steric effects caused by the more 
flexible linker.  
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Chapter 5 Experimental 
General Experimental 
All 1H NMR spectra were recorded on a Bruker AV 400 FT at 400 MHz and at 
298 K. Data are reported as follows: chemical shifts in ppm relative to residual 
SURWLFVROYHQWVKLIWRQ WKHįVFDOH&'&O3 (7.26 ppm), D2O (4.79 ppm), CD3OD 
(3.31 ppm), d6 DMSO (2.50 ppm) or CD3COCD3 (2.05 ppm), integration, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = 
broad), coupling constants (J, Hz) and assignment. All multiplicity and coupling 
constants are reported as viewed. 13C NMR spectra were recorded on a Bruker 
AV 400 at 100 MHz, and at 298 K. Data are reported as follows: chemical shifts 
in ppm relative to residual CDCl3 (77.1 ppm), CD3OD (49.0 ppm), d6 DMSO 
(39.5 ppm), or CD3COCD3 SSPRQWKHįVFDOH$VVLJQPHQWVZHUHPDGH
using DEPT 135 and DEPT 90 (pulse experiments), HMBC and HSQC 
experiments.  
All electrospary ionisation accurate mass spectrometry was recorded on a 
Bruker MicrOTOF time of flight spectrometer. All electron ionisation was 
recorded on either a VG AutoSpec magnetic sector spectrometer or a Bruker 
Apex IV 4.7 T ICR FTMS an ion cyclotron resonance fourier transform 
spectrometer with a 4.7 tesla magnet.  
DCM, DMSO, acetone and piperidine were dried by distillation from calcium 
hydride or sodium and stored over preactivated 4 Å molecular sieves. Dry DMF 
was purchased from Alfa Aesar. All other reagents were purchased from either 
Sigma Aldrich Chemicals, Alfa Aesar, Fisher, Fluka and Strem Chemicals and 
used as supplied unless otherwise stated. Thin layer chromatography was 
120 
 
performed using Merck Kieselgel 60 F254 plates. Visualisation was by UV light 
and staining with potassium permanganate, vanillin or phosphomolybdic acid 
(PMA) with heating. Column chromatography was performed using Merck 
Kieselgel 35-ȝ  c XQOHVV RWKHUZLVH VWDWHG Reverse phase column 
chromatography was performed using Fluka Silica gel 100 C18-Reversed 
phaseDQGWKHFRUUHVSRQGLQJ7/&¶VZHUHUXQRQMerck HX615476 RP-18 F254s 
plates. 
All HPLC was run on an Aglient 1200 system, using either a Zorbax Eclipse 
XBD-&DQDO\WLFDOFROXPQ[PPȝPSRUHVL]HRUD=RUED[(FOLSVH
XBD-C18 semi-SUHSFROXPQ[PPȝPSRUHVL]H Solvent A was milli 
Q water and solvent B was acetonitrile. 
All centrifugation was run on a Beckman GS-15R centrifuge for 5 minutes at 
3000 rpm, 25 °C. 
All chemical names were generated using ChemBioDraw Ultra 12.0.  
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Chemical Experimental 
1,4,7,10-Tetraaza-cyclododecane-1,4,7-tricarboxylic acid-tri-tert-
butyl ester (36).  
 
A solution of di-tert-butyl dicarbonate (9.5 mL, 41.4 mmol, 2.4 equiv) was added 
to a stirred solution of cyclen (35) (3.0 g, 17.4 mmol, 1 equiv) in 
dichloromethane (20 mL) at room temperature and under a nitrogen 
atmosphere. The solution was stirred for 2 h before concentrating in vacuo. The 
residue was purified by flash chromatography on silica (DCM/MeOH, 96/4) to 
yield the protected amine as a colourless foam (36). Reproduced from Gaillard 
(8)
 (4.0 g, 49%).  
mp, 56 ± 57 °C (Lit, (168) 54 ± 55 °C); Ȟmax (CHCl3)/cm-1, 1681 (C=O); įH (400 
MHz; CDCl3) 1.43 (18H, s, C(CH3)3), 1.45 (9H, s, C(CH3)3), 2.83-3.64 (16H, m, 
NCH2CH2N);  įC (100 MHz; CDCl3) 28.6, 28.4 (C(CH3)3), 50.8, 49.5, 49.2, 45.5 
(NCH2CH2N), 79.3, 79.2 (C(CH3)3), 155.6, 155.4 (C=O); HRMS m/z (+ ESI): 
Found [MH]+, 473.3334. C23H45N4O6 requires [MH]+, 473.3334. 
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1,4,7,10 Tetraaza-cyclododecane-1,4,7,10-tetra carboxylic acid tri-
tert-butyl ester 9H-fluoren-9-ylmethyl ester (37). 
 
A suspension of 1,4,7,10-tetraaza-cyclododecane-1,4,7-tricarboxylic acid tri-
tert-butyl ester (36) (4.01 g, 8.5 mmol, 1 equiv) and 10% aqueous sodium 
hydrogen carbonate (10 mL) in 1,4-dioxane (10 mL) was treated with 9-
fluorenylmethoxycarbonyl chloride (3.22 g, 12.7 mmol, 1.5 equiv). The 
suspension was stirred at room temperature for 16 h. Water (10 mL) was added 
and the aqueous layer was extracted with chloroform (3 x 20 mL). The 
combined organic extracts were dried over magnesium sulfate, filtered and 
concentrated in vacuo to yield the amine as a colourless foam (37). 
Reproduced from Gaillard (8)(5.80 g, 98%).  
mp, 84 °C (Lit, (8) 94-96 °C); Ȟmax (CHCl3)/cm-1, 3068 (CHAr), 1686 (C=O); įH 
(400 MHz; CDCl3) 1.46 ppm (18H, s,  C(CH3)3), 1.50 (9H, s, C(CH3)3), 3.00-
3.60 (16H, m, NCH2CH2N), 4.25 (1H, t, J = 5.5 Hz, COOCH2CH), 4.55 (2H, bs, 
COOCH2CH), 7.37 (2H, td, J = 7.4 Hz, 1.0 Hz, CHAr), 7.42 (2H, t, J = 7.4 Hz, 
CHAr), 7.62 (2H, d, J = 7.4 Hz, CHAr), 7.78 (2H, d, J = 7.4 Hz,  CH$UįC (100 
MHz; CDCl3) 28.4, 28.5 ppm (C(CH3)3), 47.3 (COOCH2CH), 49.5-51.0 (bs, 
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NCH2CH2N), 67.0 (COOCH2CH), 80.0 (C(CH3)3), 127.7, 127.2, 124.7, 120.0 
(CHAr), 144.0,141.4 (CAr), 156.2 (C=O); HRMS m/z (+ ESI): Found [MH]+, 
695.3982 C38H55N4O8 requires [MH]+, 695.4020. 
 
1,4,7,10-Tetraaza-cyclododecane-1-carboxylic acid 9H-fluoren-9-
ylmethyl ester (38). 
 
A solution of 1,4,7,10 tetraaza-cyclododecane-1,4,7,10-tetracarboxylic acid tri-
tert-butyl ester 9H-fluoren-9-ylmethyl ester (37) (5.80 g, 8.3 mmol, 1 equiv) in 
dichloromethane (25 mL) was treated with trifluoroacetic acid (15 mL) at room 
temperature and stirred for 16 h. The solution was then concentrated in vacuo 
with dichloromethane (2 x 10 mL) to yield the triamine as an orange oil (38). 
Reproduced from Gaillard (8)(2.82 g, 86%).  
Ȟmax (CHCl3)/cm-1, 3662 (NH),  & 2 įH (400 MHz; CDCl3), 2.59-3.41 
(16H, m, NCH2CH2N), 4.19 (1H, t, J = 2.0 Hz, COOCH2CH), 4.69 (2H, s, 
COOCH2CH), 7.32 (2H, t, J = 7.3 Hz, CHAr), 7.39 (2H, t, J = 7.3 Hz, CHAr), 
7.51 (2H, d, J = 7.3 Hz, CHAr), 7.73 (2H, d, J = 7.3 Hz,  CHAr); įC (100 MHz; 
CDCl3), 47.8 (COOCH2CH), 44.9, 45.1, 46.9, 53.4 (NCH2CH2N), 66.9 
(COOCH2CH), 120.0, 125.0, 127.4, 128.0 (CHAr), 141.4, 143.4 (CAr), 160.6 
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(C=O); HRMS m/z (+ ESI): Found [MH]+, 395.2427 C23H32N4O2 requires [MH]+ 
395.2447;  
 
4,7,10-Tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-
cyclododecane-1-carboxylic acid 9H-fluoren-9-ylmethyl ester (39). 
 
A solution of 1,4,7,10-tetraaza-cyclododecane-1-carboxylic acid 9H-fluoren-9-
ylmethyl ester (38) (2.82 g, 7.1 mmol, 1 equiv) in dimethylformamide (15 mL) 
was added dropwise to a stirred solution of tert-butyl bromoacetate (4.7 mL, 
32.0 mmol, 4.5 equiv) and potassium carbonate (4.80 g, 34.7 mmol, 5 equiv) in 
dimethylformamide (5 mL) at room temperature under a nitrogen atmosphere. 
The suspension was stirred for 16 h at room temperature and then filtered. The 
filtrate was concentrated in vacuo and the residue was purified by column 
chromatography (DCM/MeOH, 100/0 ± 9/1 gradient) to yield the triester as a 
yellow oil (39). Reproduced from Gaillard (8) (2.26 g, 43 %).  
Ȟmax (CHCl3)/cm-1, 1726, 1692 (C=O); įH (400 MHz; CDCl3), 1.21 (18H, s, 
C(CH3)3), 1.24 (9H, s, C(CH3)3), 2.40-3.45 (22H, m, NCH2CH2N, NCH2COO), 
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3.98 (1H, t, J = 5.9 Hz, COOCH2CH), 4.23 (2H, d, J = 5.9 Hz, COOCH2CH), 
7.07 (2H, td, J = 7.4 Hz, CHAr), 7.15 (2H, t, J = 7.4 Hz, CHAr), 7.35 (2H, d, J = 
7.4 Hz, CHAr), 7.52 (2H, d, J = 7.4 Hz, CHAr); HRMS m/z (+ ESI): Found 
[MH]+, 737.4480 C41H62N4O8 requires [MH]+, 737.4484. 
 
(4,10-Bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-
yl)-acetic acid tert-butyl ester (40).  
Method 1 
 
A solution of piperidine in dimethylformamide (piperidine/DMF, 1/9, 10 mL) was 
added dropwise to 4,7,10-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza- 
cyclododecane-1-carboxylic acid 9H-fluoren-9-ylmethyl ester (39) (2.26 g, 3.1 
mmol, 1 equiv). The resulting solution was stirred at room temperature for 10 
min prior to concentration in vacuo. The residue was triturated with diethyl ether 
and the resulting solid filtered and dried under vacuum to yield the triester as a 
white solid (40). Reproduced from Gaillard (8) (0.65 g, 41%).  
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HRMS m/z (+ ESI): Found [MH]+, 515.3783 C26H52N4O6 requires [MH]+, 
515.3803.  
 
 (4,10-Bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-
1-yl)-acetic acid tert-butyl ester .HBr salt (40).  
Method 2 
N N
HNN
O
O
OO
O
O
.HBr
 
To a solution of cyclen (35) (200 mg, 1.3 mmol, 1 equiv) in acetonitrile (150 
mL), sodium bicarbonate (350 mg, 4.2 mmol, 3 equiv) was added. This was 
then stirred for 15 min at room temperature under a nitrogen atmosphere. A 
solution of tert-butyl bromoacetate (800 mg, 4.2 mmol, 3 equiv) in acetonitrile 
(50 mL) was stirred at room temperature under a nitrogen atmosphere. The 
cyclen solution was added dropwise to the tert-butyl bromoacetate solution and 
stirred for 30 min at ambient temperature, prior to reflux at 80 °C for 24 h. The 
precipitate was filtered and the solution concentrated in vacuo. The residue was 
recrystallised from toluene, and washed in diethyl ether to yield the HBr salt as 
a white solid (40). Reproduced from Machitani et al. (73) (589 mg, 85%).  
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mp, 186-188 °C (Lit: 190-191 °C (169));Ȟmax (CHCl3)/cm-1  & 2 įH (400 
MHz; CDCl3), 1.40 (9H, s, C(CH3)3), 1.41 (18H, s, C(CH3)3), 2.75-3.12 (16H, m, 
NCH2CH2N), 3.24 (2H, s, NCH2COO), 3.33  (4H, s, NCH2COO); įC (100 MHz 
CDCl3): 27.4, 27.8 (C(CH3)3), 30.7, 35.8 (CH2COO), 41.8-56.1 (NCH2CH2N), 
80.5, 81.2 (C(CH3)3), 162.3, 170.5 (C=O); HRMS m/z (+ ESI): Found [MH]+, 
515.3804 C26H52N4O6 requires [MH]+, 515.3803.  
 
(4,7,10-Tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza -
cyclododec-1-yl)acetic acid benzyl ester (75). 
 
To a solution of (4,10-bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-
cyclododec-1-yl)-acetic acid tert-butyl ester .HBr (40) (200 mg, 0.3 mmol, 1 
equiv) in dimethylformamide (4 mL) potassium carbonate (64 mg, 0.5 mmol, 1.7 
equiv) was added and this was stirred at room temperature under a nitrogen 
atmosphere. A solution of benzyl bromoacetate (172 mg, 0.8 mmol, 2.7 equiv) 
in dimethylformamide (1 mL) was added dropwise to the suspension and stirred 
for 16 h. The precipitant was filtered from the reaction and the solution was 
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concentrated in vacuo to yield the crude amine as a white solid (75). 
Reproduced from Wangler et al. (121) (196 mg).  
HRMS m/z (+ ESI): Found [MH]+, 663.4315 C35H58N4O8 requires [MH]+, 
663.4327.  
 
 (4,7,10-Tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza -
cyclododec-1-yl)acetic acid (tris-t-Bu-DOTA) (76). 
 
To a solution of 4,10-bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-
cyclododec-1-yl)acetic acid tert-butyl ester .HBr (40) (100 mg, 0.15 mmol, 1 
equiv) in dimethylformamide (4 mL), potassium carbonate (60 mg, 0.5 mmol, 
3.3 equiv) and this was stirred under a nitrogen atmosphere at ambient 
temperature. A solution of bromoacetate (32 mg, 0.2 mmol, 1.3 equiv) in 
dimethylformamide (1 mL) was added dropwise to the suspension prior to 
stirring for 16 h. The reaction was then filtered to remove precipitate and the 
solution was concentrated in vacuo to yield the crude amine as a white solid 
(76). Adapted from Wangler et al. (121) (126 mg). 
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HRMS m/z (+ ESI): Found [MH]+ 573.3858 C28H52N4O8 requires 573.3858. 
 
 (1,4,7-Tris-tert-butoxycarbonylmethyl-10-prop-2-ynyl 
carbamoylmethyl-1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid 
tert-butyl ester (78). 
N N
NN
O
O
OO
O
O
O NH
 
To a suspension of (4,7,10-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza -
cyclododec-1-yl)acetic acid (76) (50 mg, 0.08 mmol, 1.3 equiv), propargyl 
amine (3 mg, 0.06 mmol, 1 equiv), o-(benzotriazol-1-yl)-111ƍ1ƍ-
tetramethyluronium hexafluorophosphate (43 mg, 0.08 mmol, 1.3 equiv) and 1-
hydroxybenzotriazole hydrate (10 mg, 0.08 mmol, 1.3 equiv) in 
GLPHWK\OIRUPDPLGHP/GLLVRSURS\OHWK\ODPLQHȝ/PPROHTXLY
was added. This was stirred at ambient temperature for 2 h before being 
concentrated in vacuo, to obtain the crude product as an off white solid (78). 
Adapted from Montalbetti et al. (172) 
HRMS m/z (+ ESI): Found [MH]+, 610.4164, C31H55N4O8 requires [MH]+, 
610.4174 
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(4,10-Bis-tert-butoxycarbonylmethyl-7-methoxycarbonylmethyl-
1,4,7,10tetraaza-cyclododec-1-yl)-acetic acid tert-butyl ester (77). 
 
To a suspension of (4,10-bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-
cyclododec-1-yl)-acetic acid tert-butyl ester .HBr (40) (100 mg, 0.15 mmol, 1 
equiv) and potassium carbonate (30 mg, 0.21 mmol, 1.4 equiv) in 
dimethylformamide (2 mL), methyl bromoacetate (33 mg, 0.21 mmol, 1.4 equiv) 
was added. The reaction was stirred overnight at room temperature under a 
nitrogen atmosphere. The product was then concentrated in vacuo and purified 
using column chromatography (DCM/MeOH, 95/5) to yield the amine as a 
yellow oil (77). Adapted from Wanger et al. (121) (79 mg, 93%) 
įH (300 MHz; CDCl3): 1.42 (27H, s, CH3), 2.00-3.60 (24H, m, CH2), 3.67 (3H, s, 
OCH3); įC (100 MHz CDCl3): 27.9 (C(CH3)3), 51.9 (OCH3), 53.5, 54.7, 55.6, 
55.7 (CH2), 82.0 (C(CH3)3), 172.9, 173.0, 174.0 (C=O); HRMS m/z (+ ESI): 
Found [MH]+, 587.4015 C29H54N4O8 requires [MH]+, 587.4014. 
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(4,7,10-Tris-tert-butoxycarbonyl methyl-1,4,7,10-tetraaza-
cyclododec-1-yl)-acetic acid (76). 
 
To a solution of (4,10-bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-
cyclododec-1-yl)-acetic acid tert-butyl ester (77) (71 mg, 0.12 mmol, 1 equiv) in 
methanol (3 mL) and water (1 mL), lithium hydroxide (30 mg, 0.61 mmol, 5 
equiv) was added. The solution was stirred overnight at room temperature 
under a nitrogen atmosphere, before being neutralised with hydrochloric acid (1 
M), and concentrated in vacuo. The residue was then taken up in methanol and 
filtered to yield the free carboxylic acid as a yellow oil (76). Adapted from Green 
et al. (122) (13 mg, 19%). 
Ȟmax (CHCl3)/cm-1, 3433 (OH), 1585 (C=O); įH (300 MHz; MeOD): 1.46 (27H, s, 
C(CH3)3), 2.24-3.05 (24H, m, CH2); įC (75 MHz MeOD): 27.1 (C(CH3)3), 50.3, 
53.3, 55.4, 59.2 (CH2), 81.0 (C(CH3)3), 179.15 (C=O); HRMS m/z (+ ESI): 
Found [MH]+, 573.3862 C28H52N4O8 requires [MH]+, 573.3858. 
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2-Bromo-N-(prop-2-yn-1-yl) acetamide (80). 
N
H
Br
O
 
A suspension of bromo acetylbromide (79) (500 mg, 2.5 mmol, 1.1 equiv) and 
potassium carbonate (622 mg, 4.5 mmol, 2 equiv) in anhydrous 
dichloromethane (5 mL) was cooled to 0 °C and stirred for 15 mins under a 
nitrogen atmosphere. Propargyl amide (124 mg, 2.3 mmol, 1 equiv) was then 
added dropwise over half an hour, before the suspension was brought to room 
temperature and stirred for 2 h before quenching with water (20 mL). The 
product was then extracted with dichloromethane (3 x 10 mL), and washed with 
citric acid (5% solution, 10 mL) and water (10 mL), before concentrating in 
vacuo to yield the amine as a brown solid (80). Reproduced from Mani et al. 
(125)
 (386 mg, 89%). 
Ȟmax (CHCl3)/cm-1, 3422 (NH), 2944, 2837 (CH), 2255 (Alkyne), 1671 (C=O); įH 
(400 MHz; CDCl3): 2.27 (1H, t, J = 2.6 Hz, CH2CCH), 3.88 (2H, s, BrCH2), 4.75 
(2H, dd, J = 5.3, 2.6 Hz, CH2CCH), 6.98 (1H, bs, NH įC (100 MHz CDCl3): 
28.7 (BrCH2), 29.9 (NHCH2), 72.2 (CH2CCH), 78.6 (CH2CCH), 165.3 (C=O); 
HRMS m/z (+ ESI): Found [MNa]+, 197.9517 C5H6BrNNaO requires [MNa]+, 
197.9524. 
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(1,4,7-Tris-tert-butoxycarbonylmethyl-10-prop-2-ynyl 
carbamoylmethyl-1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid 
tert-butyl ester (78). 
N N
NN
O
O
OO
O
O
O NH
 
To a suspension of (4,10-bis-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-
cyclododec-1-yl)-acetic acid tert-butyl ester .HBr (40) (242 mg, 0.35 mmol, 1 
equiv) and potassium carbonate (70 mg, 0.52 mmol, 1.5 equiv) in 
dimethylformamide (2.5 mL), 2-bromo-N-(prop-2-yn-1-yl) acetamide (80) (92 
mg, 0.52 mmol, 1.5 equiv) was added. The suspension was then stirred 
overnight at room temperature under a nitrogen atmosphere before 
concentration in vacuo. The residue was then purified using column 
chromatography (DCM/MeOH, 95/5) to yield the product as a colourless sticky 
solid (78). Reproduced from Viguler et al. (74) (158 mg, 74%). 
Ȟmax (CHCl3)/cm-1, 3439 (NH), 2976, 2825 (CH), 1676 (C=O); įH (400 MHz; 
CDCl3): 1.46 (27H, s, C(CH3)3), 2.03 (1H, s, CH2CCH), 1.80-3.80 (24H, m, 
NCH2CH2N, CH2), 3.97 (2H, s, CH2CCH), 8.80 (1H, t, J = 5.6 Hz, NHįC (100 
MHz CDCl3): 28.0 (C(CH3)3), 28.5 (CH2CCH), 55.7, 56.2 (NCH2CH2N, CH2), 
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69.6 (CH2CCH), 80.9 (C(CH3)3), 81.9 (CH2CCH), 171.9, 172.3 (C=O); HRMS 
m/z (+ ESI): Found [MH]+, 610.4154 C31H55N5O7 requires [MH]+, 610.4174. 
 
(1,4,7-Tris-carbonylmethyl-10-prop-2-ynyl carbamoylmethyl-
1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid .3HCl (81).  
N N
NN
HO
O
OHO
O
OH
O NH
.3HCl
 
To a solution of (1,4,7-tris-tert-butoxycarbonylmethyl-10-prop-2-ynyl 
carbamoylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid tert-butyl ester 
(78) (858.9 mg, 1.4 mmol, 1 equiv) in ethanol (10 mL) and water (5 mL), 
hydrochloric acid (11.8 M, 5 mL) was added. The solution was stirred for 5 h at 
room temperature before concentration in vacuo, to yield the HCl salt as an off 
white solid (81). Adapted from Prasuhn et al. (109) (614 mg, 80%).  
Ȟmax (CHCl3)/cm-1, 3433 (OH), 2925 (CH), 1733, 1636 (C=O); įH (400 MHz; 
CDCl3):, 2.64 (1H, b, CH2CCH), 2.80-4.20 (24H, m, NCH2CH2N, CH2), 3.96 
(2H, b, CH2CCH); įC (100 MHz CDCl3): 28.3 (CH2CCH), 48.6, 49.7, 51.5, 51.7 
(NCH2CH2N, CH2), 71.6 (CH2CCH), 78.8 (CH2CCH), 167.5, 172.6 (C=O); 
HRMS m/z (+ ESI): Found [MH]+, 442.2306 C19H31N5O7 requires [MH]+, 
442.2296. 
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(1,4,7-Tris-carbonylmethyl-10-prop-2-ynyl carbamoylmethyl-
1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid europium (CA1-Eu). 
 
A solution of (1,4,7-tris-carbonylmethyl-10-prop-2-ynyl carbamoylmethyl-
1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid .3HCl (81) (200 mg, 0.36 mmol, 
1 equiv) in water (1.5 mL) was adjusted to pH 6 using potassium hydroxide 
solution (1 M in water), before addition of europium (III) chloride hexahydrate 
(133 mg, 0.36 mmol, 1 equiv) in water (0.5 mL). The solution was then 
readjusted to pH 6 with more potassium hydroxide solution and stirred for 2 h at 
room temperature. The pH was adjusted again to pH 6, before freeze drying. 
The residue was then suspended in ethanol, centrifuged and the supernatant 
was collected and concentrated in vacuo to yield the product as a colourless 
solid (CA1-Eu). Reproduced from Viguier et al. (74) (184 mg, 87%). 
Ȟmax (CHCl3)/cm-1, 3378 (OH), 1584 (C=O); HRMS m/z (+ ESI): Found [MH]-, 
590.1141 C19H27152EuN5O7 requires [MH]-, 590.1128. 
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(1,4,7-Tris-carbonylmethyl-10-prop-2-ynyl carbamoylmethyl-
1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid gadolinium (CA1). 
 
A solution of (1,4,7-tris-carbonylmethyl-10-prop-2-ynyl carbamoylmethyl-
1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid .3HCl (81) (200 mg, 0.36 mmol, 
1 equiv) in water (1.5 mL) was adjusted to pH 6 using potassium hydroxide 
solution (1 M in water), before addition of gadolinium (III) chloride hexahydrate 
(135 mg, 0.36 mmol, 1 equiv) in water (0.5 mL). The solution was then 
readjusted to pH 6 with more potassium hydroxide solution and stirred for 2 h at 
room temperature. The pH was adjusted again to pH 6, before freeze drying. 
The residue was then suspended in ethanol, centrifuged and the supernatant 
was collected and concentrated in vacuo to yield the product as a colourless 
solid (CA1). Adapted from Viguier et al. (74) (194 mg, 90%). 
Ȟmax (CHCl3)/cm-1, 3383 (OH), 1580 (C=O); HRMS m/z (+ ESI): Found [MH]-, 
596.1235 C19H28158GdN5O7 requires [MH]-, 596.1223. 
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1,4,7,10-Tetraaza-cyclododecane-1,7-dicarboxylic acid di-tert-butyl 
ester (83). 
NH N
HNNO
O
O
O
 
To a solution of cyclen (35) (100 mg, 0.56 mmol, 1 equiv), in methanol (5 mL) 
boc succinimide (242 mg, 1.12 mmol, 2 equiv) was added. The reaction was 
stirred for 48 hours and monitored by mass spectrometry. Once the reaction 
was completed the product was concentrated in vacuo, and saturated sodium 
hydrogen carbonate solution was added (10 mL) before extraction with 
chloroform (3 x 10 mL). The organic layer was dried with magnesium sulphate 
and concentrated in vacuo to yield the product as a colourless foam (83). 
Reproduced from De Leon-Rodriguez et al. (120) (191 mg, 91%). 
Ȟmax (CHCl3)/cm-1, 3351 (NH), 1686 (C=O); įH (400 MHz; CDCl3): 1.39 (18H, s, 
C(CH3)3), 2.52-3.62 (16H, m, NCH2CH2N); įC (100M Hz; CDCl3); 28.4 
(C(CH3)3), 48.8-50.8 (CH2), 80.2 (C(CH3)3), 155.7 (C=O);  HRMS m/z (+ EI): 
Found [MNa]+, 395.2643, C18H36N4O4Na requires [MH]+, 395.2629 
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4,10-Bis-benzyloxycarbonylmethyl-1,4,7,10-tetraaza-
cyclododecane-1,7-dicarboxylic acid di-tert-butyl ester (84).  
N N
NN
O
O
O
O
O
O
O
O
 
To a suspension of 1,4,7,10-tetraaza-cyclododecane-1,7-dicarboxylic acid di-tert-
butyl ester (83) (100 mg, 0.3 mmol, 1 equiv), potassium dicarbonate (93 mg, 
0.7 mmol, 2.5 equiv) in anhydrous dimethylformamide (6 mL), 
benzylbromoacetate (184 mg, 0.9 mmol, 3 equiv) was added dropwise. The 
reaction was stirred overnight at room temperature under a nitrogen 
atmosphere. The suspension was then concentrated in vacuo, and purified 
using column chromatography (DCM/MeOH, 99/1) to yield the amine as a 
yellow oil (84). Reproduced from De Leon-Rodriguez et al. (120) (110 mg, 65%).  
Ȟmax (CHCl3)/cm-1, 1680 (C=O); įH (400 MHz; CDCl3): 1.43 (9H, s, C(CH3)3), 
2.34-3.89 (24H, m, CH2), 7.31-7.54 (10H, m, CHAr); įC (100 MHz CDCl3): 28.4 
(C(CH3)3), 46.7, 47.4, 51.6, 54.4 (NCH2CH2N), 66.1, 66.4 (CH2), 79.5, 79.8 
(C(CH3)3), 128.3-128.7 (CHAr), 135.8 (CAr), 155.9, 171.1 (C=O); HRMS m/z (+ 
ESI): Found [MH]+, 669.3856 C36H52N4O8 requires [MH]+, 669.3858. 
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(7-Benzyloxy carbonyl methyl-1,4,7,10-tetraaza-cyclododec-1-
yl)acetic acid benzyl ester .2TFA (85).  
NH N
HNN
O
O
O
O
.2TFA
 
To a solution of 4,10-bis-benzyloxycarbonylmethyl-1,4,7,10-tetraaza-
cyclododecane-1,7-dicarboxylic acid di-tert-butyl ester (84) (666 mg, 1 mmol, 1 
equiv) in dichloromethane (6 mL), trifluoroacetic acid (0.6 mL) was added. The 
solution was then stirred overnight at room temperature, before being 
concentrated in vacuo to yield the TFA salt as a sticky orange oil (85). 
Reproduced from De Leon-Rodriguez et al. (120) (697 mg, 98%). 
Ȟmax (CHCl3)/cm-1, 1668 (C=O); įH (400 MHz; CDCl3): 2.34-4.00 (24H, m, CH2), 
7.27-7.38 (10H, m, CHAr); įC (100 MHz CDCl3): 43.1, 49.9, 54.0, (NCH2CH2N), 
67.8 (CH2), 114.1, 116.9 (CAr) 128.4,128.6, 128.7,134.5 (CHAr), 171.6 (C=O); 
HRMS m/z (+ ESI): Found [MH]+, 469.2822 C26H36N4O4 requires [MH]+, 
469.2809. 
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(4,10-Bis-benzyloxycarbonylmethyl-7-tert-butoxycarbonyl methyl-
1,4,7,10-tetraaza-cyclododec-1-yl)acetic acid tert-butyl ester (86). 
 
To a stirred suspension of (7-benzyloxy carbonyl methyl-1,4,7,10-tetraaza-
cyclododec-1-yl)acetic acid benzyl ester .2TFA (85) (100 mg, 0.14 mmol, 1 
equiv) and potassium carbonate (88 mg, 0.6 mmol, 4 equiv) in anhydrous 
dimethylformamide (10 mL), tert-butyl bromoacetate (87 mg, 0.4 mmol, 3 equiv) 
was added. The suspension was then stirred at room temperature, overnight 
under a nitrogen atmosphere. The suspension was then concentrated in vacuo 
and purified using column chromatography (DCM/MeOH, 99/1) to yield the 
product as a sticky yellow oil (86). Reproduced from De Leon-Rodriguez et al. 
(120)
 (7 mg, 7%).  
Ȟmax (CHCl3)/cm-1, 3018 (CAr), 1733 (C=O); įH (400 MHz; CDCl3): 1.40 (18H, s, 
C(CH3)3), 2.60-4.00 (20H, m, CH2), 5.14 (4H, s, CH2), 7.29-7.40 (10H, m, 
CHAr); įC (100 MHz CDCl3): 27.9 (C(CH3)3), 55.0, 55.8, 65.1, 66.9 (CH2), 82.1 
(C(CH3)3), 127-128 (CHAr), 173.2, 173.6 (C=O); HRMS m/z (+ ESI): Found 
[MH]+, 697.4151 C38H57N4O8 requires [MH]+, 697.4171. 
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4,10-Bis-tert-butoxycarbonylmethyl-1,4,7,10tetraaza-
cyclododecane-1,7-dicarboxylicacid di-tert-butyl ester (91). 
 
To a suspension of 1,4,7,10-tetraaza-cyclododecane-1,7-dicarboxylic acid di-
tert-butyl ester (83) (100 mg, 0.3 mmol, 1 equiv) and potassium carbonate (64 
mg, 0.6 mmol, 2.2 equiv) in anhydrous dimethylformamide (2 mL), tert-butyl 
bromoacetate (90 mg, 0.6 mmol, 2.2 equiv) was added dropwise. The 
suspension was stirred overnight at room temperature under a nitrogen 
atmosphere. The reaction was then concentrated in vacuo and purified using 
column chromatography (DCM/MeOH, 99/1) to yield the product as a brown oil 
(91). Adapted from De Leon-Rodriguez et al. (120) (160 mg, 63%).  
Ȟmax (CHCl3)/cm-1, 1721 (C=O); įH (300 MHz; CDCl3): 1.43 (18H, s, C(CH3)3), 
1.44 (18H, s, C(CH3)3), 2.87-3.35 (20H, m, CH2); įC (75 MHz CDCl3): 28.2, 28.5 
(C(CH3)3), 46.6 (CH2), 54.4-55.9 (CH2), 79.3, 80.7 (C(CH3)3), 155.9, 170.5 
(C=O); HRMS m/z (+ ESI): Found [MH]+, 601.4152 C30H57N4O8 requires [MH]+, 
601.4171. 
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(7-Carboxymethyl-1,4,7,10tetraaza-cyclododec-1-yl)acetic acid 
.4TFA (92). 
 
NH N
HNNO
O
HO
OH
.4TFA
 
To a solution of 4,10-bis-tert-butooxycarbonylmethyl-1,4,7,10tetraaza-
cyclododecane-1,7-dicarboxylicacid di-tert-butyl ester (91) (100 mg, 0.2 mmol, 
1 equiv) in dichloromethane (2 mL), trifluoroacetic acid (1 mL) was added. The 
reaction was then stirred overnight at room temperature. The solution was then 
concentrated in vacuo to yield the trifluoroacetic acid salt as a sticky oil (92). 
Adapted from Green et al. (122) (124 mg, quantitative)  
Ȟmax (CHCl3)/cm-1, 3445 (NH), 3124 (OH), 1689 (C=O); įH (300 MHz; MeOD): 
2.04-5.69 (20H, m, CH2); įC (75 MHz MeOD): 42.5, 49.1, 53.1 (CH2), 173.8 
(C=O); HRMS m/z (+ ESI): Found [MNa]+, 311.1696 C12H24N4O4Na requires 
[MNa]+, 311.1690. 
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(7-Methoxycarbonylmethy-1,4,7,10tetraaza-cyclododec-1-yl) acetic 
acid methyl ester (88).  
NH N
HNNO
O
O
O
 
To a solution of (7-carboxymethyl-1,4,7,10tetraaza-cyclododec-1-yl)acetic acid 
.4TFA (92) (100 mg, 0.3 mmol, 1 equiv) in anhydrous methanol (4 mL), acetyl 
chloride (168 mg, 5.5 mmol, 16 equiv) was added dropwise at 0 °C. The 
solution was then stirred for 24 h under a nitrogen atmosphere at room 
temperature. The reaction was then concentrated in vacuo before being taken 
up in dichloromethane and filtered. The residue was then dried to yield the 
product as a yellow solid (88). Adapted from Thomas et al. (173) (105 mg, 96 %).  
Ȟmax (CHCl3)/cm-1, 3421 (NH), 1723 (C=O); įH (300 MHz; MeOD): 2.00-5.71 
(26H, m, CH2, CH3); įC (75 MHz MeOD): 43.4, 49.9, 53.6 (CH2), 52.1 (OCH3), 
173.7 (C=O); HRMS m/z (+ ESI): Found [MH]+, 317.2179 C14H28N4O4 requires 
[MH]+, 317.2183. 
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(4,10-Bis-tert-butoxycarbonylmethyl-7-methoxycarbonylmethyl- 
1,4,7,10tetraaza-cyclododec-1-yl)-acetic acid methyl ester (89). 
 
To a suspension of (7-methoxycarbonylmethyl-1,4,7,10tetraaza-cyclododec-1-
yl) acetic acid methyl ester (88) (273 mg, 0.9 mmol, 1 equiv) and potassium 
carbonate (280 mg, 1.9 mmol, 2.2 equiv) in dimethylformamide (12 mL), tert-
butylbromoacetate (168 mg, 1.9 mmol, 2.2 equiv) was added dropwise. The 
reaction was then stirred overnight under a nitrogen atmosphere at room 
temperature. The product was then concentrated in vacuo and purified using 
column chromatography (DCM/MeOH, 94/6) to yield the amine as a yellow oil 
(89). Adapted from De Leon-Rodriguez et al. (120) (300 mg, 64%). 
Ȟmax (CHCl3)/cm-1, 3018, 2951 (CH), 1737 (C=O); įH (400 MHz; CDCl3): 1.39 
(18H, s, CH3), 1.40-3.60 (24H, m, CH2), 3.65 (6H, s, OCH3); įC (100 MHz 
CDCl3): 27.1 (C(CH3)3), 52.0 (OCH3), 47.3-57.0 (CH2), 82.3 (C(CH3)3), 173.2, 
174.0 (C=O); HRMS m/z (+ ESI): Found [MNa]+, 567.3366 C26H48N4O8Na 
requires [MNa]+, 567.3364. 
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(4,10-Bis-tert-butoxycarbonyl methyl-7-carboxymethyl-
1,4,7,10tetraaza-cyclododec-1-yl)-acetic acid (90).  
N
N N
N
HO
O
O
O
OHO
O
O
 
To a solution of (4,10-bis-tert-butoxycarbonylmethyl-7-methoxycarbonylmethyl-
1,4,7,10tetraaza-cyclododec-1-yl)-acetic acid tert-butyl ester (89) (160 mg, 0.27 
mmol, 1 equiv), in water (2.5 mL) and methanol (7.5 mL), lithium hydroxide (60 
mg, 2.5 mmol, 9 equiv)  was added at 0 °C. The reaction was stirred overnight 
at room temperature under a nitrogen atmosphere. The product was then 
concentrated in vacuo, before being up taken in dichloromethane and filtered. 
The filtrate was then concentrated in vacuo to yield the dicarboxylic acid as a 
yellow powder (90). Adapted from Green et al. (122) (20 mg, 14%).  
HRMS m/z (+ ESI): Found [MH]+, 517.3225 C24H44N4O8 requires [MH]+, 
517.3232. 
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(7-tert-Butoxycarbonylmethyl-4,10-bis-prop-2-ynylcarbonylmethyl-
1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid tert-butyl ester (95). 
N N
NN
N
H
O
O O H
N
O
OO
 
To a stirred solution of (4,10-bis-tert-butoxycarbonyl methyl-7-carboxymethyl-
1,4,7,10tertaaza-cyclododec-1-yl)-acetic acid (90) (50 mg, 0.10 mmol, 1 equiv), 
N-hydroxybenzotriazole (29 mg, 0.05 mmol, 0.5 equiv) and [benzotriazol-1-
yloxy(dimethylamino)methylidene]-dimethylazanium (81 mg, 0.22 mmol, 2.2 
equiv) in dimethylformamide (2 mL), propargyl amine (12 mg, 0.22 mmol, 2.2 
equiv) was added, before the addition of diisopropylethylamine (27 mg, 0.22 
mmol, 2.2 equiv). The solution was then stirred at room temperature overnight. 
The solution was then concentrated in vacuo and purified via column 
chromatography (DCM/MeOH, 98/2) to yield the product as a brown oil (95). 
Adapted from Montalbetti et al. (172) (7 mg, 12%).  
HRMS m/z (+ ESI): Found [MNa]+, 613.3688 C30H50N6NaO8 requires [MNa]+, 
613.3684. 
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7-Carbonylmethyl-4,10-bis-prop-2-ynylcarbonylmethyl-1,4,7,10-
tetraaza-cyclododec-1-yl)-acetic acid .2TFA (96).  
N N
NN
HO O
OHO
H
N
O
N
H
O
.2TFA
 
To a solution of (7-tert-butoxycarbonylmethyl-4,10-bis-prop-2-
ynylcarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid tert-butyl 
ester (95) (20 mg, 0.03 mmol, 1 equiv) in dichloromethane (1 mL), 
trifluoroacetic acid (0.4 mL) was added. The solution was then stirred overnight 
at room temperature before concentrating in vacuo to yield the TFA salt as a 
sticky brown oil (96). Adapted from Green et al. (122) (15 mg, 68%).  
HRMS m/z (+ ESI): Found [MH]+, 479.2626 C22H35N6O6 requires [MH]+, 
479.2613. 
 
4,10-Bis-methoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododecane-
1,7-dicarboxylic acid di-tert-butyl ester (87). 
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To a suspension of 1,4,7,10-t\etraaza-cyclododecane-1,7-dicarboxylic acid di-
tert-butyl ester (83) (1.00 g, 2.7 mmol, 1 equiv) and potassium carbonate (800 
mg, 5.9 mmol, 2.2 equiv) in dimethlformamide (5 mL), methyl bromoacetic acid 
(900 mg, 5.9 mmol, 2.2 equiv) was added dropwise. The reaction was stirred 
overnight at room temperature under a nitrogen atmosphere. The suspension 
was then concentrated in vacuo, and the residue was purified using column 
chromatography (DCM/MeOH, 99/1), to yield the product as a yellow oil (87). 
Adapted from De Leon-Rodriguez et al. (120) (630 mg, 41%).  
Ȟmax (CHCl3)/cm-1, 2973 (CH), 1737, 1682 (C=O); įH (300 MHz; CDCl3): 1.43 
(18H, s, C(CH3)3), 2.67-3.62 (20H, m, CH2), 3.67 (6H, s, CH3); įC (75 MHz 
CDCl3): 28.5 (C(CH3)3), 46.5, 54.6, 54.9 (CH2), 51.3 (CH3), 79.5 (C(CH3)3), 
155.9, 171.7 (C=O); HRMS m/z (+ ESI): Found [MH]+, 573.3862 C24H44N4O8 
requires [MH]+, 573.3858. 
 
7-Methoxycarbonylmethy-1,4,7,10-tetraaza-cyclododec-1-yl) acetic 
acid methyl ester .2TFA (88).  
NH N
HNN
O O
OO
.2TFA
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To a solution of 4,10-bis-methoxycarbonylmethyl-1,4,7,10-tetraaza-
cyclododecane-1,7-dicarboxylic acid di-tert-butyl ester (87) (713 mg, 1.2 mmol, 
1 equiv) in dichloromethane (5 mL), trifluoroacetic acid (2 mL) was added. The 
reaction was then stirred at room temperature overnight before concentrating in 
vacuo to yield the TFA salt as a sticky orange oil (88). Adapted from De Leon-
Rodriguez et al. (120) (665 mg, 98%). 
Ȟmax (CHCl3)/cm-1, 3421 (NH), 1723 (C=O); įH (300 MHz; MeOD): 2.00-5.71 
(26H, m, CH2, CH3); įC (75 MHz MeOD): 43.4, 49.9, 53.6 (CH2), 52.1 (OCH3), 
173.7 (C=O); HRMS m/z (+ ESI): Found [MH]+, 317.2179 C14H28N4O4 requires 
[MH]+, 317.2183. 
 
4,10-Bis-prop-2-ynylcarbonylmethyl-1,4,7,10-tetraaza-
cyclododecane-1,7-dicarboxylic acid di-tert-butyl ester (93). (73)  
N N
NN
H
N
O
N
H
O
O
O
O
O
 
To a suspension of 1,4,7,10-tetraaza-cyclododecane-1,7-dicarboxylic acid di-
tert-butyl ester (83) (100 mg,  0.27 mmol, 1 equiv) and potassium carbonate (81 
mg, 5.6 mmol, 2.1 equiv) in dimethylformamide (2.5 mL), 2-bromo-N-(prop-2-
yn-1-yl) acetamide (80) (92 mg, 5.6 mmol, 2.1 equiv) was added. The 
suspension was then stirred overnight at room temperature under a nitrogen 
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atmosphere before concentration in vacuo. The residue was then purified using 
column chromatography (DCM/MeOH, 95/5) to yield the product as a pale 
orange oil (93). Adapted from Viguier et al. (74) (103 mg, 68%). 
Ȟmax (CHCl3)/cm-1, 3400 (NH), 2990 (CH), 2250 (Alkyne), 1650 (C=O); įH (400 
MHz; CDCl3): 1.45 (18H, s, C(CH3)3), 2.18 (2H, t, J = 2.4 Hz, CH2CCH), 2.70-
3.70 (24H, m, NCH2CH2N, CH2), 4.03 (4H, dd, J = 5.4, 2.4 Hz, CH2CCHįC 
(100 MHz CDCl3): 28.5 (C(CH3)3), 28.7 (CH2CCH), 48.4, 53.4, 55.3, 58.8 
(NCH2CH2N, CH2), 71.2 (CH2CCH), 79.8 (C(CH3)3), 80.5 (CH2CCH), 156.6, 
170.9 (C=O); HRMS m/z (+ ESI): Found [MH]+, 563.3543 C28H46N6O6 requires 
[MH]+, 563.3552. 
 
4,10-Bis-prop-2-ynylcarbonylmethyl-7-carboxymethyl-
1,4,7,10tetraaza-cyclododec-1-yl)-acetic acid .2TFA (94). 
N HN
NNH
H
N
O
N
H
O
.2TFA
 
To a solution of 4,10-bis-prop-2-ynylcarbonylmethyl-1,4,7,10-tetraaza-
cyclododecane-1,7-dicarboxylic acid di-tert-butyl ester (93) (514 mg, 0.9 mmol, 
1 equiv) in dichloromethane (10 ml), trifluoroacetic acid (7 mL)  was added. The 
reaction was stirred at room temperature overnight before concentration in 
vacuo, to yield the TFA salt as a sticky yellow oil (94). Adapted from De Leon-
Rodriguez et al. (120) (539 mg, quant).  
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Ȟmax (CHCl3)/cm-1, 3425 (NH), 2925 (CH), 1679 (C=O); įH (400 MHz; CDCl3): 
2.65 (2H, t, J = 2.5 Hz, CH2CCH), 2.70-3.70 (20H, m, NCH2CH2N, CH2), 4.03 
(4H, d, J = 2.5 Hz, CH2CCHįC (100 MHz CDCl3): 28.8 (CH2CCH), 42.8, 43.3, 
46.0, 49.5, 55.7, 66.5 (NCH2CH2N, CH2), 72.0 (CH2CCH), 79.6 (CH2CCH), 
172.4 (C=O); HRMS m/z (+ ESI): Found [MH]+, 363.2512 C18H30N6O2 requires 
[MH]+, 363.2503. 
 
1,7-Tris-tert-butoxycarbonylmethyl-4,10-bis-prop-2-ynyl 
carbamoylmethyl-1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid 
tert-butyl ester (95). 
N N
NN
H
N
O
N
H
O
O O
OO
 
To a suspension of 4,10-bis-prop-2-ynylcarbonylmethyl-7-carboxymethyl-
1,4,7,10tetraaza-cyclododec-1-yl)-acetic acid .2TFA (94) (331 mg, 0.9 mmol, 1 
equiv) and potassium carbonate (277 mg, 2.0 mmol, 2.2 equiv) in 
dimethylformamide (5 mL), tert-butyl bromoacetate (391 mg, 2.0 mmol, 2.2 
equiv) was added dropwise. The suspension was then stirred overnight at room 
temperature under a nitrogen atmosphere, before concentration in vacuo. The 
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residue was then purified using column chromatography (DCM/MeOH, 97/3) to 
yield the product as a colourless oil (95). Adapted from De Leon-Rodriguez et 
al. (120) (151 mg, 28%). 
Ȟmax (CHCl3)/cm-1, 3222 (NH), 2977, 2821 (CH), 1731, 1672 (C=O); įH (300 
MHz; CDCl3): 1.44 (18H, s, C(CH3)3), 2.65 (2H, t, J = 2.6 Hz, CH2CCH), 2.30-
3.80 (24H, m, NCH2CH2N, CH2), 4.05 (4H, dd, J = 2.5, 5.2 Hz, CH2CCH), 8.67 
(2H, t, J = 5.0 Hz, NH); įC (75 MHz CDCl3): 28.2 (C(CH3)3), 28.9 (CH2CCH), 
52.3, 55.6, 56.2, 58.4, (NCH2CH2N, CH2), 71.1 (CH2CCH), 80.1 (C(CH3)3), 81.9 
(CH2CCH), 170.2, 171.4 (C=O); HRMS m/z (+ ESI): Found [MH]+, 591.3852 
C30H50N6O6 requires [MH]+, 591.3865. 
 
1,7-Tris-carbonylmethyl-4,10-bis-prop-2-ynyl carbamoylmethyl-
1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid .2TFA (96). 
N N
NN
H
N
O
N
H
O
HO O
OHO
.2TFA
 
To a solution of 1,7-tris-tert-butoxycarbonylmethyl-4,10-bis-prop-2-ynyl 
carbamoylmethyl-1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid tert-butyl ester 
(95) (100 mg, 0.02 mmol, 1 equiv) in dichloromethane (5 mL), trifluoroacetic 
acid (3 mL) was added. The reaction was stirred overnight at room temperature 
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before concentration in vacuo to yield the TFA salt as a pale brown solid (96). 
Adapted from Green et al. (122) (118 mg, 99%).  
Ȟmax (CHCl3)/cm-1, 3406 (OH), 1671 (C=O); įH (300 MHz; CDCl3):, 2.61 (2H, t, J 
= 2.3 Hz, CH2CCH), 3.10-3.90 (24H, m, NCH2CH2N, CH2), 4.02 (4H, d, J = 2.3 
Hz, CH2CCH); įC (100 MHz CDCl3): 28.3 (CH2CCH), 48.2, 48.4, 49.2, 50.6, 
54.5, 54.8 (NCH2CH2N, CH2), 71.1 (CH2CCH), 79.1 (CH2CCH), 161.7, 168.8 
(C=O); HRMS m/z (+ ESI): Found [MH]+, 479.2628 C22H34N6O6 requires [MH]+, 
479.2613. 
 
1,7-Tris-carbonylmethyl-4,10-bis-prop-2-ynyl carbamoylmethyl-
1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid europium (CA2-Eu). 
N N
NN
H
N
O
N
H
O
O O
OO
Eu
+
 
A solution of 1,7-tris-carbonylmethyl-4,10-bis-prop-2-ynyl carbamoylmethyl-
1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid .2TFA (96) (239 mg, 0.3 mmol, 1 
equiv) in water (1.5 mL) was adjusted to pH 6 using potassium hydroxide 
solution (1 M in water), before addition of europium (III) chloride hexahydrate 
(124 mg, 0.3 mmol, 1 equiv) in water (0.5 mL). The solution was then 
readjusted to pH 6 with more potassium hydroxide solution and stirred for 2 h at 
room temperature. The pH was adjusted again to pH 6, before freeze drying. 
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The residue was then suspended in ethanol, centrifuged and the supernatant 
was collected and concentrated in vacuo to yield the product as a colourless 
solid (CA2-Eu). Adapted from Viguier et al. (74) (207 mg, 98%). 
Ȟmax (CHCl3)/cm-1, 3262 (OH), 1683, 1631 (C=O); HRMS m/z (+ ESI): Found 
[MH]-, 627.1467 C22H30152EuN6O6 requires [MH]-, 627.1445. 
 
1,7-Tris-carbonylmethyl-4,10-bis-prop-2-ynyl carbamoylmethyl-
1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid gadolinium (CA2). 
N N
NN
O O
OO
H
N
O
N
H
O
Gd
+
 
A solution of 1,7-tris-carbonylmethyl-4,10-bis-prop-2-ynyl carbamoylmethyl-
1,4,7,10- tetraaza-cyclododec-1-yl)-acetic acid .2TFA (96) (239 mg, 0.3 mmol 1 
equiv) in water (1.5 mL) was adjusted to pH 6 using potassium hydroxide 
solution (1 M in water), before addition of gadolinium (III) chloride hexahydrate 
(126 mg, 0.3 mmol, 1 equiv) in water (0.5 mL). The solution was then 
readjusted to pH 6 with more potassium hydroxide solution and stirred for 2 h at 
room temperature. The pH was adjusted again to pH 6, before freeze drying. 
The residue was then suspended in ethanol, centrifuged and the supernatant 
was collected and concentrated in vacuo to yield the product as a colourless 
solid (CA2). Adapted from Viguier et al. (74) (148 mg, 69%). 
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Ȟmax (CHCl3)/cm-1, 3258 (OH), 1685, 1631 (C=O); ); HRMS m/z (+ ESI): Found 
[M]+, 634.1632 C22H30158GdN6O6 requires [M]+, 634.1619. 
 
2-tert-Butoxycarbonylamino-3-hydroxy-propionic acid (98). 
O
H
N
O
OH
O
OH
 
To a suspension of D/L serine (97) (100 mg, 1 mmol, 1 equiv) and sodium 
carbonate (200 mg, 2 mmol, 2 equiv) in water (3 mL) and dioxane (3 mL), Boc 
anhydride (228 mg, 1.1 mmol, 1.1 equiv) was added dropwise. This was stirred 
overnight at room temperature. The reaction mixture was then concentrated in 
vacuo and recrystallised in methanol to yield a colourless solid (98). Repeated 
from Onisko et al. (128) 
Ȟmax (CHCl3)/cm-1, 3405 (OH), 1690 (C=O); įH (400 MHz; D2O): 1.38 (9H, s, 
C(CH3)3), 3.74 (1H, dd, J = 11.3, 3.8 Hz, CH2), 3.78 (1H, dd, J = 11.3, 3.8 Hz, 
CH2), 3.95 (1H, bs, CH); įC (100 MHz D2O): 27.7 (C(CH3)3), 58.0  (CH), 62.4 
(CH2), 81.2 (C(CH3)3), 157.7, 177.2 (C=O); HRMS m/z (+ EI): Found [MNa]+, 
228.0839, C8H15N1O5Na requires [MNa]+, 228.0842 
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2-tert-Butoxycarbonylamino-3-hydroxy-propionic acid methyl ester 
(99).  
O
H
N
O
OH
O
O
 
To a suspension of 2-tert-butoxycarbonylamino-3-hydroxy-propionic acid (98) 
(205 mg, 1 mmol, 1 equiv) and caesium carbonate (165 mg 0.5 mmol, 0.5 
equiv) in anhydrous dimethylformamide (5 mL), iodomethane (273 mg, 1.9 
mmol, 1.9 equiv) was added dropwise. This was stirred overnight at room 
temperature under a nitrogen atmosphere. Water (5 mL) was then added 
before extraction with ethyl acetate (3 x 10 mL). The organic layers were 
combined, washed with brine (30 mL) and concentrated in vacuo to produce a 
crude mixture. The residue was then purified via column chromatography 
(PE/EtOAc, 60/40) to yield the methyl ester as a pale yellow oil (99). Repeated 
from Onisko et al. (128) (162 mg, 78% over both steps).  
Ȟmax (CHCl3)/cm-1, 3399 (OH), 1747 (C=O); įH (400 MHz; CDCl3): 1.42 (9H, s, 
C(CH3)3), 2.71 (1H, bs, OH), 3.69 (3H, s, OCH3), 3.87 (1H, dd, J = 11.2, 3.7 Hz, 
CH2), 3.94 (1H, dd, J = 11.2, 3.7 Hz, CH2), 4.35 (1H, b, CH), 5.53 (1H, bs, NH); 
įC (100 MHz CDCl3): 28.3 (C(CH3)3), 52.6 (OCH3), 55.7 (CH), 63.4 (CH2), 80.3 
(C(CH3)3), 155.8, 171.4 (C=O); HRMS m/z (+ ESI): Found [MNa]+, 242.0999 
C9H17N1O5Na requires [MNa]+, 242.0999. 
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2-tert-Butoxycarbonylamino-acrylic acid methyl ester (100).  
 
A suspension of 2-tert-butoxycarbonylamino-3-hydroxy-propionic acid methyl 
ester (99) (100 mg, 0.4 mmol, 1 equiv) and copper (I) chloride (54 mg, 0.5 
mmol, 1.2 equiv) in anhydrous dichloromethane (4 mL) was stirred at 0 ºC 
under a nitrogen atmosphere in a covered flask. To this cooled green 
suspension 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (85 mg, 0.5 mmol, 
1.2 equiv) was added. The flask was then purged with nitrogen, before being 
allowed to reach room temperature and stirred overnight. The solution turned 
dark green, and was then purified using column chromatography (DCM/MeOH, 
99/1) to yield the amino acid as a colourless oil (100). Repeated from Zhu et al. 
(129)
 (61 mg, 72%). Note this compound decomposes quickly even in a covered 
flask.  
 
įH (300 MHz; CDCl3): 1.48 (9H, s, C(CH3)3), 3.83 (3H, s, CH3), 5.72 (1H, d, J = 
1.5 Hz, CH2), 6.15 (1H, s, CH2), 7.00 (1H, bs, NH); įC (75 MHz CDCl3): 28.2 
(C(CH3)3), 52.8 (CH3), 80.7 (C(CH3)3), 105.1 (CCH2), 131.3 (CCH2), 152.6, 
174.4 (C=O); HRMS m/z (+ ESI): Found [MNa]+, 224.0894 C9H15N1O4Na 
requires [MNa]+, 224.0893. 
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Methyl-2-[(tert-butoxycarbonyl)amino]-3-(1,4,7,10-tetraaza 
cyclododec-1-yl) propanoate (102). 
NH HN
NNH
H
N
O O
O
O
 
To a suspension of cyclen (35) (541 mg, 3.1 mmol, 1.1 equiv) and potassium 
carbonate (504 mg, 3.6 mmol, 1.3 equiv) in acetonitrile (9 mL), 2-tert-
butoxycarbonylamino-acrylic acid methyl ester (100) (619 mg, 2.8 mmol, 1 
equiv) was added. The suspension was stirred overnight at room temperature 
under a nitrogen atmosphere, before concentration in vacuo. The residue was 
then purified using column chromatography (DCM/EtOH/NH4OH, 50/50/2) yield 
the product as a colourless oil (102). Repeated from Molteni et al. (174) (180 mg, 
17%). 
Ȟmax (CHCl3)/cm-1, 3404 (NH), 2972, 2848 (CH), 1696, 1599 (C=O); įH (400 
MHz; CDCl3): 1.43 (9H, s, C(CH3)3), 2.50-2.90 (16H, m, NCH2CH2N), 3.46-3.75 
(2H, m, CH2CH), 3.76 (3H, s, OCH3), 4.40 (1H, bs, CH2CH), 5.99 (1H, b, NH); 
įC (100 MHz CDCl3): 28.3 (C(CH3)3), 45.6, 45.9, 46.1, 47.2, 49.7, 50.6 
(NCH2CH2N), 52.5 (OCH3), 52.6 (CH2CH), 53.3 (CH2CH), 79.9 (C(CH3)3), 
155.5, 172.7 (C=O); HRMS m/z (+ ESI): Found [MH]+, 374.2777 C17H35N5O4 
requires [MH]+, 374.2762. 
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1,4-Dibenzyl-6-hydroxymethyl-6-nitroperhydro-1,4-diazepine (103).  
NO2
HO N
N
 
To a solution of 11¶-dibenzylethylendiamine diacetate (46) (1.08 g, 3.0 mmol, 
1 equiv) and 2-nitroethanol (215 µL, 3.0 mmol, 1 equiv) in toluene (20 mL) and 
ethanol (20 mL), paraformaldehyde (320 mg, 10.7 mmol, 3.5 equiv) was added 
in portions. The suspension was then heated to reflux for 6 h before 
concentration in vacuo. The residue was then dissolved in dichloromethane (10 
mL) and washed with water (3 x 10 mL) before drying with magnesium sulphate 
and concentration in vacuo. This residue was then purified using column 
chromatography (PE/EtOAc, 8/2) to yield the final product as a sticky colourless 
oil (103). Repeated from Gugliotta et al. (79) (923 mg, 99.5%). 
  
Ȟmax (CHCl3)/cm-1, 3401 (OH), 3026 (CHAr), 2821 (CH), 1538, 1349 (NO2); įH 
(300 MHz; CDCl3): 2.50-2.75 (4H, m, CH2CH2), 3.07 (2H, d, J = 14.3 Hz, 
CH2C), 3.53 (2H, d, J = 14.3 Hz, CH2C), 3.66 (2H, d, J = 13.1 Hz, CH2Ph), 3.73 
(2H, s, CH2OH), 3.76 (2H, d, J = 13.1 Hz, CH2Ph), 7.27-7.36 (10H, m, CHAr); 
įC (75 MHz CDCl3): 58.7, 59.2 (CH2 ring), 63.7 (CH2Ph), 65.8 (CH2OH), 94.8 
(CNO2), 127.5, 128.5. 129.1 (CHAr), 138.9 (CAr); HRMS m/z (+ ESI): Found 
[MNa]+, 378.1797 C20H25N3O3Na requires [MNa]+, 378.1788.4 
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6-Amino-6-hydroxymethylperhydro-1,4-diazepine  (104).  
NH2
HO
H
N
N
H  
To a solution of 1,4-dibenzyl-6-hydroxymethyl-6-nitroperhydro-1,4-diazepine 
(103) (4.00 g, 11 mmol, 1 equiv) in ethanol (70 mL) and water (15 mL), 10% 
palladium on carbon (1.89 g) was added. The suspension was then 
hydrogenated at room temperature, under 60 psi of hydrogen for 40 h. The 
suspension was then filtered and concentrated in vacuo to remove the ethanol, 
and the freeze dried overnight to yield the amine as a colourless oil (104). 
Adapted from Sengar et al. (75) (1.60 g, 98%).  
 
Ȟmax (CHCl3)/cm-1, 3338 (OH); įH (400 MHz; D2O): 2.65 (2H, d, J = 14.3 Hz, 
CH2C), 2.78-2.91 (4H, m, CH2CH2), 2.85 (2H, d, J = 14.3 Hz, CH2C), 3.42 (2H, 
s, CH2OH); įC (100 MHz D2O): 50.6 (CH2CH2), 55.5 (CH2C), 57.4 (CH2C) 66.5 
(CH2OH); HRMS m/z (+ ESI): Found [MH]+, 146.1283 C6H15N3O requires [MH]+, 
146.1288. 
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1,4-Bis(t-butoxycarbonylmethyl)-6-[bis(t-
butoxycarbonylmethyl)]amino-6-hydroxymethylperhydro-1,4-
diazepine (105). 
 
A suspension of 6-amino-6-hydroxymethylperhydro-1,4-diazepine (104) (1.42 g, 
1.0 mmol, 1 equiv),  potassium carbonate (9.40 g, 7.0 mmol, 7 equiv) and 
magnesium sulfate (approx 2 g) in acetonitrile (30 mL), was cooled to 0 °C and 
tert-butyl bromoacetate (7.78 g, 4.1 mmol, 4.1 equiv) was added dropwise. The 
suspension was then stirred overnight at room temperature under a nitrogen 
atmosphere, before filtration and concentration in vacuo. The residue was then 
purified using column chromatography (PE/EtOAc, 8/2) to yield the product as a 
pale yellow oil (105). Repeated from Gugliotta et al. (79) (3.28 g, 56%).  
Ȟmax (CHCl3)/cm-1, 3451 (OH), 1729 (C=O); įH (400 MHz; CDCl3): 1.42 (18H, s, 
C(CH3)3), 1.42 (18H, s, C(CH3)3), 2.60-2.77 (4H, m, CH2CH2), 2.76 (2H, d, J = 
14.3 Hz, CH2C), 2.96 (2H, d, J = 14.2 Hz, CH2C), 3.22 (2H, s, CH2CO), 3.23 
(2H, s, CH2CO), 3.47 (2H, s, CH2OH), 3.54 (4H, s, CH2CO); įC (100 MHz 
CDCl3): 28.2, 28.3 (C(CH3)3), 52.7, 58.9 (CH2CH2, CH2C), 61.5, 62.1 (CH2CO), 
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64.4 (CCH2), 66.3 (CH2OH), 80.9, 81.0 (C(CH3)3), 170.9, 172.7 (C=O); HRMS 
m/z (+ ESI): Found [MH]+, 602.3991 C30H56N3O9 requires [MH]+, 602.4011. 
 
1,4-Bis(t-butoxycarbonylmethyl)-6-[bis(t-
butoxycarbonylmethyl)]amino-6-chloromethylperhydro-1,4-diazepine 
(106). 
 
A solution of 1,4-bis(t-butoxycarbonylmethyl)-6-[bis(t-butoxycarbonylmethyl)] 
amino-6-hydroxymethylperhydro-1,4-diazepine (105) (100 mg, 0.2 mmol, 1 
equiv) in thionyl chloride (3 mL) was stirred at room temperature under nitrogen 
for 2 h. The solution was then concentrated in vacuo to yield the crude HCl salt 
as a yellow solid (106). Adapted from Aime et al. (80) 
ESI m/z (+ ESI): Found [MH]+, 620.35 C30H54ClN3O8 requires [MH]+, 620.37. 
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1,4-Bis(t-butoxycarbonylmethyl)-6-[bis(t-
butoxycarbonylmethyl)]amino-6-(prop-2-yn-1-
ylamino)methylperhydro-1,4-diazepine (110). 
 
To a crude suspension of 1,4-bis(t-butoxycarbonylmethyl)-6-[bis(t-
butoxycarbonylmethyl)]amino-6-chloromethylperhydro-1,4-diazepine (106) (103 
mg, 0.16 mmol, 1 equiv) magnesium sulfate (200 mg) and triethylamine (40 mg, 
0.21  mmol, 1.25 equiv) in acetonitrile (5 mL), propargyl amine (13 mg, 0.27 
mmol, 1.6 equiv) was added. The solution was then stirred overnight at room 
temperature under a nitrogen atmosphere. Water (5 mL) was then added to the 
suspension and extracted with dichloromethane (3 x 5 mL), dried over 
magnesium sulphate and concentrated in vacuo. The residue was then purified 
using column chromatography (PE/EtOAc, 8/2-6/4) to yield the alkyne as a pale 
yellow oil (110). Adapted from Gugliotta et al. (79) (37 mg, 35%).  
įH (400 MHz; CDCl3): 1.43 (9H, s, C(CH3)3), 1.44 (9H, s, C(CH3)3), 1.45 (18H, 
s, C(CH3)3), 2.13 (1H, t, J = 2.2 Hz, CCH), 2.35-3.60 (16H, m, CH2CH2, 
CH2CO), 2.89 (2H, d, J = 16.2 Hz, CH2C), 3.04 (2H, d, J = 16.2 Hz, CH2C); įC 
(100 MHz CDCl3): 28.1, 28.1, 28.2 (C(CH3)3), 38.1 (CH2CCH), 48.0, 51.5, 53.2, 
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56.8, 57.3, 60.3 (CH2CH2, CH2C, CH2CO, CH2NH), (CH2CCH), 80.7, 80.8, 80.8 
(C(CH3)3), 81.0 (CH2CCH), 169.8, 171.2, 171.3 (C=O); HRMS m/z (+ ESI): 
Found [MH]+, 639.4324 C33H58N4O8 requires [MH]+, 639.4327. 
 
To a crude suspension of 1,4-bis(t-butoxycarbonylmethyl)-6-[bis(t-
butoxycarbonylmethyl)]amino-6-chloromethylperhydro-1,4-diazepine (106) 
(1.52 g, 2.5 mmol, 1 equiv) magnesium sulfate (1 g) and triethylamine (596 mg, 
4.4 mmol, 1.8 equiv) in acetonitrile (50 mL), propargyl amine (324 mg, 5.8 
mmol, 2.4 equiv) was added. The solution was then stirred overnight at room 
temperature under a nitrogen atmosphere. Water (50 mL) was then added to 
the suspension and extracted with dichloromethane (3 x 50 mL), dried over 
magnesium sulphate and concentrated in vacuo. The residue was then purified 
using column chromatography (PE/EtOAc, 8/2-1/1) to yield the alkyne as a 
yellow oil (566 mg, 40%).  
įH (400 MHz; CDCl3): 1.38 (9H, s, C(CH3)3), 1.39 (18H, s, C(CH3)3), 2.12 (1H, t, 
J = 2.5 Hz, CCH), 2.50-2.90 (6H, m, CH2CH2, CH2NH), 2.62 (2H, d, J = 13.3 Hz, 
CH2C), 2.77 (2H, d, J = 13.3 Hz, CH2C), 3.26 (4H, s, CH2CO), 3.28 (2H, s, 
CH2CO), 3.34 (2H, s, CH2CO), 3.99 (2H, dd, J = 5.5, 2.5 Hz, CH2CCH), 8.10 
(1H, t, J = 5.4 Hz, NH); įC (100 MHz CDCl3): 28.1, 28.1 (C(CH3)3), 28.5 
165 
 
(CH2CCH), 55.8, 59.2, 60.3, 61.0, 61.7, 62.6, 63.5 (CH2CH2, CH2C, CH2CO, 
CH2NH), 70.9 (CH2CCH), 80.0 (CH2CCH), 81.2, 81.3 (C(CH3)3), 170.8, 171.0, 
171.5 (C=O); HRMS m/z (+ ESI): Found [MH]+, 583.3687 C29H51N4O8 requires 
[MH]+, 583.3701. 
 
1,4-Bis(t-butoxycarbonylmethyl)-6-[bis(t-
butoxycarbonylmethyl)]amino-6-(prop-2-yn-1-
ylcarbamate)methylperhydro-1,4-diazepine (114). 
O
O
N
N
N
O
O
O
O
OO
O
HN
O
 
A suspension of 1,4-bis(t-butoxycarbonylmethyl)-6-[bis(t-
butoxycarbonylmethyl)]amino-6-(prop-2-yn-1-ylamino)methylperhydro-1,4-
diazepine (105) (4.10 g, 6.8 mmol, 1 equiv), dimethylaminopyridine (2.50 g, 
21.8 mmol, 3.2 equiv) and triphosgene (0.81 g, 2.7 mmol, 0.4 equiv) in 
anhydrous dichloromethane (250 mL) is stirred at room temperature under 
nitrogen for 10 min. Propargyl amine (0.69 g, 6.8 mmol, 1 equiv) was then 
added and the suspension was stirred overnight. The reaction was then 
quenched with ice water (100 mL), and extracted with dichloromethane (3 x 100 
mL) before concentration in vacuo. The residue was the purified using column 
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chromatography (PE/EtOAc, 8/2) to yield the product as a sticky pale yellow oil 
(114). Adapted from Deshmukh et al. (133) (1.48 g, 32%).  
įH (400 MHz; CDCl3): 1.44 (36H, s, C(CH3)3), 2.23 (1H, dt, J = 8.3, 2.5 Hz, 
CCH), 2.60-2.85 (4H, m, CH2CH2), 2.73 (2H, d, J = 14.4 Hz, CH2C), 3.09 (2H, d, 
J = 14.4 Hz, CH2C), 3.26 (2H, s, CH2) 3.27 (2H, s, CH2), 3.69 (4H, s, CH2), 3.95 
(2H, dd, J = 5.4, 2.5 Hz, CH2CCH), 4.16 (2H, s, CH2), 5.14 (1H, t, J = 5.4 Hz, 
NH įC (100 MHz CDCl3): 28.1, 28.2 (C(CH3)3), 30.8 (CH2CCH), 51.4, 53.4, 
58.8, 59.0, 59.3, 62.1, 62.3, 63.2, 68.1 (CH2CH2, CH2C, CH2CO, CH2NH), 71.5 
(CH2CCH), 79.7 (CH2CCH), 80.5, 80.8 (C(CH3)3), 155.8, 170.8, 172.7 (C=O); 
HRMS m/z (+ ESI): Found [MH]+, 683.4229 C34H58N4O10 requires [MH]+, 
683.4226. 
 
1,4-Bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-(prop-2-yn-1-
yl carbamate)methyl perhydro-1,4-diazepine .4TFA (115). 
N
N
N
OH
O
O
OH
OHO
HO
O
O
HN
O
.4TFA
 
A solution of 1,4-bis(t-butoxycarbonylmethyl)-6-[bis(t-butoxycarbonylmethyl)] 
amino-6-(prop-2-yn-1-ylcarbamate)methylperhydro-1,4-diazepine (114) (1.42 g, 
2.1 mmol, equiv) in trifluoroacetic acid (20 mL) was stirred overnight at room 
temperature under a nitrogen atmosphere, before concentration in vacuo, to 
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yield the trifluoroacetic acid salt as a sticky brown oil (115). Adapted from 
Green et al. (122) (0.94 g, 98%). 
Ȟmax (CHCl3)/cm-1,3279 (OH), 2997 (CH), 1760 (C=O); įH (400 MHz; MeOD): 
2.57 (1H, dt, J = 18.0, 2.1  Hz, CCH), 3.35-4.19 (20H, m, CH2)įC (100 MHz 
MeOD): 29.7 (CH2CCH), 50.2, 51.5, 53.2, 53.3, 57.6, 58.1, 61.8, 65.8, 70.5 
(CH2CH2, CH2C, CH2CO, CH2NH), 70.9 (CH2CCH), 79.5 (CH2CCH), 169.5, 
175.5, 175.7 (C=O); HRMS m/z (+ ESI): Found [MH]+, 459.1716 C18H26N4O10 
requires [MH]+, 459.1722. 
 
1,4-Bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-(prop-2-yn-1-
yl carbamate)methyl perhydro-1,4-diazepine europium (CA4-Eu). 
Eu
N
N
N
O
O
O
O
OO
O
O
O
HN
O
-
 
To a solution of 1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-(prop-2-
yn-1-yl carbamate)methyl perhydro-1,4-diazepine .4TFA (115) (274 mg, 0.3 
mmol, 1 equiv) in water (2 mL), europium (III) chloride hexahydrate (124 mg, 
0.3 mmol, 1 equiv) was added. The pH was then adjusted to pH 9 using 
potassium hydroxide (1 M), and the reaction was stirred for 2 h before freeze 
drying. The residue was then centrifuged and the supernatant, was 
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concentrated in vacuo to yield the final product as a pale brown solid (CA4-Eu). 
Adapted from Viguier et al. (74) (166 mg, 90%). 
Ȟmax (CHCl3)/cm-1, 3436 (OH), 2929 (CH), 1685, 1606 (C=O); HRMS m/z (+ 
ESI): Found [MH]-, 607.0550 C18H22N4O10152Eu requires [MH]-, 607.0554. 
 
1,4-Bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-(prop-2-yn-1-
yl carbamate)methyl perhydro-1,4-diazepine gadolinium (CA4). 
Gd
N
N
N
O
O
O
O
OO
O
O
O
HN
O
-
 
To a solution of 1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-(prop-2-
yn-1-yl carbamate)methyl perhydro-1,4-diazepine .4TFA (115) (274 mg, 0.3 
mmol, 1 equiv) in water (2 mL), gadolinium (III) chloride hexahydrate (126 mg, 
0.3 mmol, 1 equiv) was added. The pH was then adjusted to pH 9 using 
potassium hydroxide (1 M), and the reaction was stirred for 2 h before freeze 
drying. The residue was then centrifuged and the supernatant was 
concentrated in vacuo to yield the final product as a pale brown solid (CA4). 
Adapted from Viguier et al. (74) (182 mg, 99%). 
Ȟmax (CHCl3)/cm-1, 3416 (OH), 2977 (CH), 1683, 1608 (C=O); HRMS m/z (+ 
ESI): Found [MH]-, 612.0591 C18H22N4O10158Gd requires [MH]-, 612.0582. 
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2-Nitroimidazole (117). 
N NH
NO2
 
A solution of 2-aminoimidazole hemisulfate (116) (418 mg, 3.1 mmol, 1 equiv) 
in 40 % fluoroboric acid (2.5 mL) and distilled water (4.1 mL) was stirred at -10 
°C. Sodium nitrite (1.09 g, 15.8 mmol, 5 equiv) in distilled water (2.5 mL) was 
then added dropwise below the surface and stirred for 30 min. To solution of 
copper sulfate pentahydrate (2.18 g, 8.7 mmol, 3 equiv) and 4-dimethylamino 
pyridine (252 mg, 2.1 mmol, 0.7 equiv) in water (33.6 mL) the 2-aminoimidazole 
solution was added dropwise, followed by a second addition of sodium nitrite 
(1.09 g, 15.8 mmol, 5 equiv) before being brought to ambient temperature and 
stirred for 2 h. The pH was then adjusted to pH 2 using hydrochloric acid, and 
the product extracted into ethyl acetate (6 x 40 mL). The ethyl acetate layer was 
dried over magnesium sulfate, filtered and concentrated to produce a yellow 
solid. The solid was then recrystallised in ethanol to yield 2-nitroimidazole as 
yellow crystals (117). Repeated from Takuma et al. (134) (249 mg, 70 %).  
mp, 284-286 °C (Lit: 287-288 °C172); Ȟmax (CHCl3)/cm-1, 3420 (NH), 1538 (NO2); 
įH (400 MHz; D2O): 7.3 (2H, s, CH); HRMS m/z (+ EI): Found [MH]+, 113.0215, 
C3H3N3O2 requires [MH]+, 113.0220 
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1-(2-Nitro-imidazol-1-yl)-propan-1-ol (119b). 
N N
NO2
OH
 
A suspension of 2-nitroimidzole (117) (50 mg, 0.44 mmol, 1 equiv), caesium 
carbonate (161 mg, 0.48 mmol, 1.1 equiv), propene oxide (33.6 mg, 0.58 mmol, 
1.3 equiv) in acetonitrile (7 mL) and water (3 mL) was placed in a sealed tube. 
The sealed tube was heated in a microwave at 100 °C for 10 min, left to cool for 
5 min, before being heated at 100 °C for a further 10 min. The reaction was 
then purified using column chromatography (DCM/MeOH, 9/1) to yield the 
product as a yellow solid (119b). Adapted from Kim et al. (175) (20 mg, 26%).  
Ȟmax (CHCl3)/cm-1, 3162 (OH), 2973 (CH), 1520, 1345 (NO2); įH (400 MHz; 
MeOD): 0.94 (1H, d, J = 2.4 Hz, OH), 1.24 (3H, d, J = 6.2 Hz, CH3), 4.08 (1H, 
m, CH), 4.29 (1H, dd, J = 13.8, 8.5 Hz, CH2), 4.58 (1H, dd, J = 13.8, 3.2 Hz, 
CH2), 7.14 (1H, d, J = 1.1 Hz, CHAr), 7.45 (1H, d, J = 1.1 Hz, CHAr)įC (100 
MHz MeOD): 19.3 (CH3), 56.0 (CH2), 65.8 (CH), 126.6 (CHAr), 127.7 (CHAr). 
HRMS m/z (+ EI): Found [MH]+, 171.0642, C6H9N3O3 requires [MH]+, 171.0638 
 
1-(2-Nitro-1H-imidazol-1-yl)propan-2-yl methanesulfonate (121). 
 
To a solution of 2-(2-nitro-imidazol-1-yl)-propan-1-ol (119b) (50 mg, 0.3 mmol, 1 
equiv) in anhydrous dichloromethane (5 mL) methanesulfonyl chloride (22 µL, 
0.3 mmol, 1 equiv) and diisopropylamine (104 µL, 0.6 mmol, 2 equiv) were 
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added. The solution was then stirred for 4 hours under a nitrogen atmosphere 
at room temperature before concentration in vacuo. The residue was then 
purified using column chromatography (DCM/MeOH, 95/5) to yield the primary 
alcohol as a pale yellow oil (121). Adapted from Zheng et al. (131) (6 mg, 8%).  
įH (400 MHz; MeOD): 1.50 (3H, d, J = 6.4 Hz, CH3), 2.91 (3H, s, SCH3), 4.55 
(1H, dd, J = 14.5, 9.0 Hz, CH2), 4.80 (1H, dd, J = 14.5, 2.8 Hz, CH2), 5.13 (1H, 
m, CH), 7.15 (1H, d, J = 1.2 Hz, CHAr), 7.48 (1H, d, J = 1.2 Hz, CHAr). 
 
2-Nitro-1-(2-p-toluenesulfonyloxyethyl)-1H-imidazole (122). 
S OO
O
N
N NO2
 
To a solution of 2-nitroimidazole (117) (1.00 g, 8.8 mmol, 1 equiv) and 
triethylamine (5.1 mL, 35.4 mmol, 4 equiv) in dimethylformamide (20 mL), 
ethylene glycol bis-p-toluenesulfonate (6.56 g, 17.7 mmol, 2 equiv) was added. 
The suspension was then stirred under a nitrogen atmosphere at room 
temperature for 4 days. Water was then added to the reaction before extraction 
with dichloromethane (3 x 40 mL), the organic layers were then washed with 
brine (80 mL) before drying over magnesium sulfate and concentration in 
vacuo. The remaining residue was then purified using column chromatography 
(DCM - MeOH/DCM 0.5/99.5) to yield the product as pale yellow crystals (122). 
Repeated from Lin et al. (114) (2.5 g, 86%).  
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įH (400 MHz; CDCl3): 2.45 (3H, s, CH3), 4.39 (2H, t, J = 4.8 Hz, NCH2CH2), 
4.67 (2H, t, J = 4.8 Hz, NCH2CH2), 7.14 (1H, d, J = 1.0 Hz,  CHAr imidazole), 7.15 
(1H, d, J = 1.0 Hz,  CHAr
 imidazole), 7.30 (2H, dd, J = 8.4, 0.5 Hz, CHAr tosyl), 7.61 
(2H, d, J = 8.4 Hz, CHAr tosyl) įC (100 MHz CDCl3): 21.7 (CH3), 49.1 
(NCH2CH2), 67.2 (NCH2CH2), 127.4 (CHAr imidazole), 127.7 (CHAr tosyl), 128.5 
(CHAr imidazole), 130.1 (CHAr tosyl), 131.6 (CAr tosyl), 145.8 (CAr tosyl); HRMS m/z 
(+ ESI): Found [MH]+, 312.0639 C12H13N3O5S requires [MH]+, 312.0649.  
 
1-(2-Azidoethyl)-2-nitro-1H-imidazole (TV1). 
N3
N
N NO2
 
To a solution of 2-nitro-1-(2-p-toluenesulfonyloxyethyl)-1H-imidazole (122) (170 
mg, 0.54 mmol, 1 equiv) in dimethylformamide (4 mL), sodium azide (134 mg, 
2.18 mmol, 4 equiv) was added. The suspension was then stirred overnight at 
room temperature under a nitrogen atmosphere, before drying under a stream 
of nitrogen. The residue was then filtered through a pad of silica (MeOH/,DCM 
2/98) and concentrated in vacuo to yield the product as a yellow oil (TV1). 
Repeated from Lin et al. (114) (90 mg, 96%). 
Ȟmax (CHCl3)/cm-1, 3090 (CHAr), 2094 (N3), 1537, 1356 (NO2); įH (400 MHz; 
CDCl3): 3.80 (2H, t, J = 5.5 Hz, CH2CH2N3), 4.56 (2H, t, J = 5.5 Hz, CH2CH2N3), 
7.16 (11H, d, J = 1.1 Hz,  CHAr), 7.19 (1H, d, J = 1.1 Hz,  CHAr)įC (100 MHz 
CDCl3): 49.2 (CH2CH2N3), 50.8 (CH2CH2N3), 126.9 (CHAr), 128.6 (CHAr). 
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tert-Butyl-dimethy-(2-nitro-benzyloxy)-silane (124). 
NO2 O
Si
 
To a stirred solution of 2-nitrobenzyl alcohol (123) (153 mg, 1 mmol, 1 equiv) 
and tert-butyl-chloro-dimethyl-silane (180 mg, 1.2 mmol, 1.2 equiv) in 
dimethylformamide (7 mL), imidazole (170 mg, 2.5 mmol, 2.5 equiv) in 
dimethylformamide (0.5 mL) was added dropwise. The reaction was then stirred 
for 2 h at room temperature under a nitrogen atmosphere, before being 
concentrated in vacuo. The remaining residue was then purified with column 
chromatography (DCM) to yield the protected alcohol as a yellow oil (124). 
Adapted from Corey et al. (176) (256 mg, quantitative). 
Ȟmax (CHCl3)/cm-1, 1530, 1342 (NO2); įH (400 MHz; CDCl3): 0.15 (6H, s, CH3), 
0.97 (9H, s, C(CH3)3), 5.12 (2H, s, CH2), 7.40 (1H, dd, J = 7.8, 1.1 Hz, CHAr), 
7.66 (1H, dd, J = 7.8, 1.1 Hz, CHAr), 7.91 (1H, dd, J = 7.8, 1.1 Hz, CHAr), 8.08 
(1H, dd, J = 7.8, 1.1 Hz CHAr); įC (100 MHz CDCl3): -5.3 (CH3), 18.5 (C(CH3)3), 
26.0 (C(CH3)3), 62.2 (CH2), 124.6, 127.5, 128.1. 133.9 (CHAr), 138.4, 146.6 
(CAr); HRMS m/z (+ ESI): Found [MNa]+, 290.1177 C13H21N1O3SiNa requires 
[MNa]+, 290.1183. 
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1-(4-Nitrophenyl)prop-2-en-ol (129). 
NO2
HO
 
To a solution of 4-nitrobenzaldehyde (127) (855 mg, 5.6 mmol, 1 equiv) in 
anhydrous THF (20 mL), vinylmagnesium bromide (1 M in THF, 6.8 mL, 1.2 
equiv) was added dropwise at -78 °C. The solution was then stirred at -50 °C 
for 40 min under a nitrogen atmosphere before quenching with saturated 
ammonium chloride (10 mL). Ethyl acetate (2 x 60 mL) was then added before 
the organic layer was washed with brine (100 mL), dried over magnesium 
sulfate and concentrated in vacuo. The residue was then purified using column 
chromatography (PE/EtOAc, 8/2) to yield the product as a yellow oil (129). 
Repeated from Jiang et al. (116) (775 mg, 76%). 
Ȟmax (CHCl3)/cm-1, 3300 (OH), 1519, 1347 (NO2); įH (400 MHz; CDCl3): 3.16 
(1H, bs, OH), 5.15-5.38 (3H, m, CHCH2), 5.88-5.99 (1H, m, CHOH), 7.48 (2H, 
d, J = 8.9 Hz, CHArb), 8.09 (2H, d, J = 8.9 Hz, CHAra); įC (100 MHz CDCl3): 
74.4 (CHOH), 116.6 (CH2CH), 123.6 (CH2CH), 127.0 (CHArb), 139.0 (CHAra), 
147.0 (CAr), 150.0 (CNO2Ar); HRMS m/z (+ ESI): Found [MNa]+, 202.0468 
C9H9NNaO3 requires [MNa]+, 202.0475. 
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1-Methoxymethoxy-1-(4-nitrophenyl)-2-propene (131). 
NO2
OO
 
A stirred solution of 1-(4-nitrophenyl)prop-2-en-ol (129) (200 mg, 1.1 mmol, 1 
equiv) in anhydrous dichloromethane (4 mL) was cooled to 0 °C, before 
addition of diisopropylethylamine (1.1 mL, 6.3 mmol, 6 equiv). Chloromethyl 
methyl ether (0.5 mL, 6.6 mmol, 6 equiv) was then added dropwise and the 
reaction was allowed to reach room temperature and stirred for 24 h under a 
nitrogen atmosphere. The reaction was then quenched with saturated sodium 
bicarbonate, before concentration in vacuo. The residue was then taken up in 
diethyl ether (3 x 20 mL), washed with brine (20 mL), dried over magnesium 
sulfate and concentrated in vacuo to yield the product as a yellow oil (131). 
Repeated from Jiang et al. (116) (249 mg, quant).  
Ȟmax (CHCl3)/cm-1, 2932 (CH), 1522, 1347 (NO2); įH (400 MHz; CDCl3): 3.35 
(3H, s, CH3), 4.61 (1H, d, J = 6.8 Hz, CH2OCH3), 4.77 (1H, d, J = 6.8 Hz, 
CH2OCH3), 5.16 (1H, d, J = 7.2 Hz, CHO), 5.32 (2H, m, CHCH2), 5.94 (1H, m, 
CHCH2), 7.53 (2H, d, J = 8.8 Hz, CHArb), 8.18 (2H, d, J = 8.8 Hz, CHAra); įC 
(100 MHz CDCl3): 55.6 (CH3), 77.5 (CHO), 93.9 (OCH2O), 118.2 (CH2CH), 
123.7 (CH2CH), 127.6 (CHArb), 136.9 (CHAra), 147.4 (CAr), 148.2 (CNO2Ar); 
HRMS m/z (+ ESI): Found [MNa]+, 246.0727 C11H13NNaO4 requires [MNa]+, 
246.0737. 
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3-Methoxymethoxy-3-(4-nitrophenyl)propan-1-ol (133). 
NO2
OO OH
 
A solution of 1-methoxymethoxy-1-(4-nitrophenyl)-2-propene (131) (3.70 g, 17 
mmol, 1 equiv) in anhydrous tetrahydrofuran (100 mL) was cooled to 0 °C, 
borane (1M in THF, 17 mL, 1.0 equiv) was then added dropwise, and then 
stirred overnight at 0 °C under a nitrogen atmosphere. Sodium hydroxide (3M, 
17 mL) was then added followed by dropwise addition of hydrogen peroxide 
(30%, 17 mL), before stirring for 30 min at 0 °C. The reaction was then 
quenched with a saturated sodium bisulfite solution (25 mL) and ethyl acetate 
(50 mL) was added. The organic layer was then washed with sodium hydrogen 
carbonate (50 mL) and brine (50 mL), before concentration in vacuo. The 
residue was then purified using column chromatography (PE/EtOAc, 2/1-1/1) to 
yield the primary alcohol as a yellow oil (133). Repeated from Jiang et al. (116) 
(2.21 g, 55%).  
Ȟmax (CHCl3)/cm-1, 3416 (OH), 1520, 1347 (NO2);įH (400 MHz; CDCl3): 1.92-
1.96 (1H, m, CH2CH2OH), 1.98-2.08 (1H, m, CH2CH2OH), 2.18 (1H, bs, OH), 
3.38 (3H, s, CH3), 3.71-3.76 (1H, m, CH2CH2OH), 3.80-3.86 (1H, m, 
CH2CH2OH), 4.51 (1H, d, J = 6.8 Hz, CH2OCH3), 4.61 (1H, d, J = 6.8 Hz, 
CH2OCH3), 4.95 (1H, dd, J = 8.9, 4.4 Hz, CHOMOM), 7.51 (2H, d, J = 8.8 Hz, 
CHArb), 8.21 (2H, d, J = 8.8 Hz, CHAra); įC (100 MHz CDCl3): 40.5 
(CH2CH2OH), 55.9 (CH3), 59.6 (CH2CH2OH), 75.7 (CHOMOM), 94.9 (OCH2O), 
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123.8 (CHArb), 127.4 (CHAra), 147.5 (CAr), 149.5 (CNO2Ar); HRMS m/z (+ 
ESI): Found [MNa]+, 264.0835 C11H15NNaO5 requires [MNa]+, 264.0842. 
 
1-Azido-3-methoxymethyl-3-(4-nitrophenyl) propane (135). 
NO2
OO N3                                                                  
To a solution of 3-methoxymethoxy-3-(4-nitrophenyl)propan-1-ol (133) (1.00 g, 
4.1 mmol, 1 equiv) in tetrahydrofuran (30 mL), diphenyl phosphorylazide (2.28 
g, 8.2 mmol, 2 equiv) and 1,8-diazabicycloundec-7-ene (1.89 g, 12.3 mmol, 3 
equiv) were added. The solution was then stirred overnight at room temperature 
under a nitrogen atmosphere. Sodium azide (1.35 g, 20.5 mmol, 5 equiv) and 
15-crown-5 (80 mg, 0.4 mmol, 0.1 equiv) were then added to form a suspension 
that was refluxed for 4 h. The suspension was then filtered, and the filtrate 
concentrated in vacuo. The remaining residue was then purified using column 
chromatography (PE/EtOAc, 8/2) to yield the azide as a pale yellow oil (135). 
Adapted from Liu et al. (143) (1.07 g, 97%).  
Ȟmax (CHCl3)/cm-1, 2099 (N3), 1519, 1345 (NO2); įH (400 MHz; CDCl3): 1.83-
1.94 (1H, m, CH2CH2N3), 1.99-2.10 (1H, m, CH2CH2N3), 3.35 (3H, s, CH3), 
3.36-3.42 (1H, m, CH2CH2N3), 3.45-3.53 (1H, m, CH2CH2N3), 4.50 (1H, d, J = 
7.0 Hz, CH2OCH3), 4.59 (1H, d, J = 7.0 Hz, CH2OCH3), 4.82 (1H, dd, J = 8.9, 
4.5 Hz, CHOMOM), 7.50 (2H, d, J = 8.7 Hz, CHArb), 8.21 (2H, d, J = 8.7 Hz, 
CHAra); įC (100 MHz CDCl3): 37.0 (CH2CH2N3), 47.7 (CH2CH2N3), 56.0 (CH3), 
74.3 (CHOMOM), 94.8 (OCH2O), 123.9 (CHArb), 127.4 (CHAra), 147.6 (CAr), 
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149.0 (CNO2Ar); HRMS m/z (+ ESI): Found [MNa]+, 289.0908 C11H14N4NaO4 
requires [MNa]+, 289.0907. 
 
3-Azido-1-(4-nitrophenyl)propan-1-ol (137). 
NO2
HO N3
 
To an emulsion of 1-azido-3-methoxymethyl-3-(4-nitrophenyl) propane (135) (1 
g, 3.8 mmol, 1 equiv) in tetrahydrofuran (3 mL) and water (5 mL), hydrochloric 
acid (5 mL) was added. The emulsion was then stirred at 50 °C for 8 h, before 
extraction with ethyl acetate (2 x 20 mL). The organic layer was then dried over 
magnesium sulphate and concentrated in vacuo. The residue was then purified 
using column chromatography (PE/EtOAc, 8/2) to yield the alcohol as a pale 
yellow oil (137). Adapted from Meyers et al. (177) (572 mg, 69%). 
Ȟmax (CHCl3)/cm-1, 3399 (OH), 2100 (N3), 1518, 1348 (NO2); įH (400 MHz; 
CDCl3): 1.88-2.04 (2H, m, CH2CH2N3), 2.52 (1H, bs, OH), 3.40-3.62 (2H, m, 
CH2CH2N3), 4.98 (1H, dd, J = 8.0, 4.8 Hz, CHOH), 7.53 (2H, d, J = 8.6 Hz, 
CHArb), 8.21 (2H, d, J = 8.6 Hz, CHAra); įC (100 MHz CDCl3): 37.9 
(CH2CH2N3), 48.2 (CH2CH2N3), 70.9 (CHOH), 123.9 (CHArb), 126.5 (CHAra), 
147.4 (CAr), 151.2 (CNO2Ar); HRMS m/z (+ ESI): Found [MNa]+, 245.0645 
C9H10N4NaO3 requires [MNa]+, 245.0644. 
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1-(3-Azido-1-chloropropyl)-4-nitrobenzene (TV3).  
NO2
Cl N3
 
A solution of 3-azido-1-(4-nitrophenyl)propan-1-ol (137) (100 mg, 0.45 mmol, 1 
equiv) in anhydrous dichloromethane (5 mL) was cooled to 0 °C under a 
nitrogen atmosphere. Thionyl chloride (5 mL) was then added dropwise and the 
solution was left to stir at room temperature for 6 h. The reaction was then 
concentrated in vacuo and the residue was purified using column 
chromatography (PE/EtOAc, 8/2) to yield the product as a pale yellow oil (TV3). 
Adapted from Nakamura et al. (178) (65 mg, 60%).  
Ȟmax (CHCl3)/cm-1, 3112, 3079 (CHAr), 2100 (N3), 1520, 1347 (NO2); įH (400 
MHz; CDCl3): 2.13-2.26 (1H, m, CH2CH2N3), 2.26-2.37 (1H, m, CH2CH2N3), 
3.42-3.51 (1H, m, CH2CH2N3), 3.57-3.66 (1H, m, CH2CH2N3), 5.08 (1H, dd, J = 
9.4, 5.1 Hz, CHCl), 7.58 (2H, d, J = 8.8 Hz, CHArb), 8.24 (2H, d, J = 8.8 Hz, 
CHAraįC (100 MHz CDCl3): 38.9 (CH2CH2N3), 48.4 (CH2CH2N3), 58.4 (CH), 
124.1 (CHArb), 127.9 (CHAra), 147.7 (CAr), 147.9 (CNO2Ar); HRMS m/z (+ 
ESI): Found [MNa]+, 263.0303 C9H9ClN4NaO2 requires [MNa]+, 263.0306.  
 
1-(2-Nitrophenyl)prop-2-en-1-ol (130). 
HO
O2N
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A solution of 2-nitrobenzaldehyde (128) (5.00 g, 33 mmol, 1 equiv) in 
tetrahydrofuran (20 mL) was cooled to 0 °C before dropwise addition of vinyl 
magnesium bromide (1 M in THF, 33 mL, 1 equiv). The solution was then 
stirred at room temperature under a nitrogen atmosphere for 2 h before 
quenching with saturated ammonium chloride (50 mL). Ethyl acetate (50 mL) 
was then added and the reaction was washed with saturated sodium 
bicarbonate (50 mL) and brine (50 mL) before concentration in vacuo. The 
residue was then purified using column chromatography (PE/EtOAc, 9/1), to 
yield the product as a yellow oil (130). Adapted from Jiang et al. (116) (1.54 g, 
26%). 
Ȟmax (CHCl3)/cm-1, 3406 (OH), 1525, 1349 (NO2); įH (400 MHz; CDCl3): 1.63 
(1H, bs, OH), 5.27 (1H, dt, J = 10.4, 1.4 Hz CHCH2y), 5.42 (1H, dt, J = 17.3, 1.4 
Hz CHCH2z), 5.80 (1H, dt, J = 5.2, 1.4 Hz, CHOH), 6.08 (1H, ddd, J = 17.3, 
10.4, 5.2 Hz CHCH2), 7.45 (1H, ddd, J = 8.2, 7.7, 1.5 Hz, CHArc), 7.64 (1H, td, 
J = 7.7, 1.2 Hz, CHArb), 7.77 (1H, dd, J = 7.7, 1.5 Hz, CHAra), 7.92 (1H, dd, J = 
8.2, 1.2 Hz, CHArd); įC (100 MHz CDCl3): 69.9 (CHOH), 116.0 (CH2CH), 124.4 
(CHArd), 128.4 (CHAra), 128.6 (CHArc), 133.6 (CHArb), 137.7 (CAr) 138.1 
(CH2CH), 148.0 (CNO2Ar). 
 
1-[1-(Methoxymethoxy)prop-2-en-1-yl]-2-nitrobenzene (132). 
O
O2N
O  
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A solution of 1-(2-nitrophenyl)prop-2-en-1-ol (130) (3.89 g, 21 mmol, 1 equiv) in 
anhydrous dichloromethane (50 mL) was cooled to 0 °C before dropwise 
addition of diisopropylamine (11.0 mL, 63 mmol, 3 equiv). Chloromethyl methyl 
ether (5.0 mL, 66 mmol, 3.1 equiv) was then added dropwise and the reaction 
was allowed to reach room temperature and stirred for 24 h under a nitrogen 
atmosphere. The reaction was then quenched with saturated sodium 
bicarbonate, before concentration in vacuo. The residue was then taken up in 
diethyl ether (3 x 20 mL), washed with brine (20 mL), dried over magnesium 
sulfate and concentrated in vacuo. The residue was then purified using column 
chromatography (PE/EtOAc, 8/2), to yield the product as a yellow oil (132). 
Adapted from Jiang et al. (116) (3.00 g, 62%). 
Ȟmax (CHCl3)/cm-1, 3083 (CHAr), 1528, 1355 (NO2); įH (400 MHz; CDCl3): 3.29 
(3H, s, CH3), 4.57 (1H, d, J = 6.6 Hz, CH2O), 4.70 (1H, d, J = 6.6 Hz, CH2O), 
5.21 (1H, dt, J = 10.4, 1.4 Hz, CHCH2y), 5.34 (1H, dt, J = 17.2, 1.4, Hz, 
CHCH2z), 5.75 (1H, d, J = 6.1 Hz, CHO), 5.94 (1H, ddd, J = 17.1, 10.3, 6.1 Hz, 
CHCH2), 7.40 (1H, ddd, J = 7.9, 7.7, 1.4 Hz, CHArb), 7.61 (1H, ddd, J = 8.0, 7.9, 
1.4 Hz, CHArc), 7.75 (1H, dd, J = 7.7, 1.4 Hz, CHAra), 7.86 (1H, dd, J = 8.0, 1.4 
Hz, CHArd); įC (100 MHz CDCl3): 55.7 (CH3), 73.3 (CHO), 94.5 (OCH2O), 117.2 
(CH2CH), 124.2 (CHArd), 128.3 (CHAra), 128.7 (CHArc), 133.2 (CHArb), 136.2 
(CAr), 136.5 (CH2CH), 148.4 (CNO2Ar); HRMS m/z (+ ESI): Found [MNa]+, 
246.0740 C11H13NNaO4 requires [MNa]+, 246.0737. 
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3-(2-Nitrophenyl)-3-(methoxymethoxy) propan-1-ol (134). 
O
O2N
O OH
 
A solution of 1-[1-(methoxymethoxy)prop-2-en-1-yl]-2,4-dinitrobenzene (132) 
(1.83 g, mmol, 1 equiv) in anhydrous tetrahydrofuran (50 mL) was cooled to 0 
°C, borane (1M in THF, 7.4 mL, equiv) was then added dropwise, and stirred 
overnight at 0 °C under a nitrogen atmosphere. Sodium hydroxide (3M, 7.5 mL) 
was then added followed by dropwise addition of hydrogen peroxide (30%, 7.5 
mL), before stirring for 30 min at 0 °C. The reaction was then quenched with a 
saturated sodium bisulfite solution (20 mL) and ethyl acetate (50 mL) was 
added. The organic layer was then washed with sodium hydrogen carbonate 
(50 mL) and brine (50 mL), before concentration in vacuo. The residue was 
then purified using column chromatography (PE/EtOAc, 7/3) to yield the primary 
alcohol as a brown oil (134). Adapted from Jiang et al. (116) (1.10 g, 56%).  
Ȟmax (CHCl3)/cm-1, 3425 (OH), 1526, 1346 (NO2); įH (400 MHz; CDCl3): 1.85-
2.08 (2H, m, CH2CH2OH), 3.21 (3H, s, CH3), 3.71-3.76 (2H, m, CH2CH2OH), 
4.36 (1H, d, J = 6.7 Hz, CH2OCH3), 4.47 (1H, d, J = 6.7 Hz, CH2OCH3), 5.28 
(1H, dd, J = 9.1, 3.4 Hz, CHOMOM), 7.33 (1H, ddd, J = 8.2, 7.5, 1.2 Hz, 
CHArb), 7.56 (1H, ddd, J = 8.0, 7.5, 1.3 Hz, CHArc), 7.67 (1H, dd, J = 8.2, 1.3 
Hz, CHAra), 7.80 (1H, dd, J = 8.0, 1.2 Hz, CHArdįC (100 MHz CDCl3): 40.1 
(CH2CH2OH), 55.8 (CH3), 59.8 (CH2CH2OH), 71.9 (CHOMOM), 95.2 (OCH2O), 
124.3 (CHArd), 128.2 (CHAra), 128.5 (CHArc), 133.4 (CHArb), 138.0 (CAr), 
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148.2 (CNO2Ar); HRMS m/z (+ ESI): Found [MNa]+, 264.0843 C11H15NNaO5 
requires [MNa]+, 264.0842. 
 
1-[Azido-1-(methoxymethoxy)propyl]-2-nitrobenzene (136).  
O
O2N
O N3                                                                  
To a solution of 3-(2-nitrophenyl)-3-(methoxymethoxy) propan-1-ol (134) (200 
mg, 1 equiv) in tetrahydrofuran (30 mL), diphenyl phosphorylazide (456 mg, 2 
equiv) and 1,8-diazabicycloundec-7-ene (378 mg, 3 equiv) were added. The 
solution was then stirred overnight at room temperature under a nitrogen 
atmosphere. Sodium azide (270 mg, 5 equiv) and 15-crown-5 (16 mg, 0.1 
equiv) were then added to form a suspension that was refluxed for 4 h. The 
suspension was then filtered, and the filtrate concentrated in vacuo. The 
remaining residue was then purified using column chromatography (PE/EtOAc, 
8/2) to yield the azide as a pale yellow oil (taken on with some slight impurities) 
(136). Adapted from Liu et al. (143)  
Ȟmax (CHCl3)/cm-1, 2098 (N3), 1526, 1345 (NO2); įH (400 MHz; CDCl3): 1.96-
2.06 (1H, m, CH2CH2N3), 2.14-2.24 (1H, m, CH2CH2N3), 3.33 (3H, s, CH3), 
3.51-3.57 (2H, m, CH2CH2N3), 4.47 (1H, d, J = 6.8 Hz, CH2OCH3), 4.57 (1H, d, 
J = 6.8 Hz, CH2OCH3), 5.32 (1H, dd, J = 9.2, 3.1 Hz, CHOMOM), 7.44 (1H, 
ddd, J = 8.2, 7.4, 1.4 Hz, CHArb), 7.65 (1H, ddd, J = 8.0, 7.4, 1.3 Hz, CHArc), 
7.75 (1H, dd, J = 8.2, 1.3 Hz, CHAra), 7.95 (1H, dd, J = 8.0, 1.4 Hz, CHArd). 
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3-Azido-1-(2-nitrophenyl)propan-1-ol (138). 
HO
O2N
N3
 
To an emulsion of crude 1-azido-3-methoxymethyl-3-(4-nitrophenyl) propane 
(136) (300 mg, 1 equiv) in tetrahydrofuran (1 mL) and water (2 mL), 
hydrochloric acid (2 mL) was added. The emulsion was then stirred at 50 °C for 
8 h, before extraction with ethyl acetate (2 x 20 mL). The organic layer was then 
dried over magnesium sulphate and concentrated in vacuo. The residue was 
then purified using column chromatography (PE/EtOAc, 8/2) to yield the alcohol 
as a pale yellow oil (138). Adapted from Meyers et al. (177) (46 mg, 25% over 2 
steps). 
Ȟmax (CHCl3)/cm-1, 3431 (OH), 2099 (N3), 1524, 1346 (NO2); įH (400 MHz; 
CDCl3): 1.88-1.99 (1H, m, CH2CH2N3), 2.04-2.14 (1H, m, CH2CH2N3), 2.95 (1H, 
d, J = 3.2 Hz, OH), 3.55 (2H, dd, J = 7.0, 6.3 Hz, CH2CH2N3), 5.34 (1H, dd, J = 
9.0, 3.2 Hz, CHOH), 7.43 (1H, ddd, J = 8.2, 7.5, 1.3 Hz, CHArb), 7.65 (1H, ddd, 
J = 8.0, 7.5, 1.2 Hz, CHArc), 7.81 (1H, dd, J = 8.2, 1.2 Hz, CHAra), 7.91 (1H, dd, 
J = 8.0, 1.3 Hz, CHArd); įC (100 MHz CDCl3): 36.9 (CH2CH2N3), 48.7 
(CH2CH2N3), 67.3 (CHOH), 124.5 (CHArd), 128.0 (CHAra), 128.4 (CHArc), 133.8 
(CHArb), 139.6 (CAr), 147.5 (CNO2Ar); HRMS m/z (+ ESI): Found [MNa]+, 
245.0644 C9H10N4O3 requires [MNa]+, 245.0645. 
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1-(3-azido-1-chloropropyl)-2-nitrobenzene (TV4). 
Cl N3
NO2
 
A solution of 3-azido-1-(2-nitrophenyl)propan-1-ol (138) (221 mg, 1.8 mmol, 1 
equiv) in anhydrous dichloromethane (5 mL) was cooled to 0 °C under a 
nitrogen atmosphere. Thionyl chloride (5 mL) was then added dropwise and the 
solution was left to stir at room temperature for 6 h. The reaction was then 
concentrated in vacuo and the residue was purified using column 
chromatography (PE/EtOAc, 8/2) to yield the product as a pale yellow oil (TV4). 
Adapted from Nakamura et al. (178) (104 mg, 43%).  
Ȟmax (CHCl3)/cm-1, 2100 (N3), 1525, 1349 (NO2); įH (400 MHz; CDCl3): 2.38-
2.46 (2H, m, CH2CH2N3), 3.59-3.63 (2H, m, CH2CH2N3), 5.69 (1H, dd, J = 9.8, 
3.9 Hz, CHCl), 7.48 (1H, ddd, J = 8.2, 7.6, 1.3 Hz, CHArb), 7.68 (1H, ddd, J = 
8.3, 7.6, 1.3 Hz, CHArc) 7.48 (1H, dd, J = 8.2, 1.3 Hz, CHAra), 8.24 (1H, dd, J = 
8.3, 1.3 Hz, CHArdįC (100 MHz CDCl3): 39.0 (CH2CH2N3), 48.6 (CH2CH2N3), 
54.5 (CH), 124.5 (CHArd), 129.3 (CHAra), 129.7 (CHArc), 133.6 (CHArb), 135.8 
(CAr), 147.7 (CNO2Ar); HRMS m/z (+ ESI): Found [MNa]+, 263.0303 
C9H9ClN4NaO2 requires [MNa]+, 263.0306.  
 
1-(2-Nitrophenyl) propane-1,3-diol (139). (114) (149)  
HO
O2N
OH
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A solution of 1-(2-nitrophenyl)prop-2-en-1-ol (130) (1.70 g, 9.5 mmol, 1 equiv) in 
anhydrous tetrahydrofuran (40 mL) was cooled to 0 °C, borane (1M in THF, 9.5 
mL) was then added dropwise, and stirred overnight at 0 °C under a nitrogen 
atmosphere. Sodium hydroxide (3M, 9.5 mL) was then added followed by 
dropwise addition of hydrogen peroxide (30%, 9.5 mL), before stirring for 30 
min at 0 °C. The reaction was then quenched with a saturated sodium bisulfite 
solution (20 mL) and ethyl acetate (50 mL) was added. The organic layer was 
then washed with sodium hydrogen carbonate (50 mL) and brine (50 mL), 
before concentration in vacuo. The residue was then purified using column 
chromatography (PE/EtOAc, 8/2-1/1 gradient) to yield the primary alcohol as a 
brown oil (139). Adapted from Jiang et al. And Matteucci et al. (116), (151) (870 mg, 
47%).  
Ȟmax (CHCl3)/cm-1, 3367 (OH), 1523, 1346 (NO2); įH (400 MHz; CDCl3): 1.83-
2.10 (2H, m, CH2CH2OH), 3.01 (1H, bs, CHOH), 3.82-3.96 (2H, m, 
CH2CH2OH), 4.05-4.13 (1H, m, CH2OH), 5.44 (1H, d, J = 7.8 Hz, CHOH), 7.39 
(1H, ddd, J = 8.2, 7.6, 1.3 Hz, CHArb), 7.63 (1H, ddd, J = 8.2, 7.6, 1.2 Hz, 
CHArc), 7.85 (1H, dd, J = 8.2 1.2 Hz, CHAra), 7.89 (1H, dd, J = 8.2, 1.3 Hz, 
CHArd įC (100 MHz CDCl3): 39.5 (CH2CH2OH), 61.7 (CH2CH2OH), 69.5 
(CHO), 124.4 (CHArd), 128.1 (CHAra), 128.2 (CHArc), 133.7 (CHArb), 139.9 
(CAr), 147.3 (CNO2Ar); HRMS m/z (+ ESI): Found [MNa]+, 220.0596 
C9H11NNaO4 requires [MNa]+, 220.0580. 
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3-Hydroxy-3-(2-nitrophenyl)propyl-4-methylbenzene sulfonate (140). 
HO
O2N
O S O
O
 
To a solution of 1-(2-Nitrophenyl) propane-1,3-diol (139) (837 mg, 4.2 mmol, 1 
equiv) in anhydrous dichloromethane (20 mL) toluenesulfonyl chloride (810 mg, 
4.2 mmol, 1 equiv) and diisopropylamine (1.5 mL, 8.4 mmol, 2 equiv) were 
added. The solution was then stirred overnight under a nitrogen atmosphere at 
room temperature before concentration in vacuo. The residue was then purified 
using column chromatography (PE/EtOAc, 8/2-7/3 gradient) to yield the primary 
alcohol as a pale yellow oil (140). Adapted from Elban et al. (179) (492 mg, 33%).  
Ȟmax (CHCl3)/cm-1, 3520 (OH), 1524, 1349 (NO2); įH (400 MHz; CDCl3): 1.97-
2.08 (1H, m, CH2CH2OTs), 2.16-2.28 (1H, m, CH2CH2OTs), 2.45 (3H, s, CH3), 
2.59 (1H, dd, J = 4.2, 0.7 Hz, CHOH), 4.21-4.29 (1H, m, CH2CH2OTs), 4.34-
4.44 (1H, m, CH2CH2OTs),  5.32 (1H, ddd, J = 9.4, 4.2, 3.0 Hz, CHOH), 7.36 
(2H, d, J = 8.2 Hz, CHArTs), 7.43 (1H, ddd, J = 8.2, 7.5, 1.4 Hz, CHArb), 7.64 
(1H, ddd, J = 7.8, 7.5, 1.2 Hz, CHArc), 7.77 (1H, dd, J = 8.2, 1.2 Hz, CHAra), 
7.81 (2H, d, J = 8.2 Hz, CHArTs), 7.92 (1H, dd, J = 7.8, 1.4 Hz, CHArdįC (100 
MHz CDCl3): 21.7 (CH3), 36.9 (CH2CH2OTs), 66.1 (CH2CH2OH), 67.4 (CHO), 
124.6 (CHArd), 127.9 (CHArTs), 128.0 (CHAra), 128.5 (CHArc), 129.9 (CHArTs), 
132.9 (CArTs) 133.8 (CHArb), 139.0 (CAr), 144.9 (CArTs), 147.6 (CNO2Ar); 
HRMS m/z (+ ESI): Found [MNa]+, 374.0668 C16H17NNaO6S requires [MNa]+, 
374.0669. 
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3-Azido-1-(2-nitrophenyl)propan-1-ol (138). 
HO
O2N
N3
 
To a solution of 3-hydroxy-3-(2-nitrophenyl)propyl-4-methylbenzene sulfonate 
(140) (492 mg, 1.4 mmol, 1 equiv) in dimethylformamide (3 mL), sodium azide 
(456 mg, 7.0 mmol, 5 equiv) was added. The suspension was then stirred 
overnight at room temperature under a nitrogen atmosphere. The suspension 
was filtered before purification using column chromatography (PE/EtOAc, 8/2) 
to yield the alcohol as a pale yellow oil (138). Adapted from Meyers et al. (177) 
(198 mg, 64%). 
Ȟmax (CHCl3)/cm-1, 3431 (OH), 2099 (N3), 1524, 1346 (NO2); įH (400 MHz; 
CDCl3): 1.88-1.99 (1H, m, CH2CH2N3), 2.04-2.14 (1H, m, CH2CH2N3), 2.95 (1H, 
d, J = 3.2 Hz, OH), 3.55 (2H, dd, J = 7.0, 6.3 Hz, CH2CH2N3), 5.34 (1H, dd, J = 
9.0, 3.2 Hz, CHOH), 7.43 (1H, ddd, J = 8.2, 7.5, 1.3 Hz, CHArb), 7.65 (1H, ddd, 
J = 8.0, 7.5, 1.2 Hz, CHArc), 7.81 (1H, dd, J = 8.2, 1.2 Hz, CHAra), 7.91 (1H, dd, 
J = 8.0, 1.3 Hz, CHArd); įC (100 MHz CDCl3): 36.9 (CH2CH2N3), 48.7 
(CH2CH2N3), 67.3 (CHOH), 124.5 (CHArd), 128.0 (CHAra), 128.4 (CHArc), 133.8 
(CHArb), 139.6 (CAr), 147.5 (CNO2Ar); HRMS m/z (+ ESI): Found [MNa]+, 
245.0644 C9H10N4O3 requires [MNa]+, 245.0645. 
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1-(2,4-Dinitrophenyl)prop-2-en-1-ol (142). 
NO2
HO
O2N
 
A solution of 2,4-dinitrobenzaldehyde (141) (100 mg, 0.5 mmol, 1 equiv) in 
tetrahydrofuran (5 mL) was cooled to 0 °C before dropwise addition of vinyl 
magnesium bromide (1 M in THF, 0.6 mL, 1.2 equiv). The solution was then 
stirred at room temperature under nitrogen for 3 h before quenching with 
saturated ammonium chloride. Ethyl acetate (10 mL) was then added and the 
reaction was washed with saturated sodium bicarbonate (10 mL) and brine (10 
mL) before concentration in vacuo. The residue was then purified using column 
chromatography (PE/EtOAc, 8/2), to yield the product as a brown oil (142). 
Adapted from Jiang et al. (116) (59 mg, 51%). 
Ȟmax (CHCl3)/cm-1, 3542 (OH), 3108 (CHAr), 1534, 1348 (NO2); įH (400 MHz; 
CDCl3): 3.34 (1H, bs, OH), 5.24 (1H, dt, J = 10.3, 1.1 Hz CHCH2y), 5.37 (1H, dt, 
J = 17.1, 1.1 Hz CHCH2z), 5.88 (1H, d, J = 5.8 Hz, CHOH), 5.92-6.04 (1H, m 
CHCH2), 8.05 (1H, d, J = 8.7 Hz, CHAra), 8.41 (1H, dd, J = 8.7, 2.3 Hz, CHArb), 
8.65 (1H, d, J = 2.3 Hz, CHArc); įC (100 MHz CDCl3): 69.7 (CHOH), 117.8 
(CH2CH), 120.1 (CHArc), 127.5 (CHArb), 130.2 (CHAra), 136.9 (CH2CH), 144.1 
(CAr), 147.1 (CNO2Ar), 147.9 (CNO2Ar).  
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1-[1-(Methoxymethoxy)prop-2-en-1-yl]-2,4-dinitrobenzene (143). 
NO2
O
O2N
O
 
A solution of 1-(2,4-dinitrophenyl)prop-2-en-1-ol (142) (150 mg, 0.67 mmol, 1 
equiv) in anhydrous dichloromethane (5 mL) was cooled to 0 °C before 
dropwise addition of diisopropylethylamine (0.72 mL, 4.0 mmol, 6 equiv). 
Chloromethyl methyl ether (0.30 mL, 4.0 mmol, 6 equiv) was then added 
dropwise and the reaction was allowed to reach room temperature and stirred 
for 24 h. The reaction was then quenched with saturated sodium bicarbonate, 
before concentration in vacuo. The residue was then taken up in diethyl ether (3 
x 10 mL), washed with brine (10 mL), dried over magnesium sulfate and 
concentrated in vacuo. The residue was then purified using column 
chromatography (PE/EtOAc, 9/1), to yield the product as a yellow oil (143). 
Adapted from Jiang et al. (116) (99 mg, 55%). 
Ȟmax (CHCl3)/cm-1, 3108 (CHAr), 1536, 1348 (NO2); įH (400 MHz; CDCl3): 3.29 
(3H, s, CH3), 4.60 (1H, d J = 6.8 Hz, CH2O), 4.76 (1H, d J = 6.8 Hz, CH2O), 
5.28 (1H, d, J = 10.1 Hz, CHCH2y), 5.39 (1H, d, J = 16.8, Hz, CHCH2z), 5.79-
5.93 (2H, m CHO, CHCH2), 8.04 (1H, d, J = 8.7 Hz, CHAra), 8.44 (1H, dd, J = 
8.7, 2.3 Hz, CHArb), 8.72 (1H, d, J = 2.3 Hz, CHArc); įC (100 MHz CDCl3): 55.9 
(CH3), 73.3 (CHO), 94.8 (OCH2O), 118.7 (CH2CH), 119.9 (CHArc), 127.3 
(CHArb), 130.4 (CHAra), 135.1 (CH2CH), 143.2 (CAr), 147.0 (CNO2Ar), 148.0 
(CNO2Ar); HRMS m/z (+ ESI): Found [MNa]+, 291.0579 C11H12N2NaO6 requires 
[MNa]+, 291.0588. 
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3-(2,4-Dinitrophenyl)-3-(methoxymethoxy) propan-1-ol (144). 
NO2
O
O2N
O OH
 
A solution of 1-[1-(methoxymethoxy)prop-2-en-1-yl]-2,4-dinitrobenzene (143) 
(100 mg, 0.3 mmol, 1 equiv) in anhydrous tetrahydrofuran (2 mL) was cooled to 
0 °C, borane (1M in THF, 0.4 mL, 1 equiv) was then added dropwise, and then 
stirred overnight at 0 °C under a nitrogen atmosphere. Sodium hydroxide (3M, 
0.4 mL) was then added followed by dropwise addition of hydrogen peroxide 
(30%, 0.4 mL), before stirring for 30 min at 0 °C. The reaction was then 
quenched with a saturated sodium bisulfite solution (5 mL) and ethyl acetate (5 
mL) was added. The organic layer was then washed with sodium hydrogen 
carbonate (5 mL) and brine (5 mL), before concentration in vacuo. The residue 
was then purified using column chromatography (PE/EtOAc, 2/1-1/1) to yield 
the primary alcohol as a brown oil (144). Adapted from Jiang et al. (116) (43 mg, 
41%).  
Ȟmax (CHCl3)/cm-1, 3425 (OH), 3109 (CHAr), 1535, 1348 (NO2); įH (400 MHz; 
CDCl3): 1.90-2.02 (1H, m, CH2CH2OH), 2.08-2.19 (1H, m, CH2CH2OH), 3.31 
(3H, s, CH3), 3.81-3.93 (2H, m, CH2CH2OH), 4.49 (1H, d, J = 6.8 Hz, 
CH2OCH3), 4.64 (1H, d, J = 6.8 Hz, CH2OCH3), 5.48 (1H, dd, J = 9.3, 3.3 Hz, 
CHOMOM), 8.03 (1H, d, J = 8.6 Hz, CHAra), 8.47 (1H, dd, J = 8.6, 2.4 Hz, 
CHArb), 8.79 (1H, d, J = 2.4 Hz, CHArc); įC (100 MHz CDCl3): 40.0 
(CH2CH2OH), 56.3 (CH3), 59.7 (CH2CH2OH), 72.4 (CHOMOM), 90.1 (OCH2O), 
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120.1 (CHArc), 127.4 (CHArb), 130.4 (CHAra), 145.5 (CAr), 147.0 (CNO2Ar), 
147.8 (CNO2Ar). 
 
1-[3-azido-1-(Methoxymethoxy)propyl]-2,4-dinitrobenzene (145). 
NO2
O
O2N
O N3
 
To a solution of 3-(2,4-dinitrophenyl)-3-(methoxymethoxy) propan-1-ol (144) 
(200 mg, 0.7 mmol, 1 equiv) in tetrahydrofuran (5 mL), diphenyl 
phosphorylazide (385 mg, 1.4 mmol, 2 equiv) and 1,8-diazabicycloundec-7-ene 
(319 mg, 2.1 mmol, 3 equiv) were added. The solution was then stirred 
overnight at room temperature under a nitrogen atmosphere. Sodium azide 
(228 mg, 3.5 mmol, 5 equiv) and 15-crown-5 (15 mg, 0.07 mmol, 0.1 equiv) 
were then added to form a suspension that was refluxed for 4 h. The 
suspension was then filtered, and the filtrate concentrated in vacuo. The 
remaining residue was then purified using column chromatography (PE/EtOAc, 
8/2) to yield the azide as a pale yellow oil (145). Adapted from Liu et al. (143) 
(107 mg, 49%).  
Ȟmax (CHCl3)/cm-1, 3107 (CHAr), 2099 (N3),  1535, 1348 (NO2); įH (400 MHz; 
CDCl3): 1.92-2.02 (1H, m, CH2CH2N3), 2.11-2.21 (1H, m, CH2CH2OH), 3.30 
(3H, s, CH3), 3.53-3.59 (2H, m, CH2CH2N3), 4.49 (1H, d, J = 6.9 Hz, CH2OCH3), 
4.62 (1H, d, J = 6.9 Hz, CH2OCH3), 5.37 (1H, dd, J = 9.3, 3.0 Hz, CHOMOM), 
8.01 (1H, d, J = 8.6 Hz, CHAra), 8.48 (1H, dd, J = 8.6, 2.3 Hz, CHArb), 8.82 (1H, 
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d, J = 2.3 Hz, CHArc); įC (100 MHz CDCl3): 36.6 (CH2CH2N3), 47.8 
(CH2CH2N3), 56.3 (CH3), 71.5 (CHOMOM), 96.1 (OCH2O), 120.3 (CHArc), 
127.5 (CHArb), 129.9 (CHAra), 145.1 (CAr), 147.2 (CNO2Ar), 147.9 (CNO2Ar). 
 
3-Azido-1-(2,4-dinitrophenyl)propan-1-ol (146). 
NO2
HO
O2N
N3
 
To a suspension of 1-[3-azido-1-(methoxymethoxy)propyl]-2,4-dinitrobnzene in 
(145) (213 mg, 0.7 mmol, 1 equiv) in tetrahydrofuran (2 mL) and water (5 mL), 
hydrochloric acid (11.8 M, 5 mL) was added. The suspension was then stirred 
at 70 °C for 5 h. The suspension was cooled and ethyl acetate was added. The 
organic layer was separated, dried and concentrated in vacuo. The residue was 
then purified using column chromatography (PE/EtOAc, 8/2) to yield the product 
as a yellow oil (146). Adapted from Meyers et al. (177) (111 mg, 65%).  
įH (400 MHz; CDCl3): 1.84-1.95 (1H, m, CH2CH2N3), 2.06-2.17 (1H, m, 
CH2CH2OH), 3.06 (1H, bs, OH), 3.64 (2H, dd, J = 6.6, 6.1 Hz, CH2CH2N3), 5.52 
(1H, dd, J = 9.2, 2.2 Hz, CHOH), 8.15 (1H, d, J = 8.7 Hz, CHAra), 8.48 (1H, dd, 
J = 8.7, 2.3 Hz, CHArb), 8.80 (1H, d, J = 2.3 Hz, CHArc). 
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1-(3-Azido-1-chloropropyl)-2,4-dinitrobenzene (TV5).  
Cl N3
NO2
NO2
 
A solution of 3-azido-1-(2,4-dinitrophenyl)propan-1-ol (146) (368 mg, 1.4 mmol, 
1 equiv) in anhydrous dichloromethane (5 mL) was cooled to 0 °C under a 
nitrogen atmosphere. Thionyl chloride (5 mL) was then added dropwise and the 
solution was left to stir at room temperature for 6 h. The reaction was then 
concentrated in vacuo and the residue was purified using column 
chromatography (PE/EtOAc, 8/2) to yield the product as a pale yellow oil (TV5). 
Adapted from Nakamura et al. (178) (46 mg, 12%).  
Ȟmax (CHCl3)/cm-1, 2101 (N3), 1527, 1348 (NO2 įH (400 MHz; CDCl3): 2.12-
2.43 (2H, m, CH2CH2N3), 3.15-3.68 (2H, m, CH2CH2N3), 6.18-6.24 (1H, m, 
CHCl), 8.06 (1H, d, J = 8.7 Hz, CHAra), 8.45 (1H, dd, J = 8.7, 2.3 Hz, CHArb) 
8.74 (1H, d, J = 2.3 Hz, CHArc); įC (100 MHz CDCl3): 37.6 (CH2CH2N3), 48.5 
(CH2CH2N3), 56.2 (CHCl), 121.0 (CHArc), 126.6 (CHArb), 129.3 (CHAra), 144.3 
(CAr), 146.9 (CNO2Ar), 147.8 (CNO2Ar). 
 
1-N-Methyl-2-amino imidazole-5-carboxylic acid ethyl ester (149). 
N N
NH2
O
O
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To a suspension of sarcosine methyl ester hydrochloride (147) (5 g, 35.8 mmol, 
1 equiv), potassium carbonate (5 g, 36.2 mmol, 1.1 equiv) in ethanol (50 mL), 
ethyl formate (22 mL) was added. The suspension was stirred for 48 h at room 
temperature, filtered and the filtrate concentrated in vauco. Water was then 
added and extracted with ethyl acetate (3 x 20 mL), dried over magnesium 
sulfate and concentrated in vacuo. The residue was then dissolved in ethyl 
formate (16 mL) and cooled to 0 °C, before portionwise addition of sodium 
hydride (1.6 g, 66 mmol, 1.9 equiv) over 1 hour. The suspension was then left 
to stir overnight at room temperature before being triturated twice with hexane 
(2 x 20 mL). The residue was then dissolved in ethanol (15 mL) and 
concentrated hydrochloric acid (11.8 M, 6 mL), and heated to 110 °C for 1 hour. 
The suspension was then filtered and washed with ethanol before the filtrate 
was concentrated in vacuo to produce a thick brown oil. Acetic acid in water 
(10%, 20 mL), cyanamide (3.5 g, 83 mmol, 2.3 equiv) and sodium acetate (15 
g, 110 mmol, 3.1 equiv) were then added to the residue, before being stirred at 
95 °C for 1 hour. The reaction was then adjusted to pH 9 using sodium 
hydrogen carbonate and a pale yellow precipitate was filtered to yield the 
imidazole as a yellow powder (149). Repeated from Matteucci et al. (151) (4.17 g, 
75%). 
Ȟmax (CHCl3)/cm-1, 3391 (NH), 3132 (CHAr), 1651 (C=O); įH (400 MHz; DMSO): 
1.23 (3H, t, J = 7.1 Hz, CH2CH3), 3.52 (3H, s, NCH3), 4.15 (2H, q, J = 7.1 Hz, 
CH2CH3), 6.16 (2H, d, J = 5.2 Hz, NH2), 7.27 (1H, s, CHAr); įC (100 MHz 
DMSO): 14.8 (CH2CH3), 30.7 (NCH3), 59.3 (CH2CH3), 117.3 (CAr), 136.6 
(CHAr), 154.8 (CAr), 160.2 (C=O); HRMS m/z (+ ESI): Found [MH]+, 170.0925 
C7H11N3O2 requires [MH]+, 170.0924. 
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1-N-Methyl-2-nitroimidazole-5-carboxylic acid ethyl ester (150). 
N N
NO2
O
O
 
A suspension of 1-N-methyl-2-amino imidazole-5-carboxylic acid ethyl ester 
(149) (500 mg, 2.9 mmol, 1 equiv), sodium nitrite (4.5 g, 65.2 mmol, 22 equiv) 
and water (25 mL) was cooled to 0 °C and sulphuric acid (7%, 22.5 mL) was 
added dropwise keeping the temperature below 5 °C. The solution was then 
stirred for 30 min before being raised to room temperature and stirred for a 
further 2 h. The solution was then extracted with chloroform (6 x 50 mL) and 
dried with magnesium sulfate before concentration in vacuo. The residue was 
then stirred in ether and filtered, the filtrate was then washed with ice water, 
and concentrated in vacuo, to yield the product as a red/brown solid (150). 
Repeated from Asato et al. (155) (255 mg, 43%). 
Ȟmax (CHCl3)/cm-1, 3132 (CHAr), 2984 (CH), 1727 (C=O), 1553, 1368 (NO2); įH 
(400 MHz; MeOD): 1.39 (3H, t, J = 7.1 Hz, CH2CH3), 4.30 (3H, s, NCH3), 4.39 
(2H, q, J = 7.1 Hz, CH2CH3), 7.72 (1H, s, CHAr); įC (100 MHz MeOD): 13.0 
(CH2CH3), 34.5 (NCH3), 61.4 (CH2CH3), 126.5 (CAr), 133.3 (CHAr), 158.9 
(C=O); HRMS m/z (+ EI): Found [MH]+, 199.0593 C7H9N3O4 requires [MH]+, 
199.0588. 
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1-Methyl-2-nitro-1H-imidazole-5-carboxylic acid (153). 
N
N
NO2
HO
O
 
A suspension of 1-N-methyl-2-nitroimidazole-5-carboxylic acid ethyl ester (150) 
(2.66 g, 13.4 mmol, 1 equiv) in sodium hydroxide solution (3M, 100 mL) was 
stirred overnight at room temperature or until dissolution. The solution was then 
adjusted to pH 3 using hydrochloric acid (1M) before extraction with ethyl 
acetate (3 x 50 mL). The organic layer was then concentrated in vacuo to yield 
the product as a pale brown solid (153). Repeated from Matteucci et al. (151) 
(1.71 g, 75%). 
Ȟmax (CHCl3)/cm-1,2856 (CH), 1714 (C=O), 1560, 1364 (NO2); įH (400 MHz; 
MeOD): 4.30 (3H, s, CH3), 5.03 (1H, bs, OH), 7.69 (1H, s, CHAr); įC (100 MHz 
MeOD): 34.5 (CH3), 127.0 (CAr), 133.4 (CHAr), 160.2 (C=O). 
 
(1-Methyl-2-nitro-1H-imidazol-5-yl)methanol (152). 
N
N
NO2
HO
 
A stirred solution of 1-methyl-2-nitro-1H-imidazole-5-carboxylic acid (153) (200 
mg, 1.17 mmol, 1 equiv) in tetrahydrofuran (2 mL) was cooled to 0 °C, before 
dropwise addition of borane (1M in THF, 0.24 mL, 1.2 equiv). The reaction was 
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then stirred at room temperature under a nitrogen atmosphere for 5 h before 
addition of methanol and concentration in vacuo. The residue was then purified 
using column chromatography (DCM/MeOH 95/5), to yield the product as a 
pale yellow solid (152). Adapted from Yoon et al. (180) (83 mg, 45%). 
Ȟmax (CHCl3)/cm-1, 3391 (OH), 2922 (CH), 1546, 1349 (NO2); įH (400 MHz; 
DMSO): 3.92 (3H, s, CH3), 4.23 (1H, bs, OH), 4.55 (2H, s, CH2), 7.69 (1H, s, 
CHAr); įC (100 MHz DMSO): 34.6 (CH3), 56.4 (CH2), 127.0 (CHAr), 139.1 
(CAr). 
2-Nitro-1H-imidazole-5-carbaldehyde (155). 
N
NH
NO2
O
 
A solution of 1H-imidazole-4-carbaldehyde (154) (100 mg, 1.0 mmol, 1 equiv) in 
nitric acid (2 mL) was stirred at room temperature for 30 min before 
concentration in vacuo. This yielded the product as a pale yellow solid (155). 
Repeated from Baliani et al. (160) (147 mg, quant). 
įH (400 MHz; DMSO): 8.51 (1H, s, CHAr), 9.18 (1H, s, NH), 9.84 (1H, s, 
C=OH); įC (100 MHz DMSO): 128.9 (CHAr), 132.9 (CCHO), 138.8 (CNO2), 
181.7 (C=O); HRMS m/z (+ EI): Found [MH]+, 141.0169 C4H3N3O3 requires 
[MH]+, 141.0169. 
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1-Methyl-2-nitro-1H-imidazole-5-carbaldehyde (151). 
 
A solution of 1-methyl-1H-imidazole-5-carbaldehyde (156) (100 mg, 1.0 mmol, 
1 equiv) in nitric acid (2 mL) was refluxed for 30 min before concentration in 
vacuo. This yielded the product as a pale yellow solid (151). Adapted from 
Baliani et al. (160) (135 mg, 96%). 
įH (400 MHz; DMSO): 3.73 (3H, s, CH3), 8.53 (1H, s, CHAr), 9.16 (1H, s, NH), 
9.85 (1H, s, C=OH); įC (100 MHz DMSO): 28.9 (CH3), 128.8 (CHAr), 133.1 
(CCHO), 138.7 (CNO2), 182.3 (C=O); HRMS m/z (+ EI): Found [MH]+, 155.1124 
C5H5N3O3 requires [MH]+, 155.1121. 
 
EG180 3-(Acetamino)-2-oxo-2H-chromen-7-yl acetate (159).  
 
A solution of 2,4-dihydroxybenzaldehyde (158) (2.76 g, 20.0 mmol, 1 equiv), N-
acetylglycine (2.34 g, 20.0 mmol, 1 equiv) and anhydrous sodium acetate (4.94 
g, 60.0 mmol, 3 equiv) in acetic anhydride (100 mL) was heated at reflux (150 
°C) for 4 h. The solution was then poured over ice to form a precipitate. The 
suspension was then filtered and washed with ice water to yield the product as 
a fluffy yellow solid (159). Repeated from Sivakumar et al. (162) (549 mg, 11%) 
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Ȟmax (CHCl3)/cm-1, 3341 (NH), 1759, 1720, 1681 (C=O); įH (400 MHz; CDCl3): 
2.24 (3H, s, NHCOCH3), 2.34 (3H, s, OCOCH3), 7.07 (1H, dd, J = 8.5, 2.2 Hz, 
ChHAr), 7.13 (1H, d, J = 2.2 Hz, CfHAr), 7.51 (1H, d, J = 8.5 Hz, CiHAr), 8.03 
(1H, bs, NH), 8.67 (1H, s, CcHAr); įC (100 MHz CDCl3): 21.1 (NHCOCH3), 24.7 
(OCOCH3), 110.1 (CfHAr), 117.6 (CdAr), 119.1 (ChHAr), 122.8 (CbAr), 123.6 
(CcHAr), 128.4 (CiHAr), 150.1 (CeAr), 151.4 (CgAr), 158.5 (CaAr), 168.9, 169.4 
(C=O); HRMS m/z (+ ESI): Found [MNa]+, 284.0529 C13H11NNaO5 requires 
[MNa]+, 284.0529. 
 
3-Azido-7-hydroxy-2H-chromen-2-one (DYE1).  
OHO
N3
O
 
A solution of 3-(acetamino)-2-oxo-2H-chromen-7-yl acetate (159) (549 mg, 1.6 
mmol, 1 equiv) in ethanol (10 mL) and hydrochloric acid (11.8M, 20 mL) was 
heated at reflux for 1 hour. Ice water was then added and the solution was 
allowed to cool to <5 °C, before addition of sodium nitrite (1.3 g, 18.8 mmol. 
11.8 equiv). The solution was then stirred for 5 min before portion wise addition 
of sodium azide (1.5 g, 23.1 mmol, 14.4 equiv), before stirring for a further 15 
min. A precipitate was formed and this was filtered and washed with ice water 
to yield the azide as a brown powder (DYE1). Repeated from Sivakumar et al. 
(162)
 (363 mg, 85%).  
Ȟmax (CHCl3)/cm-1, 3418 (OH), 2116 (N3), 1695 (C=O); įH (400 MHz; DMSO): 
6.76 (1H, d, J = 2.2 Hz, CfHAr), 6.81 (1H, dd, J = 8.5, 2.2 Hz, ChHAr), 7.48 (1H, 
d, J = 8.5 Hz, CiHAr), 7.60 (1H, s, CcHAr); įC (100 MHz DMSO): 102.5 (CfHAr), 
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111.8 (CdAr), 114.3 (ChHAr), 121.6 (CbAr), 128.3 (CcHAr), 129.6 (CiHAr), 153.2 
(CeAr), 157.8 (CgAr), 160.8 (CaAr); HRMS m/z (+ EI): Found [MH]+, 203.0329 
C9H5N3O3 requires [MH]+, 203.0325. 
 
6\QWKHVLVRIDOOµclick¶ products. 
A solution of targeting vector (1.8 equiv, 0.077 mmol) in methanol (1.0 mL), was 
added to a solution of contrast agent (1 equiv, 0.042 mmol) in water (0.5 mL) 
and under nitrogen. To this a solution of copper sulphate (0.1 equiv, 0.0042 
mmol) and sodium ascorbate (0.2 equiv, 0.0084 mmol) in water (0.5 mL) was 
added. The resulting suspension was then stirred for 24 hours under nitrogen, 
before concentration in vacuo. The residue was then purified using reverse 
phase silica chromatography (MeOH ± H2O) before freeze drying the water 
fraction. The residue was then dissolved in MeOH and centrifuged, before the 
supernatant taken and concentrated in vacu to produce the final product as a 
colourless or off white solid.  
All analytical HPLC of the final compounds was run using the following method: 
0-0% B over 7 minutes, 0-100% B over 15 minutes before returning to 0% B. 
 
 
Compound Data 
C1 ± 42% HRMS m/z (+ ESI): Found [MH]+, 779.1848 C24H35N11O9Gd 
requires [MH]+, 779.1855. 
Rf on HPLC 1.39 min. 
C2 ± 8% HRMS m/z (+ ESI): Found [MNa]+, 859.1539 
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C28H37N9O9ClGdNa requires [MNa]+, 859.1536. 
Rf on HPLC 1.56 min. 
C3 ± 21% HRMS m/z (+ ESI): Found [MH]+, 837.1693 C28H38N9O9Gd 
requires [MH]+, 837.1717. 
Rf on HPLC 1.38 min. 
CA1 + dye ± 
19% 
HRMS m/z (+ ESI): Found [MNa]+, 822.1444 C28H35N8O9GdNa 
requires [MNa]+, 822.1459. 
Rf on HPLC 1.26 min. 
 
NMR Relaxivity Testing 
The NMR experiments were carried out by Dr Walter Köckenberger at the Sir 
Peter Mansfield Magnetic Resonance Centre, School of Physics and 
Astronomy, University Park, University of Nottingham. The field strength used 
was 20 MHz at 298 K. Nine NMR tubes 500 µL, containing the following 
concentrations of contrast agent were made up in milli q water, 0.1, 0.4, 0.6, 
0.8, 1.0, 1.2, 1.6, 2.0, 2.5 mM. Inversion recovery experiments were carried out 
acquiring 128 x 128 pixel images with a field of view of 3cm. A conventional 
spin echo experiment was used, and the 180 inversion pulse was an adiabatic 
hyperbolic secant pulse with inversion recovery delays set at 20, 40, 60, 80, 
100, 150, 200, 250, 300, 400, 500, 700, 1000, 1800, 2500 ms. Signal intensity 
in each NMR tube was averaged over a region of 11 x 11 pixels. 
Enzymatic Assay 
Aerobic Assay. 
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To a solution of Xanthine (0.45 mL, 0.5mM) in PBS buffer (50mM), a solution of 
azole (0.45 mL, 0.25 mM) in PBS buffer (50Mm) was added. This was heated in 
an incubator at 37 °C for >30 minutes before addition of xanthine oxidase (30 
µL, 0.003 U/mL) in PBS buffer (50mM). The cuvette was then monitored every 
15 minutes by UV spectroscopy and kept in an incubator at 37 °C between 
each run.  
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